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Abstract 
Brachytherapy using low dose rate (LDR) permanent seed implant or high 
dose rate (HDR) temporary implant is a well established treatment for 
prostate cancer. This study investigates the use of advanced dose calculation 
and imaging techniques to improve clinical prostate brachytherapy 
treatments. Monte Carlo (MC) simulations are used to assess the impact of 
source interactions and tissue composition effects that are ignored by the 
TG-43U1 dose calculation algorithm used in clinical practice. MC 
simulation results are validated using experimental phantom measurements. 
The development of prostate cancer may be driven by a dominant intra-
prostatic lesion (DIL) but standard brachytherapy treatments prescribe the 
same dose level to the whole prostate. This study assesses the feasibility of 
multi-parametric (mp-MRI) guided focal boost treatments that escalate dose 
to the DIL to improve tumour control and of focal treatments that target the 
DIL to reduce treatment related side effects.  
 
Source interactions and tissue effects are shown to reduce the dose that is 
delivered to patients in LDR treatments, particularly for patients with 
calcifications, however the dosimetric impact is small compared to other 
uncertainties in LDR seed implant brachytherapy. For HDR treatments 
attenuation by steel catheters has only a small impact on dose distributions. 
Feasibility of mp-MRI guided focal boost HDR prostate brachytherapy is 
demonstrated in terms of tumour delineation and the ability to dose escalate 
the DIL without increased dose to normal tissues. The dosimetric feasibility 
of LDR and HDR focal therapy treatments is demonstrated. Focal therapy 
treatments are shown to be more sensitive to source position errors than 
whole gland treatments. MC simulations of focal therapy treatments show 
that there are no additional concerns in terms of dosimetric accuracy 
compared to standard whole gland treatments. Advanced dose calculation 
and imaging techniques can improve clinical prostate brachytherapy 
treatments. 
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1 Introduction 
1.1 Research project overview 
Brachytherapy is an established treatment option for prostate cancer (1), 
either as a stand alone or in combination with external beam radiotherapy 
and/or hormone therapy. Brachytherapy uses radioactive sources that are 
implanted into the prostate using needles inserted through the perineum. The 
sources are permanently implanted for low dose rate (LDR) treatments 
using iodine-125 (125I) or palladium-103 (103Pd) seeds. Temporary high dose 
rate (HDR) prostate brachytherapy treatments are delivered using an 
afterloader device driving a single iridium-192 (192Ir) source through 
catheters inserted into the prostate. Brachytherapy treatments have been 
shown to have comparable results to other radical treatments such as 
prostatectomy and external beam radiotherapy in terms of tumour control 
and survival (2).  
 
This research investigates whether advanced dose calculation methods and 
imaging techniques can improve routine clinical treatment planning of 
prostate brachytherapy, as follows.  
• Advanced dose calculations using Monte Carlo (MC) simulation are 
applied to clinical prostate brachytherapy treatment plans to 
investigate whether more accurate knowledge of clinical dose 
distributions can be applied to improve the effectiveness of patient 
treatments.  
• MC simulations are used to assess the impact of simplifying 
assumptions made by the TG-43U1 (3) dose calculation algorithm 
used in routine clinical dose calculations. Effects are compared for 
several brachytherapy sources. Simulation results are verified using 
experimental phantom measurements. 
• Multi-parametric MRI (mp-MRI) imaging techniques are 
investigated as a means to define tumour volumes for targeted 
treatments. 
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• Dosimetry of targeted treatments that escalate dose to tumour within 
the prostate, or that treat a sub-volume of the prostate incorporating 
the tumour, are compared to standard treatments that prescribe the 
same dose level to the whole prostate gland.  
 
The remainder of this chapter explores the background to prostate cancer 
treatments and describes the brachytherapy techniques that are investigated 
in this study. The technical background to the study is explained, including 
TG-43U1 (3), advanced dose calculations and mp-MRI techniques. Finally a 
detailed overview of the objectives and work included in the study is 
presented. 
1.2 Prostate cancer overview 
Prostate cancer is the most common cancer in men in the UK (1) with 
41,736 new cases and 10,793 deaths in the UK in 2011 (4). Incidence 
increases with age: cases in men younger than 45 are rare and post-mortem 
studies have shown malignancies are present in the majority of men over 80 
years old. The overall incidence of prostate cancer in the UK is rising due to 
an ageing population and increased use of screening. The latest UK survival 
data (from 2005-2009) shows relative survival (survival of prostate cancer 
patients relative to the general population) across all age groups of 93.5% 1 
year after diagnosis and 81.4% 5 years after diagnosis (5). Prostate cancer 
can be a slow progressing disease so patients surviving 5 years are not 
considered cured and survival rates continue to fall beyond 5 years. Survival 
is strongly linked to the stage of disease at diagnosis: five year relative 
survival recorded in 1999-2002 was 90% for patients with disease confined 
to the prostate and only 30% for patients with metastatic disease (5). 
Survival rates are improving which may be due to increased use of 
screening, leading to earlier diagnosis, as well as improvements to 
treatments.  
 
Men with prostate cancer may present with urinary symptoms but many are 
asymptomatic with investigations carried out only after an abnormal result 
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in a prostate-specific antigen (PSA) test and/or digital rectal examination 
(1). PSA blood tests measure levels of prostate-related protein in circulation. 
PSA levels are often raised in prostate cancer but may also be high due to 
benign prostate conditions. The UK advises against routine PSA screening 
because of the sub-optimal sensitivity and specificity of this test. Despite 
this, unofficial ‘screening’ with the PSA test has contributed to an increase 
in the number of prostate cancer cases that are diagnosed at an early stage 
(1). If the possibility of prostate cancer is raised, patients are investigated 
using ultrasound guided prostate biopsies to obtain histology and grade the 
aggressiveness of any cancer present. Almost all prostate cancers found in 
adults are adenocarcinomas, and are generally multi-focal and 
heterogeneous (6). The Gleason score is used to grade prostate 
adenocarcinomas with the score ranging from 1 (well differentiated, 
resembling normal prostate tissue) to 5 (poorly differentiated, hardly 
recognizable as glandular tissue). The scores for the two most common 
appearances are combined to give an overall score, for example 6 (3+3),  
Gleason  scores of 6, 7 and 8-10 are defined as low, intermediate and high 
grade respectively. Higher Gleason score has been shown to correlate with 
poorer survival outcomes (6). Following a positive biopsy, MRI or CT scans 
and nuclear medicine bone scans are used to determine the extent of the 
primary tumour, and look for evidence of nodal or distant spread. 
 
A small proportion of men (12% in UK population (1)) will present with 
disease that has spread outside the pelvis and in this situation hormone 
manipulation to suppress testosterone and control the prostate cancer is the 
mainstay of treatment. A higher proportion (25%) will present with locally 
advanced disease where the cancer has breached the prostate capsule (T3a), 
grown into the seminal vesicles (T3b) or spread to local lymph glands (N1). 
Treatment again is aimed at controlling cancer and involves long-term 
hormones combined with radiotherapy treatments. The majority of patients 
present with localised prostate cancer and are classified as low, intermediate 
and high risk according to their PSA level, Gleason score and tumour stage. 
In these men treatments are aimed at curing the cancer and in some with low 
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risk disease a policy of observation (active surveillance) is preferred as these 
cancers often take many years to progress and the individual patient may be 
more likely to die with rather than from their disease. Table 1 summarises 
the definitions of prostate cancer tumour stages and classifications.  
 
Radical treatments aiming at curing prostate cancer may have permanent 
side effects impacting sexual, bowel and urinary function. For this reason 
the 2014 UK guidelines recommend active surveillance should be offered to 
men with low risk prostate cancer and to men with intermediate risk prostate 
cancer who do not want immediate radical treatment (1). However patients 
suitable for active surveillance may still prefer radical treatment to avoid 
anxiousness caused by the knowledge of carrying untreated cancer (7). 
 
Following treatment, outcomes are assessed by serial PSA blood test 
measurements. PSA is expected to drop to a low level, referred to as 
biochemical control. Small rises in PSA, so called ‘PSA bounce’, can be 
seen particularly in the first 3 years after treatment. Consistent rises in PSA 
may represent cancer recurrence and require investigation with repeat 
imaging. As survival rates for localised prostate cancer are high, prostate 
cancer treatments are often compared in terms of biochemical control which 
is assumed to be a surrogate for an actual survival benefit. It is also an early 
indicator of recurrence as biochemical relapse can precede clinical 
progression by three to five years. The toxicities of treatments are assessed 
using standardized tests of urinary and sexual function. 
 
The majority of radical treatments are prostatectomy or radiotherapy, with 
high-intensity focused ultrasound and cryotherapy also offered as radical 
treatments in clinical trials. There is insufficient evidence from randomised 
controlled trials to establish whether any particular treatment is superior in 
terms of patient outcomes (8). Therefore choice of treatment is often 
determined by patient preferences, particularly in terms of the relative 
likelihood of treatment induced side-effects. All prostate brachytherapy 
treatments result in urethritis although in the majority of patients this will 
resolve after 6 weeks (for HDR) or 9 months (for LDR). LDR seed implant 
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brachytherapy has been shown to have the lowest rate of erectile 
dysfunction of all prostate cancer treatment modalities (6).  
 
Table 1 Prostate cancer tumour stage and risk classification  (1) 
Tumour stage Description 
T1 Tumour too small to be seen on scans or felt during 
examination 
T2 Tumour is completely inside the prostate capsule (T2a-c 
depending on how much of prostate contains tumour) 
T3a Tumour has broken through the prostate capsule 
T3b Tumour has invaded the seminal vesicles 
T4 Tumour has spread to other organs close to the prostate 
  
Classification Criteria 
Low risk PSA < 10ng ml-1 
Gleason score <= 6 
T1-T2a 
Intermediate 
risk 
At least one of: 
PSA 10-20ng ml-1 
Gleason score = 7 
T2b 
High risk At least one of: 
PSA > 20ng ml-1 
Gleason score = 8-10 
T2c, T3 or T4 
 
A systematic review of radical prostate cancer treatments comparing 
prostatectomy, external beam radiotherapy and brachytherapy by Grimm et 
al. (9) concluded that in terms of biochemical control, brachytherapy 
achieves superior outcomes for low risk patients and equivalent outcomes to 
combined external beam and brachytherapy for intermediate risk patients. 
For high risk patients external beam and brachytherapy combination 
treatments were found to be superior any of the three treatments alone. 
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There are many published studies of prostate brachytherapy clinical follow-
up data showing that the majority of patients remain biochemical relapse 
free even 10 or more years after treatment. However biochemical relapse 
occurs more often in higher risk patients. Typical results from our own 
centre analysing 1298 patients treated with LDR seed implants and median 
follow up of 10 years showed that the percentage of patients free of 
biochemical failure was 72%, 74% and 58% in low risk, intermediate risk 
and high risk patients respectively (10). Results for HDR brachytherapy 
combined with external beam show very good results with many centres 
reporting biochemical relapse free survival greater than 80% even in high 
risk patients (6). However comparison with LDR seed implant results is 
difficult as follow up duration is much lower for HDR brachytherapy, due to 
it being a relatively recently developed technique.  
1.3 Radiotherapy for prostate cancer 
Radiotherapy for prostate cancer may be external beam radiotherapy, 
brachytherapy or a combination of the two. Tumour control in prostate 
radiotherapy has been shown to improve when increased dose is delivered to 
the prostate (11). Brachytherapy treatments are well suited for dose 
escalation as the radiation is delivered by sources placed inside the prostate. 
Radiation dose falls off rapidly with distance from a brachytherapy source – 
this means that a highly conformal radiation dose can be delivered to the 
prostate whilst minimizing toxicity to surrounding normal tissues such as 
the bladder or rectum. However this high conformality also limits the 
volume that can be treated, so that brachytherapy on its own is not suitable 
for patients whose cancer has spread extensively beyond the prostate 
capsule.  
 
External beam radiotherapy without brachytherapy is widely used for all 
patients suitable for radical treatment. Reasons for using external beam 
rather than brachytherapy include patient preference, patients being unfit for 
surgery, large prostate glands, tumour extending significantly beyond the 
prostate capsule or patients having existing urinary symptoms. Standard UK 
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external beam treatment delivers at least 74Gy to the prostate using a 
schedule of the order of 2 Gy per fraction delivering treatment over 7 to 8 
weeks treating Mondays to Fridays.  
 
LDR brachytherapy treatment using permanent 125I seed implants is offered 
as monotherapy for patients with low and selected intermediate risk 
localised prostate cancer (12-14) and whose prostate volume is <60 cm3. 
Larger prostates may still be treated with seed implants after three months 
of hormone therapy to reduce the size of the gland.  
 
HDR brachytherapy in combination with external beam therapy is suitable 
for patients with intermediate and high risk localised disease or those with 
locally advanced disease (15). Earlier guidelines suggested a limit on 
prostate volume of <60 cm3 for HDR treatments but a recent update has 
removed this restriction (15). Nonetheless difficulties in access to the 
prostate due to pubic arch interference can make implantation technically 
difficult for larger prostates. Neo-adjuvant hormone therapy is 
recommended for intermediate and high risk patients in addition to 
radiotherapy (1) as it has been shown to improve cancer control rates, and 
this will generally reduce the prostate volume. There is growing evidence to 
support HDR brachytherapy as monotherapy, even using single fraction 
treatments (16). 
 
There may be a radiobiological advantage in delivering a small number of 
very high dose treatments for prostate cancer (17) as it appears that prostate 
cancer has a low radiation fractionation sensitivity and more cancer cell 
killing occurs with a small number of high dose per fraction treatments 
rather than a large number of lower dose treatments as traditionally used in 
external beam radiotherapy.   
 
Pathological studies looking at the distribution of cancer in surgical 
specimens demonstrate that prostate cancer is a multi-focal disease. 
Conventional therapies address this by treating the whole gland. There is 
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evidence that a dominant intra-prostatic lesion (DIL) within the prostate 
may drive the aggressiveness of the disease and be the focus of post-
treatment recurrence (18). Pathological studies suggest that the DIL drives 
prostate cancer progression whereas it may be safe to leave satellite lesions 
with lower Gleason grade untreated (19). Studies of patients in whom 
prostate cancer has recurred after treatment have shown that the DIL is the 
most common site of recurrence (20, 21). This has lead to interest in 
targeting the DIL using either focal boost or focal treatments.  
 
Focal boost treatments 
In higher risk patients there is interest in escalating the dose delivered to the 
DIL while treating the whole gland. Treatments that escalate dose to the 
DIL in an attempt to increase tumour control have been investigated using 
intensity modulated radiotherapy (IMRT), stereotactic radiotherapy and 
both LDR and HDR brachytherapy but there is no consensus on the best 
approach to achieve these treatments (18). For focal boost dose escalation 
with whole gland treatment, very large numbers of patients would be 
required to achieve a statistically significant improvement in actual or 
biochemical relapse free survival compared to standard whole gland 
treatment. Therefore published studies have focused on demonstrating that 
focal boost dose escalation can be achieved without increasing treatment 
related toxicities. A recent systematic review of these studies covering 
external beam and brachytherapy treatments concluded that toxicity rates 
were low but the boost doses achieved were modest, and there was too 
much difference between the methodologies used in individual studies to 
allow more robust conclusions to be drawn (18). Because of this relative 
lack of evidence, the focal boost treatments described in this work were 
introduced as a pilot study. Meanwhile a prospective randomized trial is 
also underway (22). 
 
Focal therapy treatments 
In lower risk patients, there is increasing interest in focal treatments, where 
only the region containing the DIL is treated, as a potential way of reducing 
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overall treatment related toxicity (23-26). These treatments aim to achieve 
equivalent levels of tumour control to conventional whole gland treatments 
but with reduced side effects of urinary, bowel and sexual function. Focal 
therapy using LDR and HDR brachytherapy techniques is at an early stage 
but there have been some pilot studies and initial investigations (24, 27). 
Focal therapy is seen as a treatment option for patients who may be suitable 
for active surveillance yet prefer to receive radical treatment (25). Potential 
disadvantages of focal treatments are that PSA can’t be used to monitor 
response to treatment (26) because some of the prostate gland remains 
untreated, and the complexities of planning subsequent treatments if the 
initial treatment fails. There is only one study reporting long term results for 
focal therapy, and it concluded that after 5.1 years median follow up, for 
low risk patients it was too early to say whether cancer control rates were 
equivalent to whole gland treatments, but that for intermediate risk patients 
the focal treatment was not suitable. In that study the treatment targeted the 
entire peripheral zone of the prostate (28). Current ongoing studies 
mentioned above are investigating a different focal treatment technique 
treating either a hemi-gland or the DIL alone – techniques for which there is 
currently no long term evidence. In this study focal therapy is investigated 
in a retrospective planning study to evaluate dosimetry and uncertainties of 
potential focal therapy treatment approaches. 
1.4 Prostate brachytherapy techniques 
1.4.1 Permanent 125I seed implants 
125I is an ideal radionuclide for permanent implantation as the low energy of 
its emissions (mean energy 28 keV) minimizes the radiation hazard to 
others. Prostate cancer treatments using implanted 125I seeds have been 
under development since the 1960s (29). Initially small numbers of high 
activity seeds were implanted using an open retropubic approach. Two 
major developments that improved the quality of seed implants were the 
introduction of trans-rectal ultrasound (TRUS) guided transperineal 
implantation in the later 1960s, which made the procedure much less 
invasive and provided image guidance, and the use of larger numbers of low 
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activity seeds by a group in Seattle in the 1980s, which substantially 
improved the dosimetry of the technique (29). The Seattle technique is 
essentially the approach now used around the world and in Leeds, the first 
and remaining one of the largest practices in the UK, nearly 3000 patients 
have been implanted since 1995 (10).  
 
Treatments are planned on intra-operative 2-D TRUS acquired with the 
patient under anaesthetic in the lithotomy position. A 0.5 cm spaced grid is 
overlaid on the TRUS images – the grid points correspond to the positions 
of holes in the template through which needles are inserted. The prostate 
gland is delineated on the TRUS images and the treatment is planned by 
determining the seed positions required to deliver the prescribed dose of 145 
Gy to the prostate. The seeds are inserted using needles placed through the 
template and perineum, using TRUS guidance to verify the needle grid 
position and depth. This procedure is often delivered in a single procedure. 
However the TRUS volume study for treatment planning and the seed 
implantation may be in separate sessions – for example if there are doubts 
over whether an implant will be technically feasible. Figure 1 illustrates the 
treatment set up. The procedure is described in more detail in 0. 
 
In prostate seed implant brachytherapy, the actual dose delivered can be 
different from the planned treatment, because seeds may not be positioned 
exactly as planned, or because of seed migration or the effects of prostate 
oedema. Therefore, as a quality control check, post-implant dosimetry is 
carried out using CT and/or MRI to assess the actual dose received for each 
patient (30).  
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Figure 1 Trans-rectal ultrasound guided prostate brachytherapy (reproduced with 
permission of Jane Garrud, Medical Illustrations Services, LTH NHS Trust) 
 
Studies have shown a correlation between the dose assessed in post-implant 
scans and the probability of achieving biochemical control (31, 32). LDR 
prostate brachytherapy has been demonstrated to have excellent patient 
outcomes, with many centres having patient data stretching back 10-20 
years. A recent systematic review by Rodrigues et al (33) found that 
permanent seed implant brachytherapy is at least as effective as external 
beam radiotherapy or radical prostatectomy. Seed implant brachytherapy 
was associated with less urinary incontinence and sexual impotency but 
more urinary irritation and rectal morbidity than radical prostatectomy, in 
the 6 months to 3 years after treatment. Seed implant brachytherapy was 
also associated with less risk of impotency and rectal morbidity than 
external beam radiotherapy in the 3 years after treatment.  
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1.4.2 Temporary high dose rate 192Ir treatments 
Temporary transperineal implants for prostate cancer have been applied 
since the mid 1980's (34). The technique has some similarities to that 
presented for LDR permanent implants above – TRUS is used to guide 
implantation of steel or plastic catheters through a template grid and the 
perineum with the patient under anaesthetic in the lithotomy position. The 
treatment may be planned using TRUS, MRI or CT  (14, 15). Treatment is 
delivered by a single 192Ir source driven by a remote afterloader to different 
positions (dwell positions) within the catheters.  The time that the source 
spends in each dwell position (dwell time) is optimised to achieve dose 
objectives. Unlike LDR seed implant brachytherapy, there is not yet a single 
well established prescription dose, or fractionation schedule. Multiple 
fraction treatments may use a single implant to deliver all fractions or a 
separate implant for each fraction. Given the evidence of radiobiological 
advantage of high doses per fraction in prostate cancer, discussed in 1.3, 
there has been a move to single fraction treatments and in Leeds patients 
receive 15Gy in a single fraction followed by external beam therapy 
delivering a further 37.5 Gy in 15 fractions over three weeks to the prostate 
and seminal vesicles(35). Since July 2007 over 300 patients have received 
this treatment in our centre (the first 50 patients used a different HDR 
fractionation schedule of 2 x 8.5 Gy fractions). Many patients receiving the 
combined HDR prostate brachytherapy and external beam treatment are also 
prescribed neo-adjuvant and adjuvant hormone therapy as they fall into 
higher risk groups.   
 
A recent systematic review of HDR brachytherapy in combination with 
external beam therapy demonstrated excellent patient outcomes but did not 
find sufficient multi-centre or trial data to compare the technique to other 
prostate cancer treatments (36). A UK randomized controlled trial 
comparing HDR brachytherapy combined with external beam to external 
beam alone found a statistically significant improvement in biochemical 
control in patients receiving the combined treatment (37). HDR 
brachytherapy has potential advantages in that there is less risk of 
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geographical miss compared to external beam radiotherapy and less risk of 
source position errors and no risk of source migration compared to LDR 
permanent implants (2). A recent review of brachytherapy uncertainties 
estimated the total uncertainty (k=1) in key dosimetric parameters of 5% for 
TRUS planned HDR prostate brachytherapy compared to 11% for LDR 
permanent seed implants (38). Use of a remote afterloader means that there 
is no need for staff to handle sources and no radioactive sources remain in 
the patient after the procedure.  
1.5 Brachytherapy dosimetry 
1.5.1 TG-43U1 
The TG-43U1 (3) algorithm is routinely used for dose calculations in LDR 
and HDR prostate brachytherapy treatments. In TG-43U1 the dose due to a 
single source is calculated using the 2D formalism shown in Equation 1. For 
prostate brachytherapy implants with multiple sources, dose at a point is 
calculated using a superposition of the doses due to all sources in the 
implant. Brachytherapy sources are designed with cylindrical symmetry so 
this method allows a 3D dose distribution to be derived. The values of the 
terms and functions in the TG-43U1 dose formalism for a given source type 
are derived from single source dose distributions, either from phantom 
measurements or from MC simulation. As independent measurements of 
source dose distributions may vary due to experimental or source 
construction uncertainties, TG-43U1 also defines consensus datasets for 
commonly used sources. 
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Equation 1 TG-43U1 dose formalism 
 
Figure 2 shows the dose calculation co-ordinate system and defines r, θ, r0 
and θ0.  
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Figure 2 TG-43U1 dose calculation co-ordinate system (from TG-43U1 (3)) 
 
The terms in Equation 1 are as follows: 
Sk - air kerma strength, is the air kerma rate (AKR) at a calibration distance 
d measured along the transverse bisector of the source, multiplied by the 
square of d. It has units U (Gyh-1m2). Sk is usually specified at reference 
distance of 1m, where the value will be the same as AKR. 
 Λ- dose rate constant, the dose rate to a water phantom at r0, θ0 for unit Sk. 
GL(r,θ) - geometry function, defines the fall off of dose with distance from 
the source based on the spatial distribution of the source radioactivity 
approximated to a line source. 
gL(r) - radial dose function, which defines the fall off of dose due to 
attenuation and scatter along the source transverse axis. 
F(r,θ) - anisotropy function, describes the variation in dose with polar angle 
due to attenuation and scatter in the source and the source encapsulation.  
1.5.2 Advanced dose calculations in brachytherapy 
TG-43U1 (3) dose calculations make some simplifying assumptions, as 
follows (39): 
• TG-43U1 calculates dose due to multiple sources using a 
superposition of single source dose distributions and therefore 
ignores any attenuation and scatter between sources.  
• Dose is calculated in water. This ignores any difference in density 
and composition between tissue and water, tissue heterogeneities, 
and attenuation and scatter due to applicators used for treatment 
delivery. 
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• Dose distributions are measured or calculated in a phantom assumed 
large enough to provide full scatter. However depending on the 
proximity of the treatment site to the patient surface this assumption 
may be incorrect. 
 
Approaches to addressing these potential causes of dosimetric errors are 
summarised in report TG-186(40), which also makes recommendations for 
implementing advanced dose calculations, referred to as model-based dose 
calculation algorithms (MBDCAs). Three MBDCA methods are proposed: 
collapsed-cone superposition/convolution, deterministic solutions to the 
linear Boltzmann transport equation and MC simulation. The first two 
methods are commercially available for high energy sources in 
brachytherapy treatment planning systems (TPSs): a collapsed cone 
algorithm is implemented in Oncentra® Brachy (Elekta AB, Stockholm, 
Sweden) (40) and a deterministic grid-based Boltzmann equation solver is 
implemented in the Acuros® system from Varian Medical Systems (Palo 
Alto, CA) (40). However there are no commercially available systems that 
implement these MBDCA methods for low energy sources. MC simulation 
was therefore selected for this study for the following reasons:  
• MC simulation is the method most widely used in the literature for 
brachytherapy dosimetry and is considered the current state of the art 
computational dosimetry method in brachytherapy (40). 
• There are freely available MC simulation packages that are 
benchmarked for brachytherapy dose calculations, similar packages 
are not available for the collapsed cone or linear Boltzmann 
solutions. 
• A common MC simulation framework can be implemented for low 
and high energy brachytherapy dosimetry. 
 
MC simulation uses random number sampling and probability distribution 
functions to model the processes associated with radiation emission and 
transport (41). This includes modeling source emissions, transport of 
particles and interactions in source components, encapsulation and 
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patient/phantom material, and estimating the energy deposited in defined 
“tally cells” to give a measure of dose. Simulation results are statistical in 
nature and random uncertainties reduce as the number of MC simulation 
histories is increased. For this reason MC simulation is not suitable for real-
time brachytherapy treatment planning. The accuracy of MC simulation 
results also depends on the accuracy of the simulation input model and the 
implementation of the MC simulation code.  
1.5.3 Experimental brachytherapy dosimetry 
Experimental brachytherapy dosimeters need to be small due to high dose 
gradients and very sensitive due to low dose rates (for a clinical LDR 
implant the maximum initial urethral dose rates is around 10cGyh-1) (41). 
Energy dependent detector response can also be a problem (41).  
 
Possible dosimeters include thermo-luminescent diodes (TLDs), film, metal-
oxide-semiconductor field-effect transistors (MOSFETs), scintillation 
detectors and polymer gels.  
 
TLDs 
TLDs use crystals (typically LiF doped with Mg and Ti (known as TLD-100 
(41)) with lattice defects such that electrons are raised into a metastable 
energy state between valence and conductivity bands by ionising radiation. 
When the crystal is heated the trapped electrons escape, releasing photons, 
and the light output is measured to produce a glow curve of light intensity 
versus temperature, with the area under the glow curve being related to dose 
(41). The small size and sensitivity of TLDs (doses down to cGy can be 
measured) means they are considered the standard method for 
brachytherapy dosimetry (41). However TLDs do not give instant readout 
and require a substantial amount of processing including reproducible 
annealing and readout cycles (41).  
 
Before use TLDs require individual calibration of each chip, repeat 
measurement stability checks, and  also a response linearity check if the 
dose is not in the region known to be linear (1-100cGy for TLD-100 (42)). 
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Additional corrections to experimental measurements are required to correct 
for the difference in response at measurement energy compared to 
calibration energy (this can be simulated using Monte Carlo methods and is 
~1.4 for 125I relative to Co-60 (43)).  
 
Film 
Gafchromic EBT® film (International Specialty Products, Wayne, NJ, US) 
is a self-developing radiochromic film commonly used in radiation 
dosimetry. Radiation causes polymerisation of the active layer, leading to 
changes in the absorption spectrum that can be assessed visually and 
quantified using a scanner. GafChromic films measure 2D dose distributions 
and have superior resolution compared to TLDs (44). GafChromic EBT® 
has a linear dose response over a wide range and low energy dependence but 
require larger doses compared to TLDs (41). GafChromic EBT2® can be 
used to measure dose in the cGy range (45). There are relatively few studies 
on the use of GafChromic EBT for low dose rate brachytherapy dosimetry.  
 
MOSFETs 
MOSFET dosimeters measure dose from a permanent shift in threshold 
voltage across the MOSFET due to radiation induced increase in trapped 
holes in a silicon oxide layer in a specially designed field effect transistor. 
MOSFET dosimeters have a smaller sensitive volume than the 1mm3 TLD 
chips that are typically used in brachytherapy dosimetry and have similar 
sensitivity to TLDs (41). MOSFET dosimeters can be made waterproof and 
used for in-vivo dosimetry of brachytherapy treatments (46-49). Real time 
dosimetry is possible.  
 
MOSFET response is energy dependent so calibration must be at the 
measurement energy. Individual calibration of each MOSFET detector is 
required (47), MOSFET response is linear with dose (49), is anisotropic (47, 
49) and can vary as the threshold voltage increases (with accumulated dose) 
(50), requiring frequent re-calibration. MOSFET measurement uncertainty 
varies with dose rate and total dose (50). The total accumulated dose that a 
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MOSFET can measure over its lifetime is fixed, so there are ongoing costs 
associated with a MOSFET dosimetry system.  
 
Scintillation detectors 
Scintillation detectors use a miniature glass cylinder coupled to a 
photomultiplier using fiber optic cable. They have good dose linearity and 
reproducibility and no energy dependence above 100keV. They do suffer 
from stem effects (light created in the optical fiber) but it is possible to 
correct for this (51). Typical size of the glass detector is 1x3mm. There are 
no commercial systems for brachytherapy scintillation detection at the time 
of this study and there are no published studies of low energy brachytherapy 
dosimetry using these systems.  
 
Polymer gels 
Polymer gels consist of an aqueous solution of vinyl monomers with a 
gelling agent. Ionising radiation triggers radical polymerisation increasing 
the opacity of the gel. The same process changes the tranverse relaxation 
(T2) properties of the gel, with a linear relationship between the transverse 
relaxation rate (R2=1/T2) and dose, so that an MRI acquired T2 map of the 
gel post radiation exposure gives 3D information on the spatial distribution 
of dose (41). Polymer gels effectively form phantom and detector in one and 
as a phantom material are 85% water so corrections to obtain dose to water 
are small compared to other phantom materials (~3% for I125 energies and 
negligible for Ir192 energies (52). Dose resolution of 0.7mm3 is achievable, 
with volume averaging errors <2% (41).  
 
The main disadvantage of gels for 125I dosimetry is that doses ~Gy are 
required which can lead to exposure times of weeks for single source 
measurements (53). Other disadvantages are toxicity of many gels and the 
need for access to an MRI scanner to analyse results (41). Gel response is 
energy dependent so calibration requires a source with the same energy 
distribution as the experimental source, and calibration and experimental gel 
must be handled simultaneously and identically in terms of production, 
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irradiation, storage and MR scanning (54). Gels must be tightly enclosed to 
avoid oxygen diffusion into the gel during long irradiation exposures (52) 
which creates a problem with placing the radioactive sources into the gel.  
 
Choice of dosimeter for this study 
From the dosimeters discussed above, scintillation detectors were 
disregarded due to lack of availability. Polymer gels and film were 
considered not suitable due to the low dose rates in LDR seed implant 
measurements and relative lack of existing published data using these 
dosimeters for low energy brachytherapy sources. MOSFETs and TLDs 
each have pros and cons for use in this study and could be considered 
equally suitable. MOSFETs have the advantage over TLDs of providing 
instant readout so would be more suitable for in-vivo dosimetry. As there is 
interest in pursuing in-vivo dosimetry in the future in our centre, it was 
desired to gain experience of MOSFET use and so MOSFETs were chosen 
as the dosimeter for this study. 
1.6 Prostate multi-parametric MRI 
Treatments that target dominant intra-prostatic lesion (DIL) sub-volumes 
within the prostate require advanced imaging techniques for DIL 
delineation. Conventional T2- weighted (T2W) MRI is a sensitive tool for 
locating areas of tumour tissue within the prostate but not very specific in 
terms of distinguishing tumour from benign growths (55). Using mp-MRI 
techniques such as magnetic resonance spectroscopic imaging (MRSI), 
dynamic contrast enhanced MRI (DCE-MRI) and diffusion weighted 
imaging (DWI) in combination with T2W MRI, improves sensitivity and 
specificity of prostate cancer detection (56) (57) (58) (59).  
1.6.1 Diffusion weighted imaging  
In DWI large symmetric magnetic field gradients are applied either side of 
the 180° refocusing pulse in a T2W spin-echo (SE) echo planar imaging 
(EPI) sequence. The additional gradients reduce signal from moving 
molecules. Loss of signal depends on the amount of diffusion (or other 
incoherent motion) and the strength of the diffusion weighting gradients 
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(referred to as the b-value). For prostate studies b-values are generally in the 
range 0-1000 s/mm2. Signal decay is roughly exponential with increasing b-
value and decay constant referred to as the apparent diffusion coefficient 
(ADC). Tumour tissue generally has more restricted diffusion and so a 
lower ADC value compared to normal tissue, due to tumour having higher 
cellular density (56) (60). DWI can differentiate between tumour and 
normal tissue in both the central gland and peripheral zone (61-65) and 
more aggressive, higher risk or higher Gleason score cancer is associated 
with lower ADC values (64, 66-68).  
 
DWI techniques suffer from distortions generated by the EPI sequence, 
particularly if there are susceptibility issues for example caused by air in the 
rectum (61). In DWI signal intensity decreases and noise increases with 
increasing b-value. This causes underestimation of ADC values; 
underestimation increases with increasing ADC, increasing b value and 
lower signal-noise ratio (SNR) (69). Incoherent motion also contributes to 
the loss of signal particularly at low b-values and will cause ADC values to 
be overestimated (70) unless a bi-exponential model of signal loss is used or 
low b-values are excluded (71). 
1.6.2 Dynamic Contrast Enhanced MRI 
In DCE-MRI a T1 weighted sequence is used to repeatedly image a volume 
and track changes in signal intensity caused by an intravenous contrast agent 
over time. The contrast agent acts to reduce T1 leading to signal 
enhancement. Prostate cancers induce angiogenesis so will take up contrast 
agent more avidly than normal prostate tissue (72). The concentration of 
contrast agent - and hence also the change in signal intensity - depend on 
blood perfusion, the permeability of vessel walls, and diffusion within 
extravascular space (73).  
 
The variation in signal over time in the dynamic series is used to 
characterise tissue. This can be done simply by visually reviewing the 
change in image intensity over the time course of the acquisition however 
this is subjective and labour intensive. Semi-quantitative and quantitative 
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methods of analysis have been developed to get around this and can be 
applied to regions of interest (ROIs) or on a voxel-by-voxel basis. For each 
ROI or voxel, a curve of the signal intensity over time is generated. Semi-
quantitative analysis measures the time of onset of enhancement (increase in 
signal intensity), gradient of enhancement slope (wash-in rate), maximum 
enhancement, wash-out rate and the area under the enhancement curve (74). 
Semi-quantitative analysis has the advantage of being relatively 
straightforward but the disadvantage that results for different tissue types 
can’t be directly compared, results may be influenced by scanner settings, 
and do not directly relate to tissue physiology (74).  
 
In quantitative analysis of DCE-MRI data the signal intensity/time curve is 
fitted to a model to provide estimates of physiological parameters. Model 
fitting requires an arterial input function (AIF) which can be based on 
population data but modelling results are more accurate if the AIF is 
measured for each patient by including in the field of view an artery of 
reasonable size as close as possible to the tissue of interest (75). 
 
The extended Tofts model (76) represents tissue as two compartments: the 
intravascular space and the extravascular extracellular space (EES) and fits 
the dynamic data to the formula shown in Equation 2. Here C(t) is the tissue 
contrast agent concentration and Ca(t) is the arterial contrast agent 
concentration. Contrast agent concentrations are determined from signal 
intensity using either assumed or measured tissue T1 values. The extended 
Tofts model assumes highly perfused tissue with a small blood volume.  
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Equation 2 Extended Tofts model (76) 
 
The extended Tofts model produces values for Ktrans, the volume transfer 
constant that describes the rate of transfer from the intravascular 
compartment to the EES, ve, the fractional volume of the EES, vp the 
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fractional volume of plasma, and kep, the rate constant between the EES and 
blood plasma (kep = Ktrans/ ve) (76).  
 
Quantitative DCE-MRI parameters, particularly Ktrans, can be used to 
distinguish tumour and central gland tissue in the peripheral zone of the 
prostate (74) (77) (78, 79). Higher grade tumours have higher enhancement 
gradients and wash-out rates whereas smaller low grade tumours may not 
show abnormal enhancement (80). Abnormal enhancement is also seen in 
benign prostatic hyperplasia making it hard to distinguish from tumour in 
central gland tissue (80). Accurate characterization of tissue requires a low 
temporal resolution in DCE-MRI acquisitions but there is a trade-off 
between temporal resolution and the spatial resolution and field of view that 
can be achieved (73). 
 
Ktrans incorporates two different physiological parameters, the blood plasma 
flow per unit volume and the permeability of blood vessel walls/surface area 
of perfusing vessels (permeability surface area product) (81). Flow tends to 
dominate in malignant tissue with chaotic, heterogeneous vascular structure 
consisting of highly permeable vessels, whereas permeability dominates in 
fibrotic/atrophied regions (73). More accurate characterisation of tissue may 
be achieved if these two parameters are estimated separately (82), however 
this requires more complex models that may be more difficult to apply on a 
voxel basis. For radiotherapy treatment planning voxel-by-voxel fitting is 
preferable to facilitate tumour delineation. As detailed above, studies have 
shown the Tofts model to be suitable for distinguishing tumour and normal 
tissue in the prostate, and so this model was chosen for DCE-MRI analysis 
in this study.  
1.6.3 Magnetic resonance spectroscopic imaging 
In proton MRSI of the prostate the ratio of metabolic concentrations of 
choline plus creatine to citrate is measured through analysis of the MR 
frequency spectrum on a voxel-by-voxel basis. Choline is associated with 
increased proliferation and growth and is considered a marker of 
aggressiveness. Creatine is included because it can’t be separated from the 
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choline resonance peak. Citrate levels are reduced in cancer cells. Voxels 
are considered suspicious for cancer when the metabolic ratio is at least 2 
standard deviations above the average for normal peripheral zone tissue, and 
are considered very suspicious when the ratio is more than 3 standard 
deviations above average (55). MRSI adds specificity to prostate cancer 
diagnosis and can significantly improve tumour localisation within the 
peripheral zone (72).  MRSI parameters have been shown to correlate with 
tumour aggressiveness assessed using histopathology (83). Problems with 
MRSI are low SNR and metabolic peak separation (which can be improved 
using a 3T magnet) (80), magnetic field inhomogeneities, large voxel sizes 
and the fact that MRSI data is time consuming to acquire. 
1.6.4 Other MRI issues 
Choice of coils  
Prostate MRI may be acquired using an endorectal coil or with phased-array 
pelvic coils. Histological studies have shown MRIs acquired using 
endorectal coils have better image quality, SNR and staging accuracy (84) 
(85). However images acquired with an endorectal coil suffer more from 
distortion and susceptibility artefacts which may make them less suitable as 
a basis for radiotherapy treatment planning which relies on high geometric 
accuracy. Phased-array pelvic coils are therefore acceptable for tumour 
localization in radiotherapy and brachytherapy applications (86). 
 
Effects of hormone therapy 
Hormone therapy has a number of physical and functional effects on the 
prostate gland. Hormone therapy reduces prostate volume, T2W signal 
intensity of normal tissue, and also reduces tumour volume and 
permeability(74). The volume of the peripheral zone is reduced more than 
the transition zone (87). Hormone therapy also reduces the contrast between 
normal and cancerous peripheral zone tissue in T2W, DWI, MRSI and 
DCE-MRI (88) (89) (90, 91). However it is possible to successfully identify 
prostate tumour using mp-MRI after hormone therapy (92). 
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Biopsy haemorrhage 
Biopsy haemorrhage can be confused with tumour in mp-MRI. However it 
can be distinguished using T1 weighted images where it is high intensity 
(55). Ideally mp-MRI imaging should be carried out at least 6-8 weeks post 
biopsy(72) 
1.6.5 Use of mp-MRI for tumour delineation  
Studies assessing the validity of mp-MRI for prostate cancer detection 
generally focus on the sensitivity and specificity of the technique for tumour 
detection in cancer staging and benchmark the techniques by comparison to 
histo-pathological data. Correlation to histo-pathology is not possible for 
benchmarking mp-MRI for radiotherapy treatment planning as the prostate 
remains intact. Targeted biopsies could be performed to validate mp-MRI 
results but would be much less precise than histo-pathological data and have 
associated co-morbidities. Therefore studies of mp-MRI in radiotherapy 
treatment planning, including the work described here, assume that results 
from histo-pathology based studies can be carried across to the radiotherapy 
treatment planning case even though the underlying patient groups for 
radiotherapy and radical prostatectomy may not necessarily have the same 
clinical characteristics. 
 
Several studies have successfully used MRSI to delineate tumour regions in 
studies of small numbers of prostate brachytherapy patients (permanent seed 
implant (93, 94) and HDR (95, 96)). All studies reported that DILs could be 
successfully identified, and in many cases patients had multiple DILs. The 
volumes of DILs identified in these studies ranged from 0.5-15cc and were 
located across all areas of the peripheral zone. Also DCE-MRI in 
combination with MRSI has been used to define DILs in prostate IMRT 
patients (97).  
 
A study of automatic prostate segmentation techniques by Ozer et al. (59), 
analysed three parameters from functional MRI studies: T2 values (from 
multi echo T2 mapping scans), ADC (from DWI) and kep (from DCE-MRI) 
on single slices known to contain tumour from 20 patient’s MRI studies. 
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The results were compared to radical prostatectomy sections. The study 
found that tumour detection was significantly more accurate when all 3 
parameters were used compared to T2 and ADC alone, and that detection 
using T2 and ADC together was significantly better than either T2 or ADC 
alone. Franiel et al did a similar study using MRSI in addition, compared to 
biopsy results and concluded that T2W, DWI and either DCE or MRS was 
the best combination in terms of sensitiviy and specificity (78, 79). 
 
Use of all three of DWI, DCE-MRI and MRSI would result in an 
uncomfortably long scan time for the patient. DWI is the simplest to acquire 
and is the best established technique; DCE-MRI is preferred to MRSI due to 
faster acquisition and better resolution (particularly important for accurate 
tumour delineation for treatment planning). For these reasons DWI and 
DCE-MRI, along with anatomical T2W MRI, were the techniques used in 
this study. 
 
A single tumour ROI is required for treatment planning and there are often 
differences in the tumour region that would be delineated from each of the 
mp-MRI datasets. Groenendaal et al. (58) analysed DWI and DCE-MRI 
studies from 21 patients with biopsy proven prostate cancer. The area under 
the ROC curve (AUC) was used to measure consistency between DWI and 
DCE results. It was found that AUC values could be as high as 0.9 in 
individual patients but the average was 0.6. The AUC values increased with 
tumour stage and PSA value. There is very limited published data in this 
area so it was decided for this study that the safest approach was to include 
any area that was suspicious for cancer on any one of the mp-MRI datasets 
in the delineated tumour volume. 
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1.7 Study overview 
The objective of this research is to improve clinical prostate brachytherapy 
treatments through better understanding of dose distributions from advanced 
dose calculation algorithms and more accurate targeting of dose to the 
prostate tumour using advanced imaging techniques.  
 
There is a strong dose-response relationship in prostate radiotherapy (11) 
and accurate dosimetry is important for understanding this relationship and 
also for evaluating the impact of treatments on patient’s urinary, rectal and 
sexual function. There also may be a radiobiological advantage of delivering 
increased doses to the prostate and accurate dosimetry is very important if 
higher doses are to be delivered safely. The TG-43U1 (3) dose calculation 
algorithm allows fast calculations for inter-operative treatment planning but 
ignores effects of source interactions and tissue heterogeneities on patient 
dose. Advanced dose calculation algorithms can take account of these 
effects. In this study the impact of source interactions and tissue 
heterogeneities on TG-43U1 dose distributions is evaluated using MC 
simulations of clinical brachytherapy implants. Experimental validation of 
MC simulation results is performed using a purpose built phantom and a 
MOSFET dosimeter. 
 
The dose-response relationship in prostate radiotherapy can also be 
exploited by increasing the dose that is delivered but it is not possible to 
escalate dose to the entire prostate because this would overdose organs at 
risk (OARs). As discussed in 1.3, DILs can be targeted for dose escalation 
as these may drive the development of the cancer overall, are a common site 
of recurrence and tumour control may be increased if increased dose is 
delivered to areas of known tumour tissue within the prostate (11). In this 
study two techniques for targeting DILs using mp-MRI are investigated: 
focal boost treatments where dose to the DIL is escalated with the objective 
of increasing tumour control probability (98-100) and focal therapy which 
treats only the sub-volume of the prostate where the DIL is located, with the 
objective of reducing normal tissue complication probability (25). The 
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feasibility of these techniques is investigated in terms of DIL delineation 
using mp-MRI, dosimetry of treatments for LDR and HDR and comparison 
between MC simulations and TG-43U1 (3) dose calculations. 
 
The objectives of this research are as follows: 
• Develop a framework for advanced brachytherapy dose calculations 
based on MC simulation, for permanent 125I seed implants and 192Ir 
HDR implants. Validate the framework against published source 
data and using experimental phantom measurements. 
• Investigate inter-seed attenuation and scatter (ISA) and tissue 
heterogeneity effects for 125I seed implants in terms of the 
differences from TG-43U1 dose calculations. Using retrospective 
data, assess the clinical significance of the effects and determine 
whether it is necessary or possible to allow for these effects in real-
time treatment planning. 
• Determine whether the ISA effect can be reduced by using a thinner 
125I seed model. 
• Investigate the feasibility of incorporating mp-MRI into HDR 
brachytherapy treatment planning for focal dose escalation, using 
data from a pilot study, initially as a retrospective planning study 
and then prospectively to deliver focal boost treatments to patients. 
• Compare the dosimetric feasibility of treatment planning for focal 
therapy using 125I seed implants or HDR brachytherapy, based on 
mp-MRI and template biopsy data from a clinical trial of patients 
treated with high intensity focused ultrasound (HIFU) focal therapy 
at University College London. Feasibility is assessed in terms of 
achievable dosimetry, plan robustness to source position 
uncertainties and MC simulation results.  
 
The following outlines in more detail the work undertaken and describes 
what is included in each section of this thesis. 
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Section 2 – Preliminary validation work 
In the first stage of the study the MC simulation and dose analysis 
framework is validated. The brachytherapy sources used are the 6711 and 
9011 (ThinSeed™) (Oncura, a Unit of GE Healthcare, Chalfont St Giles, 
UK) for 125I seed implant brachytherapy, and the MicroSelectron HDR v2r 
(mHDR-v2r) (Elekta AB) for 192Ir HDR brachytherapy. Each source is 
simulated as a single source in a water phantom with the results compared to 
consensus data to validate the MC source input models. Multiple source MC 
simulations are implemented using code to automatically generate MC input 
files from DICOM files exported from TPSs. Code to calculate clinical dose 
distributions by superposing dose from multiple sources, and to calculate 
plan dose-volume histogram (DVH) parameters, are benchmarked by 
comparison to TPS calculations. Finally advanced MC simulation 
techniques are investigated including phase space source files, 
implementation of lattice tissue models and an investigation into the effects 
of varying the number of simulation histories on statistical uncertainties. 
 
Section 3 – Phantom ISA and MOSFET measurements 
In this section the effects of ISA in 125I seed implant brachytherapy are 
investigated for idealised seed arrangements in a phantom using MC 
simulation and MOSFET measurements. The MOSFET measurements are 
used to validate the MC simulation framework for multiple source 
arrangements and also to assess the feasibility of using a MOSFET 
dosimeter in low energy brachytherapy. ISA is measured in symmetrical 
arrangements of 8 and 36 seeds and compared for the 6711 and 9011 source 
models.  
 
Section 4 – Clinical 125I MC simulations 
In this section MC simulations are investigated for a group of 40 125I seed 
implant patients, including the following aspects: 
• Comparison of the ISA effect in TRUS based implant plans and CT 
based post-implant plans. 
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• Comparison of the ISA effect in clinical plans for 6711 and 9011 
sources. 
• Investigation of the effects of incorporating tissue models on clinical 
dose distributions. Comparison of simple structure based and CT 
based tissue models. 
• Modelling of the effects of calcification on dose distributions in CT 
based post-implant plans. 
• Sector based analysis of MC simulation results. 
Clinical MC simulations are also investigated for HDR brachytherapy 
patients and these are included in section 6. 
 
Section 5 – Mp-MRI guided focal boost in HDR prostate brachytherapy 
Feasibility of implementing mp-MRI guided focal boost treatments in HDR 
prostate brachytherapy is investigated in a pilot study of 30 patients. The 
investigation includes evaluating uncertainties of tumour delineation using 
mp-MRI and image registration of MRI to TRUS. Dosimetry of focal boost 
treatments is compared to standard treatments to evaluate the level of boost 
dose that can be achieved while maintaining the same coverage of the 
prostate at the prescription dose level and normal tissue dose constraints as 
for standard treatments. 
 
Section 6 – Dosimetry modeling for LDR and HDR focal therapy 
Feasibility of implementing focal therapy treatments is investigated for 9 
patients who had been treated using HIFU as part of a focal therapy clinical 
trial, with comparison of 3 treatment planning approaches: standard whole 
prostate, hemi-gland focal and ultra-focal (25). Dosimetry is compared for 
LDR and HDR approaches. MC simulation of focal therapy treatment is 
performed to assess plan robustness to source position errors and the ISA 
effect. The ISA effect in focal 125I seed implants was compared for 6711 and 
9011 source models. 
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2 Preliminary validation work 
This section describes work to develop and validate a MC simulation and 
dose calculation framework to allow clinical brachytherapy dose 
distributions to be simulated. This includes the following: 
• Benchmarking MC source models against published data. 
• Validating DVH calculation code. 
• Investigating phase space source models and lattice MC simulation 
geometries for tissue models. 
• Comparison of statistical uncertainties for simulations with different 
numbers of histories. 
2.1 Background 
2.1.1 Monte Carlo modeling approaches 
All modeling was done in MCNPX v2.5.0 (101). This is benchmarked for 
use in brachytherapy dosimetry (3). Only photons were modeled (this means 
that any energy transferred to secondary electrons is assumed to be 
deposited at the interaction site, equivalent to assuming that the range of 
secondary electrons is negligible) with a cut-off energy of 1 keV. These 
assumptions are valid for 125I photon simulations (102), and for 192Ir 
>2.5mm from the source (103). The F6 tally (track length estimate of 
heating), or the mesh tally with the pedep option (101), was used to 
calculate dose, as this has been shown to be suitable for brachytherapy 
simulations (102).  
2.1.2 TG-43U1 parameter calculations 
To verify the accuracy of MC source models, single source simulations 
were performed with a spherical mesh tally (cells 0.1 mm/0.5°) in a 
spherical water phantom, radius 20 cm for 125I, 40cm for 192Ir. Results were 
used to calculate TG-43U1(3) parameters using the line source 
approximation, assuming an active length of 2.8 mm for 6711 and 9011 
sources, and an active length of 3.5mm for the 192Ir mHDR-v2r source.  
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For SK the simulations were in a vacuum with a point detector (1 cm 
diameter air tally cell at 1 m from the seed) (3). A 5 keV cut-off was used to 
exclude lower energy photons that originate in the seed encapsulation, as 
recommended in TG-43U1.  
 
Composition and density for water and air were taken from TG-43U1 and 
are as shown in Table 2. Sufficient particle histories were simulated to 
reduce the statistical component of uncertainty in individual tally cells 
below 1% in all cases. 
2.1.3 Converting MC simulation results to dose 
MCNPX tallies energy deposition as MeV per unit mass per starting particle 
(F6 tally) or MeV per unit volume per starting particle (mesh tally). Mesh 
tally results are converted to dose (MeV per unit mass per starting particle) 
by dividing by the medium density. Results are then converted to Gy as 
follows (104): 
 
Dose = MCDose*(( SK/MCSK)*1x106)*Time*NumSources 
 
• MCDose is the MCNPX dose as described above and has units 
MeV g-1 per starting particle. 
• The ((SK/MCSK)*1x106) factor converts MCDose to dose rate in 
Gyh-1. 
o MCSk is the MC simulated value for SK and has units 
MeV m2 g-1 particle-1. 
o SK is the source value (activity) at the time of implant and 
has units µGy m2 h-1. 
o The 1x106 factor converts from µGy to Gy 
• Time is the time in hours that the source is in place. For a 
permanently implanted source the dose integrated over the lifetime 
of the source is calculated by setting Time = half life (in hours) 
divided by ln(2). 
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• NumSources is the number of sources in a multiple source 
simulations, this corrects for the fact that MC tally results are per 
starting particle (so effectively are also per source). 
2.2 Single source validation – 6711 and 9011 I-125 
seeds 
The 6711 and 9011 (ThinSeed™) MC source models from Oncura were 
validated against published single source data. There are several studies that 
have modeled these sources. TG-43U1 published consensus source data 
(average values from earlier published studies based on both MC simulation 
and phantom dose measurements) for 6711 in 2004. An MC simulation 
study by Dolan et al. in 2006 examined the impact of minor changes in 
source manufacturing for the 6711 source (105). Two subsequent studies, by 
Rivard (103) and by Kennedy et al. (106) performed MC simulations for 
both 6711 and 9011 sources, using the source construction data from Dolan 
et al. as the basis for their simulation models. In this section, source 
modeling results are compared to data from TG-43U1 (for 6711 only) and 
Kennedy et al. (for 6711 and 9011). TG-43U1 is selected because it 
represents the consensus data that is used in most clinical centres for 
treatment planning. The Kennedy et al. study is chosen because the studies 
by Dolan et al., Rivard and Kennedy et al. produced very similar results and 
the Kennedy et al. study is the most complete as it also includes phantom 
dose measurements alongside MC simulation results. 
 
Source model 
Source models (see Figure 3) were based on recently published studies 
(106) (105) and also verified against technical drawings received from the 
manufacturer. The silver radio-opaque marker was assumed to be coated in 
a 1.75 µm thick layer of AgBr and AgI in a  2.5:1 molecular ratio(106). 
Material composition data is given in Table 2. 
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Figure 3 Source models used in the 6711 and 9011 simulations 
 
The I-125 energy spectrum from TG-43U1(3) was used, this has been 
shown to give equivalent dosimetric results to National Nuclear Data Centre 
(NNDC) data {Rivard, 2010 #139}, and is shown in Table 3. 
 
Table 2 125I simulation material composition and density data (3, 105-107)
 Component Material Density (g 
cm-3) 
Atomic 
number 
Relative 
proportion 
Proportion 
by weight 
Source core Silver 10.5 47 (Ag) 1  
Source coating AgBr/AgI 6.2 35 (Br) 5  
   53 (I) 2  
   47 (Ag) 7  
Encapsulation Titanium 4.54 22 (Ti) 1  
Gap inside seed Argon gas 0.001784 18 (Ar) 1  
Tally for Sk 
measurement 
Air (40% 
humidity) 
0.0019 1 (H)  0.000732 
   6 (C)  0.000123 
   7 (N)  0.750325 
   8 (O)  0.236077 
   18 (Ar)  0.012743 
Phantom Water 0.998 1 (H) 2  
   8 (O) 1  
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Table 3 125I energy spectrum (3) 
Photon  
energy (keV) 
Relative  
proportion 
27.202 40.6 
27.472 75.7 
30.98 20.2 
31.71 43.9 
35.492 66.8 
 
Results 
Dose rate constant 
Table 4 shows the dose rate constant values calculated from MC simulation, 
compared to Kennedy et al(106) and TG-43U1(3) (note that TG-43U1 does 
not have values for 9011). 
 
Radial dose function  
Table 5 shows a sample of the radial dose function values (g(r)) calculated 
from MC simulation, compared to values from Kennedy et al(106) and TG-
43U1(3) (note that TG-43U1 does not have values for 9011). 
Anisotropy function 
Table 6 shows example anisotropy function values (F(r,θ)) calculated from 
single seed MC simulations for both 6711 and 9011, compared to values 
from Kennedy et al(106) and TG-43U1(3) (note that TG-43U1 does not 
have values for 9011). 
 
Table 4 Dose rate constant value comparison from this paper (MC), Kennedy et 
al(106) and TG-43U1(3) 
 Source model MC Kennedy (diff. 
from MC) 
TG-43U1 (diff. 
from MC) 
Λ (cGy h-1 U-1) 6711 0.940 0.939 (-0.1%) 0.965 (+2.6%) 
 9011 0.926 0.928 (+0.2%) - 
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Table 5 Radial dose function (g(r)) values comparison from this paper (MC), Kennedy 
et al(106) and TG-43U1(3) 
 g(r) for 6711 g(r) for 9011 
 r  (cm) MC Kennedy TG-43U1 MC Kennedy 
0.2 1.094 1.088 1.080 1.084 1.079 
0.5 1.074 1.072 1.068 1.073 1.072 
0.7 1.046 1.046 1.048 1.047 1.047 
1 1 1 1 1 1 
2 0.814 0.815 0.814 0.810 0.811 
3 0.634 0.635 0.632 0.628 0.629 
5 0.362 0.363 0.364 0.356 0.357 
 
Table 6 Anisotropy function values comparison. from this paper (MC), Kennedy et 
al(106) and TG-43U1(3) 
 6711 F(r,θ) - MC F(r,θ) - Kennedy F(r,θ) – TG-43U1 
r          θ  0° 30° 60° 0° 30° 60° 0° 30° 60° 
0.5 cm 0.214 0.792 0.996 0.217 0.801 0.998 0.333 0.846 0.991 
1 cm 0.283 0.793 0.992 0.296 0.798 0.993 0.370 0.834 0.991 
2 cm 0.386 0.814 0.989 0.392 0.816 0.989 0.442 0.842 0.987 
5 cm 0.522 0.843 0.985 0.536 0.845 0.986 0.550 0.852 0.987 
 
9011 F(r,θ) - MC F(r,θ) - Kennedy  
 
 
r           
θ
 
0° 30° 60° 0° 30° 60° 
0.5 cm 0.213 0.792 0.972 0.221 0.800 0.974 
1 cm 0.281 0.799 0.971 0.291 0.822 0.972 
2 cm 0.386 0.820 0.972 0.390 0.822 0.972 
5 cm 0.530 0.850 0.975 0.526 0.852 0.974 
 
Conclusion 
Compared to Kennedy et al(106), for 6711 and 9011 seeds, dose rate 
constant agreed within 0.2%, radial dose function agreed within 0.7% and 
anisotropy function values agreed within <5% which proves the validity of 
the MC source model. Compared to TG-43U1(3) consensus data for the 
6711 seed, agreement is reasonable - some differences are expected as the 
consensus data includes experimentally measured data, TG-43U1 values are 
for a 3 mm active source length whereas this study used an active source 
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length of 2.8 mm, there have been minor changes in the source 
specifications from the manufacturer since TG-43U1 (105-107) and because 
of the impact of updates to the MC code itself (108). The impact of 
differences between TG-43U1 consensus data and the MC source model on 
clinical dose distributions is investigated in section 4. 
2.3 Single source validation – HDR 
The HDR 192Ir mHDR-v2r source was validated against consensus data. 
 
Source model 
 
Figure 4 Nucletron HDR 192Ir mHDR-v2r source diagram 
 
The Nucletron HDR 192Ir mHDR-v2r source model was based on the most 
recent published data, of Granero et al. (103). Figure 4 shows the source 
model as visualised in the MCNPX visual editor. Detailed dimensions are as 
in Granero et al. (103). Material composition and density data is given in 
Table 7. The 192Ir spectrum was taken from NNDC data, vol 113, issues 8-9, 
p1871-2111 (109). Details are given in Table 8.  
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Table 7 192Ir mHDR-v2r simulation material composition and density data (41, 103) 
Component Material Density (g 
cm-3) 
Atomic 
number 
Relative 
proportion 
Proportion 
by weight 
Source  Iridium 22.42 77 (Ir) 1  
Capsule AISI316L 
Stainless 
Steel 
8.02 14 (Si)  0.01 
   24 (Cr)  0.17 
   25 (Mn)  0.02 
   26 (Fe)  0.68 
   28 (Ni)  0.12 
Cable AISI316L 
Stainless 
Steel 
4.81 As for 
Capsule 
  
Catheter ANSI 
303/304 
Stainless 
Steel 
8.02 14 (Si)  0.01 
   24 (Cr)  0.19 
   25 (Mn)  0.02 
   26 (Fe)  0.68 
   28 (Ni)  0.1 
Gaps inside 
source/ 
catheter 
Air (40% 
humidity) 
0.0019 1 (H)  0.000732 
   6 (C)  0.000123 
   7 (N)  0.750325 
   8 (O)  0.236077 
   18 (Ar)  0.012743 
Phantom Water 0.998 1 (H) 2  
   8 (O) 1  
 
In addition to modeling the source in a water phantom (to compare to 
consensus data), the source was modeled inside a steel catheter. The 
catheters (interstitial bevel needle product number 083.045, Elekta AB) 
were modeled from Elekta data, verified using autoradiograph, as having 
outer diameter 1.9mm, inner diameter 1.48mm, a 7mm long plug and 3mm 
pointed end section, as shown in Figure 5. The end section was modeled as 
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a cone because in an actual implant the orientation of the bevel is not 
recorded. The source was placed at the first dwell position (11.5mm from 
the needle tip). 
 
 
 
Figure 5 The HDR source and steel catheter model 
 
Table 8 192Ir energy spectrum (109) 
Photon  
energy 
(keV) 
Relative 
proportion 
Photon  
energy 
(keV) 
Relative 
proportion 
Photon  
energy 
(keV) 
Relative 
proportion 
56.71 0.0351 155.16 0.0921 485.5 0.0047 
61.49 1.19 177 0.0043 489.1 0.438 
63.0 2.02 201.3 0.471 588.6 4.522 
63.29 0.176 205.79 3.31 593.6 0.042 
64.99 0.3 280.3 0.008 599.4 0.0039 
65.12 2.6202 283.3 0.266 604.4 8.216 
66.83 4.4403 295.96 28.7119 612.46 5.3404 
71.08 0.238 308.5 29.7 703.8 0.0053 
71.41 0.46 316.51 82.8694 765.8 0.0013 
73.36 0.2645 329.1 0.0173 884.5 0.292 
75.4 0.555 374.5 0.727 1061.5 0.0531 
75.75 1.0211 416.5 0.67 1089.9 0.0012 
77.83 0.364 420.5 0.069 1378.5 0.0014 
110.3 0.0127 468.1 47.84   
136.4 0.199 484.6 3.19   
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Results 
Dose rate constant 
The dose rate constant from the MC simulation was calculated as 1.1076, 
0.1% less than the consensus data value of 1.109 (110). 
 
Radial dose function 
 
Table 9 shows a sample of the radial dose function values (g(r)) calculated 
from MC simulation compared to consensus data values (110). 
 
Table 9 Radial dose function (g(r)) values comparison to consensus data (110) 
 g(r)  
 r  (cm) MC RPT229 % diff 
0.2 0.992 1.001 -0.9% 
0.25 0.994 0.995 -0.1% 
0.5 0.997 0.997 0.0% 
0.75 0.998 0.998 0.0% 
1 1.000 1.000 0.0% 
1.5 1.004 1.003 0.1% 
2 1.006 1.005 0.1% 
3 1.009 1.008 0.1% 
5 1.004 1.003 0.1% 
6 0.997 0.996 0.1% 
8 0.975 0.972 0.3% 
10 0.942 0.939 0.3% 
 
Anisotropy function 
Table 10 shows example anisotropy function values (F(r,θ)) compared to 
consensus data values(110). 
 
Dosimetric impact of steel catheters 
Figure 6 illustrates the dosimetric impact of including a steel catheter in a 
single source simulation. 
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Table 10 Anisotropy function compared to consensus data values (110) 
6711 F(r,θ) - MC F(r,θ) - RPT229 %diff 
r          θ  0° 30° 60° 0° 30° 60° 0° 30° 60° 
0.25 
cm 
0.778 0.941 0.990 0.787 0.961 0.993 -1.1% -2.1% -0.4 
0.75 
cm 
0.644 0.912 0.985 0.619 0.911 0.984 4.1% 0.1% 0.1 
1 cm 0.638 0.912 0.985 0.610 0.911 0.985 4.7% 0.1% 0.0% 
2 cm 0.641 0.915 0.985 0.625 0.915 0.986 2.6% 0.0% 0.0% 
5 cm 0.703 0.926 0.987 0.711 0.926 0.987 -1.1% 0.0% 0.0% 
8cm 0.756 0.934 0.988 0.768 0.934 0.988 -1.5% 0.0% 0.0% 
 
Conclusion 
Compared to consensus data (110) for the mHDR-v2r source, dose rate 
constant agreed within 0.1%, radial dose function agreed within <1% and 
anisotropy function values agreed within <5% which proves the validity of 
the MC source model. The impact of a steel catheter is small apart from at 
points along the source longitudinal axis. The greatest area of dose 
attenuation due to the steel catheter is more than 1cm beyond the last source 
dwell position, so would not impact clinical prostate dose distributions and 
may even have a beneficial effect by reducing normal tissue dose. The 
impact of steel catheters in clinical dose distributions is assessed in section 
6.  
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Figure 6 Comparison of dose for a single 192Ir mHDR-v2r source with and without a 
steel catheter. The x axis is the source transverse axis and the z axis is the longitudinal 
axis. The source is at z=101 and the needle lies along the z axis. Differences are 
expressed as %. 
2.4 Validation of dose analysis framework  
A dose analysis framework was implemented for analysis of MC simulation 
results, and also to calculate MC superposition dose distributions. MC 
superposition dose distributions are calculated by superposing single MC 
source distributions across all source co-ordinates and in many cases in later 
sections are used instead of TG-43U1 (3) for comparison with full MC 
simulation. This is so that the comparison is not affected by differences 
between MC source models and TG-43U1 consensus data, or differences 
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due to the TG-43U1 line source approximation. This section describes how 
the framework was implemented and validated.  
 
Method 
Source co-ordinates, source activity, source dwell times (HDR only) and 
structure sets were exported from the TPS (for 125I treatments the TPS is 
VariseedTM v8.0 (Varian Medical Systems, Inc., Palo Alto, CA, USA) and 
for 192Ir treatments the TPS is Oncentra Prostate™ v4.0 (Elekta AB)). For 
some cases (CT tissue based models) the underlying image set was also 
exported. The dose analysis framework was implemented in MatlabTM 
R2010a (MathWorks, Natick, MA, USA) and included code to auto-
generate MC simulation input files based on the exported patient data. 
 
The dose and DVH calculation framework involved the following steps: 
• Extract structure points from DICOM structure data and create 3D 
masks for all structures in the structure sets (for example prostate, 
urethra and rectum). 
• Calculate a 3D dose distribution. For MC simulated dose, this is the 
raw dose converted to Gy as described in 2.1.3. For the MC 
superposition dose, the dose at each point in the distribution was 
calculated by summing the dose from each source at that point. A 
single source cylindrical dose distribution calculated using MC 
simulation, with resolution 1mm and extending 10cm along and 
10cm away from the source was used to calculate the contribution 
from each source. Bi-linear interpolation was used to interpolate 
between points in the cylindrical dose grid (an inverse-square law 
correction was applied to the dose grid to smooth the interpolation, 
and then removed after interpolation). The dose calculation 
resolution was 1 mm x 1 mm in-plane, with dose calculated on the 
slices in the original imaging data (2 mm spaced for CT, either 2.5 
mm or 5 mm spaced for TRUS).  
• For 125I treatments, all sources were assumed to be oriented 
perpendicular to the plane of the CT/TRUS slices. For 192Ir 
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treatments, corrections for source orientation were applied using the 
simplifying assumption that the same rotation could be applied to all 
sources in a single catheter (Oncentra ProstateTM calculates a 
separate rotation for each source (111)).  
• For dose calculation from MC simulation results of HDR treatments, 
for voxels that intersect a catheter, dose was interpolated from 
surrounding voxels to exclude high dose catheter voxels from the 
DVH analysis.  
• Once dose calculation was completed, the 3D structure masks were 
applied to the 3D dose distributions to calculate DVH statistics. 
 
The resulting DVH calculations were benchmarked by comparing results to 
DVH statistics calculated by the TPSes. 15 clinical post-implant CT based 
plans were compared for the 6711 seed model. 5 HDR prostate treatment 
plans were compared for the 192Ir source model. For the 6711 seed 
comparison, TG-43 source data calculated from single seed MC simulations 
was added to Variseed and used instead of 6711 consensus data. This is to 
remove any effects due to differences between the MC seed model and the 
consensus data, as noted in 2.2. This was not necessary for validation for the 
192Ir source, as MC simulation of that source showed good agreement with 
consensus data. 
 
Results 
Table 11 compares mean DVH parameter values for 15 post-implant 6711 
seed implant plans, as calculated by Variseed using the MC source data 
from 2.2 and the dose analysis framework for the MC superposition dose 
distribution.  
 
Table 12 compares the mean DVH parameter values for 5 HDR prostate 
patients from Oncentra Prostate (TG-43U1(3) calculation) and MC 
superposition dose calculations. Planning target volume (PTV) data is 
included. 
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Table 11 Results from benchmarking DVH calculation code comparing Variseed 
output for the MC simulated source data (MC-SRC) and output from the dose 
analysis framework MC superposition dose (MC-SUP). All results are mean values for 
15 patients using the 6711 seed. 
DVH Parameter Variseed 
MC-SRC 
MC-SUP Difference Variseed 
MC-SUP – MC-SRC 
Prostate volume 35.1 cm3 35.2 cm3 0.3% 
Prostate D90  136.6 Gy 137.5 Gy 0.7% 
Prostate V100  87.3% 87.6% 0.3% 
Prostate V150  56.1% 57.0% 0.9% 
Prostate V200  25.8% 26.7% 0.9% 
Urethra D10  248.0 Gy 255.4 Gy 3.0% 
Rectum D2cm3  118.3 Gy 119.2 Gy 0.8% 
 
Table 12 Mean DVH parameter values for 5 HDR prostate patients comparing 
Oncentra Prostate and MC-SUP dose calculations 
DVH Parameter Oncentra 
Prostate 
MC-SUP 
 
Difference 
Oncp –MC-SUP 
PTV volume (cm3) 46.6 46.9 0.7% 
PTV D90 (Gy) 15.5 15.5 -0.2% 
PTV V100 (%) 92.4 92.2 -0.3% 
Prostate volume (cm3) 31.9 32.5 1.8% 
Prostate D90 (Gy) 17.0 17.0 0.5% 
Prostate V100 (%) 99.6 99.5 -0.1% 
Prostate V150 (%) 27.0 27.9 0.8% 
Prostate V200 (%) 6.87 4.84 -2.0% 
Urethra D10 (Gy) 17.2 17.2 0.0% 
Rectum D2cm3 (Gy) 8.86 8.89 0.4% 
 
Conclusion 
Small differences are observed between DVH parameters calculated by the 
DVH calculation framework and the TPSes. These differences are not 
unexpected as there are differences in the dose calculation resolution and 
TPSes typically calculate DVH parameters by randomly sampling points 
within volumes for speed, whereas the DVH calculation framework 
calculates the DVH using all elements in each structure. The differences 
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observed are smaller than those that have been observed in a comparison of 
commercial treatment planning systems (112). Therefore the DVH 
comparisons demonstrate that the dose and DVH calculation framework is 
valid.  
 
2.5 Validation of phase space source  
MCNPX supports phase space source models: a pre-calculation is used to 
create a phase space source file that stores information on all particles 
crossing the source surface. The phase space source file is then used as the 
source in further simulations. Therefore all absorption and scattering inside 
a source of particles that originate from the same source is pre-calculated. 
For seed implants phase space source models have been shown to reduce 
calculation time by around one half (113). This section describes how phase 
space models were implemented and validated for the sources used in this 
study.  
 
Method 
The MCNPX ssw (surface source write) card (101) was used to calculate the 
phase space source model file. This writes all particles that cross the outer 
surface of the source. For 6711 and 9011 sources the outer surface was 
defined by the source encapsulation. For the mHDR-v2r source the outer 
surface was defined by the source encapsulation and extended to include 
5cm of source cable. 500 million histories were simulated for the creation of 
each phase space source file.  
 
For each source, the phase space source files were validated by repeating a 
single source simulation using a cylindrical mesh tally as described in 
section 2.2, and comparing tally results to the original simulation that used 
the full source simulation. In addition, to validate the use of phase space 
sources in clinical simulations, for 5 125I patient CT post implant plans MC 
simulations using both full source model and the phase space source model 
46 
 
for the 6711 source were compared using DVH parameters calculated as 
described in section 2.4.  
 
Results 
Single source simulations 
For single source simulations, the mean difference between full source and 
phase space source simulations for all points up to 10cm along and 10cm 
away from the source was 0.16% for the 6711 source, 0.09% for the 9011 
source and 0.5% for the mHDR-v2r (excluding points inside the 
source/source cable). At individual points differences were up to ±10% but 
differences appeared to be statistical (there was no trend in any particular 
direction) and were less than statistical error in each tally cell (for the 
reasons explained above, the number of histories used in the phase space 
validation is considerably less than used in the full source model validation).  
 
Clinical simulations  
Table 13 summarizes the comparison of full source and phase space source 
clinical simulations for 5 CT post implant plans for patients treated with the 
6711 source. In clinical simulations use of the phase space source model 
was found to reduce simulation time by ~55%.  
Table 13 Comparison of mean DVH parameter values for full source and phase space 
source simulations using 6711 source, for 5 patients 
DVH Parameter MC simulation – 
full source 
MC simulation – 
phase space source 
Difference: mean 
(max) 
Prostate D90 (Gy) 133.5 133.4 0.0% (0.3%) 
Prostate V100 (%) 86.3 86.3 0.0% (0.2%) 
Prostate V150 (%) 50.5 50.6 0.1% (0.5%) 
Prostate V200 (%) 24.4 24.5 0.1% (0.8%) 
Urethra D10 (Gy) 218.1 218.2 0.0% (0.8%) 
Rectum D2cm3 (Gy) 110.1 110.2 0.2% (0.3%) 
 
Conclusion 
Comparison of DVH parameter values calculated from full source and phase 
space source simulations show that the largest difference observed for any 
47 
 
parameter is <1%, therefore the results confirm that the phase space source 
models are suitable for use in this study.  
2.6 Investigation of statistical variations with number 
of histories for clinical simulation 
MC simulation results are affected by statistical uncertainties that decrease 
as the number of histories is increased. In a given tally cell, statistical 
uncertainty is inversely proportional to the square root of the number of 
histories. This section explores how individual tally cell uncertainties 
impact DVH parameters uncertainties in clinical simulations.  
 
Method 
For the 5 patients described in section 2.5, simulations were performed 
using 4 million, 1 million and 0.25 million histories per seed. Each 
reduction in the number of histories by a factor of four approximately 
doubles individual tally cell uncertainty. Each simulation was repeated 3 
times in total using different starting random numbers, to estimate the 
statistical variation in DVH parameters for a fixed number of histories. 
 
Results 
Table 14 shows the uncertainty in DVH parameter values, calculated as the 
standard deviation/mean of 3 repeat simulations for 5 clinical post-implant 
plans. The maximum difference from the mean parameter value for 4 
million history simulations is also shown. 
 
Conclusion 
The analysis of increase in DVH parameter uncertainty as the number of 
simulation histories is decreased shows that decreasing the number of 
histories does not increase DVH parameter uncertainty in proportion to tally 
cell uncertainty. As the simulations used in this study were not particularly 
time constrained, 2 million histories per seed were used in subsequent 
simulations as a compromise between levels of uncertainties and simulation 
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run time, even though adequate results could have been achieved with fewer 
histories.  
 
Table 14 Uncertainty in DVH parameter values estimated from 3 repeat simulations 
of 5 clinical post-implant plans, comparing results for different numbers of histories 
per seed. For 1 and 0.25 million histories the maximum difference from the mean 
parameter value for 4 million histories is shown in parentheses. 
DVH Parameter 4 million 
histories/seed 
1 million 
histories/seed 
0.25 million 
histories/seed 
Prostate D90  0.13% 0.13% (0.45%) 0.17% (0.97%) 
Prostate V100  0.06% 0.10% (0.22%) 0.18% (0.30%) 
Prostate V150  0.09% 0.14% (0.19%) 0.30% (0.37%) 
Prostate V200  0.20% 0.26% (0.23%) 0.35% (0.19%) 
Urethra D10  0.21% 0.40% (0.87%) 0.62% (1.8%) 
Rectum D2cm3  0.17% 0.28% (0.64%) 0.56% (1.2%) 
 
2.7 Validation of lattice tissue model 
A lattice tissue model was implemented in MCNPX to investigate tissue 
heterogeneity effects. For the clinical simulations using tissue models in this 
study an 8cm x 8cm x8cm lattice was defined, centered on the mean source 
co-ordinate implant. Lattice voxels were 1mm x 1mm x 1mm. MCNPX 
allows each voxel to be assigned to a particular tissue type. Other geometry 
can be superimposed on the lattice, for example for 125I simulations, the 
seeds are defined independently of the lattice and MCNPX automatically 
removes any parts of lattice voxels that are overlaid by a seed. The lattice 
model was validated by comparing simulations for identical geometries 
created with and without the lattice, as described in this section.  
 
Method 
For the 5 patients described in section 2.5, simulations were performed 
firstly using a simple spherical water phantom of radius 15cm and then 
using the lattice, filled with water, embedded in the same spherical water 
phantom. Everything else was identical between the simulations, so any 
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differences in the results would be entirely due to use of the lattice model. 
Simulations used 2 million histories per seed. 
 
Results 
Tally results from the two simulations were not identical, but the average 
difference in DVH parameter values was <0.1% for prostate D90, V100, 
V150, V200, urethra D10 and rectum D2cm3. Analysis of individual tally 
cell differences showed that inside the prostate, on average (across the 5 
patients) 73.2% of cells agreed within 1%, 94.5% of cells agreed within 2% 
and 100% of cells agreed within 5%. The average difference across all 
prostate tally cells was <0.1%. 
 
Conclusion 
Implementation of the lattice model causes differences in tally results but 
these appear to be purely statistical in nature, have no impact on DVH 
parameter values and are assumed to result from details of the MC code 
implementation. 
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3 Experimental validation of multi-source MC 
simulations 
This section describes experimental dosimetry work with a phantom which 
was performed to verify the results of MC simulations using multiple 
sources and measure ISA independently from the MC simulation. Phantom 
measurements were performed for 6711 and 9011 sources.  
3.1 Introduction 
Experimental dosimetry is an accepted method for brachytherapy source 
characterization (3), and the majority of experimental brachytherapy 
dosimetry studies are on single source measurements. Although Meigooni et 
al (114) measured ISA in simple seed arrangements using 
thermoluminescent dosimeters (TLDs) in a solid water phantom, other 
studies measuring ISA in phantom and clinical scenarios have used MC 
simulation without any further validation(43, 115-119). In this study 
experimental dose rate measurements are performed with a MOSFET in a 
phantom with the purpose of measuring ISA experimentally and validating 
the MC simulation framework results for simulations with multiple sources. 
MOSFET response is energy dependent so to avoid having to apply 
corrections for energy dependent response, in this study MOSFET 
calibration was performed using the 125I sources used for the measurements. 
 
 
Solid phantom materials are not water equivalent for low energy 125I 
dosimetry (41), so a MC calculated correction is required to convert 
experimental measurements to dose to water measurements. For this study, 
this was achieved by comparing measured dose rates to results from MC 
simulations performed in the phantom material. In addition, as MOSFET 
response is energy dependent, so would require corrections if the radiation 
energy spectrum changed with distance from the source, simulations were 
performed to calculate the energy spectrum at each measurement position. 
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3.2 Initial ISA modeling 
To provide some basic background information for phantom design, the ISA 
effect was measured for simple two seed arrangements. 
 
Method 
 
Figure 7 Seed arrangements for two seed ISA MC simulations 
Simulations were performed using the methodology described in 2.1 for two 
seeds placed close to the centre of a 15cm radius water phantom. To 
measure ISA along the transverse axis, simulations were performed with the 
transverse source axes aligned, with centre to centre seed separation 0.5cm, 
1cm and 1.5cm and dose was tallied in 1mm3 cells along the transverse 
source axes (Figure 7(a)). To measure ISA along the longitudinal axis, 
simulations were performed with longitudinal axes aligned and centre to 
centre seed separation 1cm and dose was tallied in 1mm3 cells along the 
longitudinal source axes (Figure 7(b)). Simulations were performed for 
6711 and 9011 seeds. The simulation results were compared to dose 
calculated by superposing dose due to the two seeds individually (from 
single seed simulations described in 2.2, so ignoring the ISA effect. 
 
Results 
For two seeds arranged with transverse axes aligned, Figure 8 (6711 seeds) 
and Figure 9 (9011 seeds) show how the ISA effect along the source 
transverse axis varies with source separation and distance (the distance is as 
measured from either seed, in the direction away from the other seed). For 
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two seeds arranged with longitudinal axes aligned and separation 1cm, the 
ISA effect along the source longitudinal axis was between 2-4%, did not 
vary greatly with distance from the source and was similar for the 6711 and 
9011 seed models. 
 
Conclusion 
The results show that the ISA effect due to two sources will be easiest to 
measure if source transverse axes are aligned, if the distance between the 
sources is decreased and at a distance 1-2cm from the source pair. At 
smaller distances from the source pair the dose due to the nearest seed 
dominates so that the ISA effect becomes hard to measure.  
 
Attenuation with distance from outer edge of two 6711 seed 
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Figure 8 Variation of ISA on the source transverse axis with source separation and 
distance for two 6711 seeds 
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Attenuation with distance from outer edge of two 9011 seed 
arrangement
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Figure 9 Variation of ISA on the source transverse axis with source separation and 
distance for two 9011 seeds 
 
3.3 Phantom work 
3.3.1 Method 
MC simulations 
Based on the results described in 3.2, a phantom was designed for 
experimental ISA measurements, with source positions a compromise 
between the positions at which the maximum ISA effect can be observed, 
and the need to reduce the distance between the source and the MOSFET to 
reduce dose rate related measurement uncertainties. The phantom is 
described in detail below. 
 
MC simulations of all phantom seed arrangements (described below) were 
performed using the methodology described in 2.1 and using the complete 
phantom geometry including all air holes. The composition of polymethyl 
methacrylate (PMMA) was taken as C5H8O2 with density 1.19 g cm-3 (41). 
The expected dose at the MOSFET position was calculated using a 0.5 mm 
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diameter spherical water cell (MCNPX F6 tally(101)). Energy spectrum 
calculations used a 1 mm diameter spherical surface (MCNPX F1 
tally(101)) at the MOSFET position, with photon energies in the range 0 
keV to 40 keV tallied in 2.5 keV bins. 
 
Seed calibration 
36 6711 and 36 9011 seeds were first calibrated in a well chamber with 
calibration traceable to the National Institute of Standards and Technology. 
Seeds were then stored in separate pots based on the measured SK and in 
subsequent measurements the expected dose rate was determined from the 
mean SK of the seeds used in that particular measurement. 
 
PMMA phantom design and measurements 
A PMMA phantom was designed for MOSFET commissioning and dose 
rate measurements to assess the ISA effect. The phantom is a 13 cm x13 cm 
x 13 cm PMMA block with swappable inserts that can be placed at the 
centre of the phantom to allow different seed configurations to be tested, 
and a 1.5 mm diameter hole drilled to allow a high sensitivity micro 
MOSFET dosimeter (Best Medical TN-1002RDM), operated under high 
bias to increase sensitivity, to be inserted (see Figure 10). Separate inserts 
were manufactured for 6711 and 9011 seeds. The seed holes are 5 mm deep 
and 0.9 mm diameter for 6711, 0.6 mm diameter for 9011. In any 
measurement, the seeds closest to the MOSFET will contribute most to the 
measured dose rate. This will lead to uncertainties due to small differences 
in individual seed SK from the mean SK and non-uniformities in the 
distribution of radioactive material on individual seeds. To reduce these 
uncertainties each MOSFET measurement result presented in this study is 
the mean of 4 independent measurements (all seeds were removed and 
randomly replaced). An accumulated dose of ~10 cGy was acquired for each 
measurement. Dose rate ranged from 2 cGy h-1 to 23 cGy h-1. Measurement 
duration ranged from 25 minutes to 5 hours. All measurements were 
corrected for source decay and background readings. For all measurements 
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the MOSFET bulb was oriented towards the front face of the phantom 
(which was identified by red dot markers – visible in Figure 10). 
 
 
Figure 10 The PMMA phantom used for MC simulation verification, with MOSFET 
inserted 
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Figure 11 Phantom seed configurations for MOSFET commissioning. The seed 
configuration for MOSFET calibration is shown in (a) the plane transverse and (b) 
the plane parallel to the seed longitudinal axis. (c)-(f) show the seed and detector 
positions for MOSFET polar angle anisotropy measurements. 
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MOSFET commissioning 
(i) For MOSFET calibration, 4 seeds were placed 1 cm from the MOSFET 
as shown in Figure 11(a) and (b). The dose rate for calibration 
measurements was ~4 cGy h-1. Calibration was repeated for every 1000 mV 
increase in MOSFET threshold voltage to assess fade in response. This gave 
13 separate calibration measurements in total. Both 6711 and 9011 sources 
were used in the calibrations. 
(ii) Azimuthal anisotropy of MOSFET response was neglected as the 
phantom seed configurations were designed to negate any anisotropic 
effects (see below). Polar angle anisotropy was assessed using 4 seeds with 
the MOSFET placed out of the plane of the seeds to create approximate 
polar angles of 30°, 60°, 90°, 120° and 150° between the MOSFET and the 
centre of each seed, as shown in Figure 11(c)-(f). (Polar angle 90° is the 
calibration position shown in Figure 11(a) and (b).) The measured dose rates 
were compared to MC simulation results for each detector position.  
(iii) As MOSFET response is energy dependent, all measurements including 
calibration were performed with I-125 seeds. However measured ISA values 
could still be affected by variations in the energy spectrum due to 
differences in source-detector distance in the PMMA phantom, or due to the 
fact that seeds may cause energy spectrum changes as well as dose 
attenuation. This was assessed using MC simulation to calculate the energy 
spectrum at the MOSFET position for each measurement configuration.  
 
Phantom dose rate and ISA measurements 
Measurements were made in configurations of 8 or 36 seeds arranged 
symmetrically around the MOSFET in two groups, inner and outer. ISA is 
measured by comparing the measured dose rate from all seeds together to 
the sum of the dose rates measured with the inner seed group alone and the 
outer seed group alone. By this method the scatter between seeds within 
either group is not accounted for, but is assumed to be negligible compared 
to seed attenuation at the MOSFET position. The seed configurations are 
designed to achieve a measurable ISA effect, remove any effects of 
58 
 
MOSFET azimuthal anisotropy, maximize the dose rate and reduce the dose 
gradient at the MOSFET position. 
 
In the 8 seed configuration there are 4 seeds at 1 cm (inner group) and 4 
seeds at 1.5 cm (outer group) from the MOSFET as shown in Figure 12(a) 
and (b). The 36 seed configuration has 3 blocks, each block having 6 seeds 
0.6 cm (inner group) and 6 seeds 1.2 cm (outer group) from the centre, as 
shown in Figure 12(c) and (d). Blocks are spaced 1 cm apart in the direction 
of the seed longitudinal axis to replicate seed separation in clinical implants, 
with the MOSFET at the centre of the middle block.  
 
Figure 12 Phantom seed configurations for ISA measurements. The 8 seed 
measurement configuration is shown in (a) the plane transverse and (b) the plane 
parallel to the seed longitudinal axis. (c) and (d) show the same views for the 36 seed 
configuration 
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3.3.2 Results 
Seed calibration 
From the well chamber seed calibration, after correction for decay, the mean 
seed SK was 0.863 U (range 0.832 U to 0.894 U). The reference SK provided 
by the manufacturer was 0.859 U.  
 
MOSFET commissioning 
(i) In the calibration seed configuration (Figure 11 (a) and (b)) the expected 
dose contribution from each of the 4 seeds is the dose rate constant (from 
TG-43U1(3) for 6711 and from Kennedy et al(106) for 9011) multiplied by 
the seed SK and a factor of 1.11 to correct for reduced attenuation in PMMA 
compared to water (from Luxton et al (120), this was also verified by MC 
simulation comparing water and PMMA dose rates). This gives a MOSFET 
sensitivity coefficient of 30.9 mV cGy-1 (mean of 13 measurements). 
Comparison of MC simulation of the calibration seed configuration to 
measured dose rates gave a sensitivity coefficient of 30.3 mV cGy-1. As the 
two sensitivity coefficients are in close agreement, the coefficient derived 
from MC simulation was used for consistency. Fade in response was <1% 
over the complete set of measurements during which the MOSFET 
threshold voltage increased from 4000 mV to 17000 mV.  
(ii) Polar angle measurements showed that the MOSFET under-responds 
relative to the MC simulation predicted dose rate by 6.7% at polar angle 30° 
and by 7.1% at 60°. Response is within 1% of expected values at 90°, 120° 
and 150°. 
(iii) Table 15 shows the calculated energy spectrum in each measurement 
configuration, compared to reference data from Chen and Nath (121). The 
mean energy for each configuration is also shown. The results for the 9011 
seed were very similar so are not presented - the mean energy in each 
configuration for the 9011 seed was <1% different from the value for the 
6711 seed. As there is no significant spectral variation across the set of 
measurement configurations, no corrections for MOSFET energy dependent 
response were applied in this study. 
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Table 15 The MC calculated energy spectrum and mean energy for each measurement 
configuration  compared to reference data from Chen and Nath (121).  Energy bins 
with <1% of the calculated spectrum are not included. Note the mean energy is taken 
directly from the MC simulation output and not calculated from the energy spectrum 
data. 
Photon 
energy bin 
(keV) 
6711 source 
reference data 
(121) 
Calculated energy spectra 
8 seeds 36 seeds 
inner 
group 
outer 
group 
inner + 
outer 
inner 
group 
outer 
group 
inner + 
outer 
20-22.5 15.3% 13.6% 12.7% 13.3% 13.3% 12.5% 13.0% 
22.5-25 4.3% 10.2% 11.7% 12.2% 9.6% 11.8% 10.3% 
25-27.5 61.4% 56.5% 55.2% 54.7% 57.2% 55.4% 56.5% 
27.5-30 - 3.4% 4.2% 4.2% 3.0% 4.2% 3.5% 
30-32.5 15.3% 12.2% 11.6% 11.6% 12.7% 11.8% 12.2% 
35-37.5 3.7% 3.3% 3.0% 3.0% 3.5% 3.0% 3.3% 
        
Mean 
energy 
6711 (keV) 
26.7 26.9 26.9 26.8 
 
27.0 26.8 26.9 
 
Phantom dose rate and ISA measurements 
 
Table 16 lists the uncertainties of measurements in this study. Sources of 
uncertainty include the calibration of the well chamber used for seed 
calibration, the uncertainty associated with repeat MOSFET measurements 
(for all measurements including calibration), MOSFET position errors 
resulting in uncertainties due to dose gradients and MC simulation 
uncertainties. Repeat measurement uncertainties are derived from the 
standard deviation of each set of measurements and will be caused by 
inconsistency in MOSFET response, variations in seed construction and 
seed SK, variations in distribution of radioactive material within the seed and 
movement of internal seed components. The repeat measurement 
uncertainty increased with decreasing dose rate and was lowest (2.5%, k=1) 
for the full 36 seed configuration and highest (5.2%, k=1) for the outer seed 
group in the 8 seed configuration. TG-43U1(3) data was used to determine 
the dose rate uncertainty due to the MOSFET position errors (estimated to 
be <=0.2 mm); this uncertainty is small as the phantom design reduces the 
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dose gradient around the measurement position. The MC simulation 
uncertainty is a combination of statistical uncertainty (<1% in all cases) and 
uncertainties associated with the MC simulation code (<1% up to 5 cm from 
a seed (122)). Phantom composition uncertainty will affect calibration and 
measurement MC simulations equivalently and is assumed to be small 
relative to the other uncertainties. Uncertainty in the polar angle anisotropy 
correction was not included as the effect of the correction itself is small (see 
below). 
 
Table 16 Uncertainty analysis for MOSFET measurements 
Description Uncertainty (k=1) 
 
MOSFET Calibration 
 
Well chamber calibration certificate uncertainty 1.2% 
MOSFET calibration measurement uncertainty  3.6% 
Dose rate uncertainty due to MOSFET position uncertainty <1% 
MC simulation uncertainty  2% 
 
MOSFET measurement/comparison to MC simulation 
 
MOSFET repeat measurement uncertainty (varies with measurement 
configuration, increasing for lower dose rate configurations) 
2.5% to 5.2% 
Dose rate uncertainty due to MOSFET position uncertainty 1% 
MC simulation uncertainty 2% 
  
Total 5.5% to 7.2% 
 
 
Table 17 compares MC simulated and MOSFET measured dose rates and 
ISA values (mean of 4 measurements, normalised to SK 1U) in each of the 
phantom seed configurations for 6711 and 9011. A correction for polar 
angle anisotropy has been applied to the 36 seed MOSFET measurements. 
The polar angle anisotropy results indicate that the MOSFET will under-
respond to the dose contribution of the upper seed block by ~7% (no 
correction is required for middle and lower seed blocks). The proportion of 
the total dose (from all 3 blocks) contributed by the upper block at the 
MOSFET position is 27%, 21% and 17% for outer seed group alone, inner 
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and outer groups together and inner seed group alone respectively (derived 
from MC simulations of each block separately). This gives corrections 
(increase) of 1.9%, 1.5% and 1.2% for these measurements respectively. 
 
Table 17 Comparison of MC simulated (MC) and phantom measured (Expt) dose 
rates and percentage ISA. ISA is calculated as the ratio of the full seed arrangement 
dose rate to the sum of the inner and outer seed group dose rates. All dose rates are 
normalised to SK 1U. 
 Sum of the 
individual dose rates 
from Inner and 
Outer seed groups 
(cGy h-1 U-1) 
Full seed arrangement 
dose rate (cGy h-1 U-1) 
 ISA  
Measurement MC Expt % diff MC Expt % diff MC  Expt  
6711 8 seeds  6.27 6.29 +0.3% 5.12 5.06 -1.2% -18.3% -19.6% 
9011 8 seeds  6.10 6.05 -0.8% 5.08 5.14 +1.2% -16.7% -15.0% 
6711 36 seeds 31.3 32.0 +2.2% 28.6 28.7  0.3% -8.63% -10.3% 
9011 36 seeds 30.9 30.8 -0.3% 28.5 28.0  -1.8% -7.77% -9.1% 
3.3.3 Discussion 
Multiple seed MC simulation results agreed with phantom MOSFET 
measurements in terms of both dose rate and the magnitude of the ISA 
effect within the estimated level of uncertainty for all seed configurations. 
This provides additional validation of the MC simulation framework beyond 
the single seed benchmarking work. The results presented are for the mean 
of 4 independent measurements; individual measurements show variations 
up to ±7% from MC values which could be due to inconsistency in 
MOSFET response, variations in seed SK across the batch of seeds used, 
variations in the distribution of radioactive material in individual seeds, and 
MOSFET positioning errors. The uncertainty analysis shows that 
uncertainty increases as dose rate decreases. The lowest uncertainty in this 
study, 5.5% (k=1), was for the mean of 4 measurements at a dose rate of 23 
cGy h-1. In a clinical implant dose rates are 7 cGy h-1 to 14 cGy h-1, 
positional uncertainties would be greater and it would not be practicable to 
perform independent repeat measurements, suggesting that the MOSFET 
would not be suitable for in-vivo dose rate measurements of this sensitivity.  
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Fade in MOSFET response with accumulated dose was observed to be 
insignificant, perhaps because the measurements began after 4000 mV (out 
of the total MOSFET lifetime of 20000 mV) had already accumulated, as 
fade has been observed to be most significant early in the lifetime of the 
MOSFET(123). A small amount of polar angle anisotropy was observed, 
likely caused by the non-uniform shape of the MOSFET bulb, and the 
presence of the MOSFET cable and radio-opaque marker above the 
MOSFET bulb. Azimuthal anisotropy of MOSFET response was neglected 
due to the geometry of the phantom seed configurations but would need to 
be investigated and included in the uncertainty budget for in-vivo 
measurements. Note that all MOSFET commissioning was performed using 
I-125 sources and the results can not necessarily be applied to higher energy 
photons due to the energy dependence of MOSFET response. For higher 
energy photons it would be necessary to correct for spectral variations 
within the phantom, which were found to be insignificant for the I-125 
sources used in this study. 
 
A study by Meigooni et al. (114) used TLDs in a solid water phantom with 
model 6702 and 6711 seeds and found ISA ranging from 6 % to 12% in 
non-clinical configurations of either 3 or 18 seeds. Other studies of non-
clinical seed arrangements have used MC simulation to evaluate ISA. Burns 
and Raeside3 found ISA up to 10% for 2 and 4 seed implants,  Mobit & 
Badragan7 simulated uniformly spaced implants of 27 seeds and found 10% 
ISA, and Zhang et al.(119) simulated a spherical prostate gland implanted 
with 48 symmetrically placed seeds and measured ISA of up to 7.5%. One 
of the objectives of this study was to measure the ISA effect in a phantom 
using a MOSFET, so the phantom was designed to maximize the ISA effect; 
this is why some of the ISA values reported in this study (up to 18.3%) are 
higher compared to previous studies. The ISA effect is lower for the 9011 
seed compared to 6711; this is demonstrated both by MC simulations and 
the phantom measurements (although for phantom measurements the 
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difference is smaller than the measurement uncertainty). This is discussed 
further in 4.1.4. 
3.3.4 Conclusion 
MOSFET phantom measurements have successfully validated the MC 
simulation framework in terms of dose measurements and measurements of 
the ISA effect. The ISA effect is lower for the 9011 seed compared to the 
6711 seed. The MOSFET has quite a high uncertainty level for LDR dose 
rate measurements and it would not be possible to measure the ISA effect 
in-vivo for LDR seed implants.
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4 Clinical I-125 investigations 
This section describes an MC simulation investigation to assess the effects 
of ISA and tissue heterogeneity on clinical 125I implant dose distributions. 
ISA and tissue effects are compared to other uncertainties in 125I implant 
brachytherapy, and assessed for both TRUS based implant plans and CT 
based post-implant plans. Tissue models based on delineated structures are 
compared to models based on CT density data, and CT based models are 
applied to patients with calcifications. Dose differences are assessed in 
terms of DVH parameters and analysed by prostate sector. The ISA effect is 
compared for 6711 and 9011 sources. 
4.1.1 Introduction 
The TG-43U1 (3) algorithm used for dose calculation routine clinical I-125 
seed implant prostate brachytherapy ignores ISA and tissue composition 
effects that can cause differences between the true dose distribution and TG-
43U1 (39). Several studies have investigated the impact of ISA and tissue 
effects in phantom and clinical scenarios (43, 113-119, 124-127). However 
only one study, by Carrier et al. (116),  has investigated more than a small 
number of clinical cases. In this study, the impact of ISA and tissue effects 
on clinical dose distributions is assessed by comparing MC simulations to 
TG-43U1 dose calculations for 40 prostate brachytherapy patients. Results 
are compared for TRUS based implant plans and CT based post-implant 
plans. Sector analysis is applied to investigate whether ISA and tissue 
effects are uniform or localised to certain sectors of the prostate. Different 
tissue models are compared: a water based model (to evaluate ISA alone), a 
simple contour based tissue model and a model based on CT density data. 
The ISA effect has been shown to depend on seed design (128) and in this 
study the 6711 and 9011 models are compared. The 9011 has 0.5 mm 
diameter compared to 0.8 mm for 6711. Section 2.2 shows the seed models 
in detail. Chibani et al. (113) investigated the effects of calcifications on 
prostate dosimetry in a study where 1% - 5% of prostate voxels were 
randomly assigned to calcified tissue. In this study, the impact of localised 
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calcifications on dosimetry was assessed for patients with visible calcified 
regions in post-implant CT data, using a tissue model where calcified 
regions are assigned to a mixture of prostate and calcification based on CT 
density values. 
4.1.2 Methods 
Clinical datasets 
Two groups of patients were selected for this study. To allow the effect of 
calcifications to be assessed separately from other tissue effects, 30 patients 
were selected from recent consecutive cases excluding patients with visible 
calcification in the post-implant CT data. Then CT datasets from the last 
100 patients treated were reviewed, all visible regions of calcification were 
segmented and the 10 patients with the largest volume of calcification in 
post-implant CT data were selected. All patients had been treated by the 
interoperative preplanned technique, as defined by TG-137 (13). All 
treatments used stranded 6711 seeds (Oncura, a Unit of GE Healthcare, 
Chalfont St. Giles, UK) with mean SK of 0.434 U (range 0.379 U to 0.496 
U) and prescribed dose of 145 Gy. At implant, the key planning objectives 
for the TRUS based plan are prostate V100 > 99.8%, prostate V150 55% - 
60%, prostate D90 > 185 Gy, PTV V100 > 95%, rectal D2cm3 < 145 Gy 
and urethral D10 < 239 Gy (this is a local dose limit different from GEC-
ESTRO recommendations (14)). The TRUS plan PTV is the prostate +3mm 
(0mm posteriorly) and is equivalent to the clinical target volume (CTV) 
defined in the GEC-ESTRO recommendations (14). All patients had a post-
implant CT scan after 4 - 6 weeks and prostate, urethra and rectum contours 
were delineated on the CT data by a consultant radiologist. 
 
Overview of dosimetric comparisons 
The patient datasets described above were used to perform the following 
dosimetric comparisons: 
 
Comparison of TRUS implant and CT post-implant TG43 dose distributions 
Post-implant dosimetry studies generally show that the dose received by the 
patient is lower than that planned at implant due to seed migration, prostate 
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oedema and other uncertainties, discussed further in 4.1.4. To allow ISA and 
tissue effects on dose to be assessed in the context of these dose differences, 
DVH statistics calculated using the TG-43U1 (3) algorithm by the TPS from 
TRUS implant and CT post-implant plans are compared for the 30 patients 
without visible calcifications. 
 
Impact of differences between MC source models and TG-43U1 consensus 
data 
If MC simulations of clinical implants are compared to TPS TG-43U1 
calculations, in addition to ISA and tissue effects, there will be dosimetric 
differences due to differences between the MC source models and TG-43U1 
source consensus data, as discussed in 2.2. Minor differences also exist 
because of the TG-43U1 line source approximation and differences in the 
DVH calculation methods used in the TPS and the dose analysis framework, 
as demonstrated in 2.4. These effects are assessed separately from ISA and 
tissue effects for the 30 patients without visible calcifications by comparing 
TG-43U1 dose distributions calculated by the TPS to superposition dose 
distributions calculated using the MC single source dose distributions. 
 
Assessment of ISA and tissue effects  
The magnitude of ISA and tissue effects was evaluated in TRUS based 
implant plans and CT based post-implant plans for 30 patients without 
visible calcifications. Plans were simulated in a water phantom to assess 
ISA alone, and in a structure based tissue model. CT based post-implant 
plans were also simulated using a CT based tissue model and the results 
compared to the structure based tissue model simulations.  
 
Assessment of the dosimetric effects of calcifications 
To allow the impact of calcifications to be assessed, for the 10 patients with 
visible calcifications, CT based post-implant plans were simulated using CT 
based tissue models and structure based tissue models (that ignore 
calcifications).  
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Comparison of the ISA effect for 6711 and 9011 seed models 
To compare the ISA effect for 6711 and 9011 seed models, CT based post-
implant plans were simulated in a water phantom using 6711 and 9011 seed 
models. This comparison was restricted to the first 15 of the 30 patients 
without visible calcifications. 
 
Dose distributions 
The following describes the dose distributions that were compared in this 
investigation:  
(i) Dose distributions calculated by the TPS using TG-43U1 (3) 
consensus data and the 2D formalism. The TPS calculates dose on 
a 0.25 mm x 0.25 mm grid on each slice in the dataset (2mm 
spacing for CT and 5mm for TRUS). 
(ii) A superposition dose calculated by summing across all seed co-
ordinates the dose from a single seed MC simulation in a water 
phantom. This excludes ISA and tissue effects but uses the same 
source as in MC simulations of implants, so that comparisons are 
not affected by any differences between the MC source and TG-
43U1 consensus data. This dose distribution is referred to as MC-
SUP.  
(iii) An MC simulation of all the seeds implanted in a uniform water 
phantom, to investigate ISA and exclude tissue effects. This dose 
distribution is referred to as MC-ISA. 
(iv) An MC simulation of the seeds implanted in a simple prostate tissue 
model based on delineated structures. This dose distribution is 
referred to as MC-STR-TISSUE. 
(v) An MC simulation of the seeds implanted in a tissue model based on 
the post-implant CT density data. This dose distribution is 
referred to as MC-CT-TISSUE. 
 
MC simulation methods 
For MC simulation of each plan, the seed coordinates and structure sets 
were exported from the TPS - VariseedTM v8.0 (Varian Medical Systems, 
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Inc., Palo Alto, CA, USA). Dose calculation from MC simulation results, 
DVH parameter calculation and all further analysis described below was 
performed as described in 2.4.  
 
Monte Carlo framework 
MC simulations were performed as described in 2.1, using phase space 
source models (see 2.5). Typical plan simulation time was ~20 hours on a 
Windows 7TM (Microsoft Corporation, Redmond, WA) PC with Intel® 
(Intel Corporation, Santa Clara, CA) i7-2600 CPU @ 3.4 GHz. All seeds 
were assumed to be oriented perpendicular to the plane of the CT or TRUS 
slices. For MC-ISA simulations the seeds were placed in a 20 cm radius 
water phantom centered at the mean seed co-ordinate. For tissue model 
simulations an 8 x 8 x 8 cm3 lattice with 1 mm3 voxels was defined, 
centered at the mean seed co-ordinate and placed inside a 20 cm radius 
water phantom. For MC-STR-TISSUE simulations, each lattice voxel inside 
the prostate contour was assigned to prostate tissue; all other voxels in the 
lattice were assigned to mean male soft tissue, using the tissue composition 
and densities recommended in TG-186 (40) Table III (density values are 
1.04 gcm-3 for prostate and 1.03 gcm-3 for mean male soft tissue). A model 
of the 6711 seed (126) was placed over the lattice at each seed co-ordinate. 
MCNPX automatically handles partial voxels by removing parts of lattice 
voxels that are overlaid by a seed. 
 
CT density based simulations 
For MC-CT-TISSUE simulations, each lattice voxel was assigned density 
and tissue composition based on the CT post-implant dataset as follows. 
First the mean CT Hounsfield unit (HU) value for each voxel was 
calculated. Voxel physical densities were assigned from HU values using 
the HU/electron density calibration curve for the CT scanner, with physical 
density calculated as -0.1746 + 1.176*(electron density) (40). Physical 
density values were rounded to the nearest 0.02 gcm-3 to simplify the 
MCNPX input model. Inside the prostate contour, voxels with HU less than 
200 (density 1.2 gcm-3) were assigned to prostate tissue, voxels with HU 
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greater than or equal to 200 were assigned to be a mixture of prostate tissue 
and calcification with the relative proportions determined from the voxel 
density, assuming prostate tissue density 1.04 gcm-3 and calcification 
density 3.06 gcm-3. Outside the prostate contour, voxels with HU less than 
200 were assigned to mean male soft tissue, voxels with HU greater than or 
equal to 200 were assigned to bone. This HU threshold was determined 
from visual inspection to achieve accurate segmentation of bone in the CT 
datasets. Tissue composition and density values recommended in TG-186 
(40) Table III were used for prostate, mean male soft tissue and bone. The 
composition of calcification was taken from values for breast calcification 
in TG-186 (40) Section IV.B.1.c. 
 
As explained above, the physical MC seed model is overlayed on the tissue 
lattice at each seed co-ordinate. Therefore the CT HU values associated with 
each seed were replaced in the tissue model as follows. For each seed co-
ordinate in turn, all voxels within 2mm of the seed co-ordinate were 
replaced with the mean HU value of the immediately surrounding voxels 
(129). This removes the seed HU values and the CT artifact associated with 
each seed, although some streaking artifacts remain. Following replacement 
of the seed HU values, density and composition of the affected lattice voxels 
were assigned as described above. 
 
Dose calculation 
For all MC simulations, dose to the medium used for the simulation (water 
for MC-ISA and tissue for MC-STR-TISSUE and MC-CT-TISSUE) was 
calculated over an 8 x 8 x 8 cm3 cube centered at the mean seed co-ordinate. 
The MCNPX mesh tally was used with tally results converted to dose using 
the method described in 2.1.3. Each tally cell was 1 mm3. DVH calculation 
was based on the slices used in the original TPS post-implant plan (2mm 
slice spacing for CT, 5mm for TRUS). 2 million particle histories per seed 
were simulated to reduce the mean statistical component of uncertainty in 
individual tally cells below 1% inside the prostate and below 2% inside the 
rectum in all cases. 
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Analysis of dose differences 
DVH statistics were calculated for the prostate, urethra and rectum, and for 
the PTV in TRUS plans (13) (14). For CT post implant plans, DVH 
statistics were also calculated for the volume enclosed by the 100% isodose 
in the MC-SUP dose distribution (hereafter referred to as ‘MC-SUP 100% 
VOL’). This volume was investigated because a PTV is not added in post-
implant plans and poorer contrast between prostate and other tissue in CT 
compared to TRUS may lead to differences in prostate delineation such that 
the CT prostate volume may not accurately reflect the intended implant 
volume (130). A sector analysis of the results was performed using the  
method devised by Bice et al. (131): the prostate was divided superior-
inferior into 3 segments: base, mid-gland and apex. Then each segment was 
divided into 4 quadrants, anterior, left, right and posterior. V100 values 
were calculated for each segment and for each dose distribution. In addition 
the seed density and volume of calcification in each sector were calculated. 
For the 30 patients without visible calcifications, statistical correlation tests 
were performed to investigate whether there was any correlation between 
the magnitude of the ISA and tissue effect on CT post-implant prostate D90, 
and the following parameters: prostate volume, prostate D90, seed density 
and the magnitude of the ISA and tissue effect on prostate D90 in the TRUS 
implant plan. 
4.1.3 Results 
Across all 40 patients, the mean prostate volume was 34.1 cm3 (range 14.3 
cm3 to 56.0 cm3). The mean number of seeds used was 84.2 (range 52 to 
112). Mean seed density was 2.6 seeds/cm3 (range 1.9 seeds/cm3 to 3.6 
seeds/cm3). 
 
Comparison of TRUS implant and CT post-implant dose distributions 
The change in DVH values from the original TRUS implant plans to the 
values post-implant, for the 30 patients without calcifications, due to 
differences in seed positions and contoured anatomy, can be seen in Table 
18 by comparing the TRUS TG43 and CT TG43 columns. These DVH 
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values are calculated using TG-43U1 (3) by the TPS, and the results are for 
the 30 patients without calcifications. 
 
Table 18 Mean DVH values for 30 patients, for dose distributions that ignore tissue 
and ISA effects. Absolute differences are shown with percentage differences in 
parentheses. 
Structure DVH  
Parameter 
TRUS 
TG43 
CT 
TG43 
Difference 
to  
TRUS-
TG43 
CT  
MC-SUP 
Difference 
to  
CT-TG43 
 
 
     
Prostate Volume 
(cm3) 
35.0  33.2 - 33.2  - 
 D90 (Gy) 185.0 149.8 -35.2 (-
19.0%) 
144.8 -5.0 (-
3.3%) 
 D98 (Gy) 170.3 115.2 -55.1 (-
32.4%) 
111.0 -4.2 (-
3.6%) 
 V100 (%) 99.9 91.0 -8.9 (-
3.0cm3) 
89.6 -1.4 (-
0.5cm3) 
 V150 (%) 58.9 61.0 2.1 
(0.7cm3) 
57.6 -3.4 (-
1.1cm3) 
 V200 (%) 19.5 30.5 11.0 
(3.7cm3) 
28.0 -2.5 (-
0.8cm3) 
       
Urethra D10  (Gy) 214.9 248.1 33.2 
(15.4%) 
243.6 -4.5 (-
1.8%) 
       
Rectum D2cm3  
(Gy) 
95.3 112.5 17.2 
(18.0%) 
110.0 -2.5 (-
2.2%) 
     
 
 
PTV Volume 
(cm3) 
46.2 - - - - 
 D90 (Gy) 175.7 - - - - 
 V100 (%) 98.0 - - - - 
TRUS-TG43: Trans-rectal ultrasound implant plan TG-43U1 dose distribution. 
CT-TG43: CT post-implant plan TG-43U1 dose distribution. 
MC-SUP: Single MC source superposition dose calculation (excludes ISA and tissue 
effects). 
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Impact of differences between MC source models and TG-43U1 consensus 
data 
The impact of using the MC source model in the dose calculation for the 30 
patients without calcifications can be seen in Table 18 by comparing the CT 
TG43 and CT MC-SUP columns. These results are also affected by use of 
the line source model in TG43-U1, and differences in the DVH calculation 
method between the TPS and the dose analysis framework, but these effects 
were shown to be small in 2.4. 
 
Assessment of ISA and tissue effects 
 
 
Figure 13 Examples for a single patient comparing superposition dose distribution 
(MC-SUP) (solid isodoses) and MC simulation dose distribution (dashed isodoses) for 
the structure based tissue model (MC-STR-TISSUE). Slices are at the base (a), mid-
gland (b) and (c) and apex (d). The delineated prostate (red), urethra (yellow) and 
rectum (green) are also shown. 
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Table 19 Mean DVH values for 30 patients without visible calcifications, for clinical 
TRUS implant plans.  
Structure DVH  
Parameter 
DVH Parameter value Difference from MC-SUP 
 MC-
SUP 
MC-
ISA  
MC-STR-
TISSUE 
MC-ISA  MC-STR-
TISSUE 
       
Prostate Volume 
(cm3) 
35.0  - - - - 
 D90 (Gy) 177.3  173.7  173.1 -3.6 (-
2.0%) 
-4.2 (-2.4%) 
 D98 (Gy) 159.6 156.1 155.7 -3.5 (-
2.2%) 
-3.9 (-2.4%) 
 V100 (%) 99.8 99.5 99.5 -0.3 (-
0.1cm3) 
-0.3 (-0.1cm3) 
 V150 (%) 51.4 47.7 47.1 -3.7 (-
1.2cm3) 
-4.3 (-1.4cm3) 
 V200 (%) 19.0 17.7 17.7 -1.3 (-
0.4cm3) 
-1.3 (-0.4cm3) 
       
Urethra D10  (Gy) 216.1 211.4 209.6 -4.7 (-
2.2%) 
-6.5 (-3.0%) 
       
Rectum D2cm3  
(Gy) 
94.2 91.6 85.9 -2.6 (-
2.8%) 
-8.3 (-8.8%) 
       
PTV Volume 
(cm3) 
46.2     
 D90 (Gy) 163.2 159.2 152.0 -4.0 (-
2.5%) 
-11.2 (-6.9%) 
 V100 (%) 96.4 95.4 92.5 -1.0 (-
0.5cm3) 
-3.9 (-1.8cm3) 
MC-SUP: Single MC source superposition dose calculation (excludes ISA and tissue 
effects). 
MC-ISA: Dose from MC simulation in a water phantom (excludes tissue effects). 
MC-STR-TISSUE: Dose from MC simulation in a structure based tissue model. 
 
Figure 13 shows examples comparing isodoses for MC-SUP and MC-STR-
TISSUE dose distributions from TRUS based implant plans for a single 
patient. Table 19 summarizes the mean DVH parameter values for these 
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dose distributions in TRUS based implant plans for the 30 patients without 
visible calcifications. Across all 30 patients, for TRUS based implant plans 
the difference between MC-ISA and MC-SUP ranged from -1.5% to -2.8% 
for prostate D90, 0.0% to -0.8% for prostate V100, -0.4% to -3.6% for 
urethra D10, -2.0% to -3.7% for rectal D2cm3, -1.9% to -3.1% for PTV D90 
and -0.4% to -2.0% for PTV V100. The difference between MC-STR-
TISSUE and MC-SUP ranged from -1.5% to -3.2% for prostate D90, 0.0% 
to -1.0% for prostate V100, -1.3% to -4.8% for urethra D10, -7.8% to -9.7% 
for rectal D2cm3, -4.9% to -8.2% for PTV D90 and -2.3% to -5.8% for PTV 
V100. 
 
Figure 14 shows examples comparing isodoses for MC-SUP and MC-CT-
TISSUE dose distributions from post-implant CT plans for a single patient.  
The mean density of prostate tissue measured from CT data was 1.03 gcm-3.  
 
Table 20 summarizes the difference in DVH parameter values between the 
MC simulated dose distributions for these patients. Across all 30 patients, 
for CT-based post-implant plans the difference between MC-ISA and MC-
SUP ranged from -1.7% to -3.9% for prostate D90, -0.7% to -2.1% for 
prostate V100, -0.8% to -4.0% for urethra D10, -3.3% to -6.3% for rectal 
D2cm3, -2.5% to -5.6% for MC-SUP 100% VOL D90 and -3.6% to -5.4% 
for MC-SUP 100% VOL V100. The difference between MC-CT-TISSUE 
and MC-SUP ranged from -1.9% to -4.5% for prostate D90, -0.9% to -2.3% 
for prostate V100, -1.8% to -5.2% for urethra D10, -8.4% to -12.2% for 
rectal D2cm3, -6.3% to -10.3% for MC-SUP 100% VOL D90 and -8.3% to 
-11.5% for MC-SUP 100% VOL V100. For the comparison between MC-
STR-TISSUE and MC-CT-TISSUE, in the 30 patients without calcifications 
all DVH parameters agreed within ±1.5%. The mean density of prostate 
tissue measured from CT data was 1.03 gcm-3. 
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Figure 14 Examples for a single patient comparing superposition dose distribution 
(MC-SUP) (solid isodoses) and MC simulation dose distribution (dashed isodoses) for 
the CT density tissue model (MC-CT-TISSUE). Slices are at the base (a), mid-gland 
(b) and (c) and apex (d). The delineated prostate (red), urethra (yellow) and rectum 
(green) are also shown. 
 
For the 30 patients without visible calcifications statistical correlation tests 
showed no statistically significant correlation between the magnitude of the 
ISA and tissue effect on CT post-implant prostate D90, and any of the 
following parameters: prostate volume, prostate D90, seed density and the 
magnitude of the ISA and tissue effect on prostate D90 in the TRUS implant 
plan. 
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Table 20 Mean DVH values for MC simulated CT post-implant plans, for 30 patients 
without visible calcifications.  
Structure DVH  
Parameter 
DVH Parameter value Difference from MC- SUP 
MC- 
SUP 
MC-
ISA  
MC-
STR-
TISSUE 
MC-
CT-
TISSUE 
MC-
ISA  
MC-
STR- 
TISSUE 
MC-
CT- 
TISSUE 
         
Prostate Volume 
(cm3) 
33.2  - -  - - - 
 D90 (Gy) 144.8 140.9 140.1 
140.6 
-3.9 (-
2.7%) 
-4.7 (-
3.2%) 
-4.2 (-
2.9%) 
 D98 (Gy) 111.0 107.9 107.2 
107.6 
-3.1 (-
2.8%) 
-3.8 (-
3.4%) 
-3.4 (-
3.1%) 
 V100 (%) 89.6 88.3 88.0 
88.2 
-1.3 (-
0.4cm3) 
-1.6 (-
0.5cm3) 
-1.4 (-
0.5cm3) 
 V150 (%) 57.6 54.6 54.2 
54.2 
-3.0 (-
1.0cm3) 
-3.4 (-
1.1cm3) 
-3.4 (-
1.1cm3) 
 V200 (%) 28.0 25.5 25.4 
25.6 
-2.5 (-
0.8cm3) 
-2.6 (-
0.9cm3) 
-2.4 (-
0.8cm3) 
         
Urethra D10  (Gy) 243.6 236.7 235.4 235.0 -6.9 (-
2.8%) 
-8.2 (-
3.4%) 
-8.6 (-
3.5%) 
         
Rectum D2cm3  
(Gy) 
110.0 105.1 99.0 98.4 -4.9 (-
4.5%) 
-11.0 (-
10.0%) 
-11.6 (-
10.5%) 
         
MC-SUP  
100%  
VOL 
Volume 
(cm3) 
48.4 - -  - - - 
D90 (Gy) 158.4 152.7 145.7 145.5 -5.7 (-
3.6%) 
-12.7 (-
8.0%) 
-12.9 (-
8.1%) 
V100 (%) 100 95.7 90.5 90.3 -4.3 (-
2.1cm3) 
-9.5 (-
4.6cm3) 
-9.7 (-
4.7cm3) 
MC-SUP: Single MC source superposition dose calculation (excludes ISA and tissue 
effects). 
MC-ISA: Dose from MC simulation in a water phantom (excludes tissue effects). 
MC-STR-TISSUE: Dose from MC simulation in a structure based tissue model. 
MC-CT-TISSUE: Dose from MC simulation in a CT based tissue model. 
MC-SUP 100% VOL: The volume enclosed by the 100% isodose in the MC-SUP dose 
distribution. 
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Assessment of the dosimetric impact of calcifications 
For the 10 patients with calcification, the mean density of the voxels 
assumed to be mixed prostate/calcification was 1.41 gcm-3 (per-patient 
mean range was 1.32 gcm-3 to 1.49 gcm-3, individual voxel range was 1.30 
gcm-3 to 2.38 gcm-3). The mean volume of calcification for these 10 patients 
was 0.34 cm3 (range 0.1 cm3 to 1.43 cm3), compared to mean prostate 
volume of 36.9 cm3 (range 20.2 cm3 to 56.0 cm3). 
 
Figure 15 Examples for patients with visible calcifications comparing superposition 
dose distribution (MC-SUP) (solid isodoses) and MC simulation dose distribution 
(dashed isodoses). For (a) and (c), MC simulations used the simple tissue model 
ignoring calcificat ions (MC-STR-TISSUE), (b) and (d) show the same slices with MC 
simulations using the CT density tissue model accounting for calcifications (MC-CT-
TISSUE). The delineated prostate (red), urethra (yellow) and rectum (green) are also 
shown. 
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Table 21 Mean DVH values for MC simulated CT post-implant plans, for 10 patients 
with visible calcifications.  
Structure DVH  
Parameter 
DVH Parameter value Difference from MC-SUP 
MC-
SUP 
MC-STR-
TISSUE 
MC-CT-
TISSUE 
MC-STR-
TISSUE 
MC-CT-
TISSUE 
       
Prostate Volume 
(cm3) 36.9 
- - - - 
 D90 (Gy) 156.0 150.9 149.0 -5.1 (-3.3%) -7.0 (-4.5%) 
 D98 (Gy) 121.5 117.6 116.2 -3.9 (-3.2%) -5.3 (-4.4%) 
 V100 (%) 
92.5 91.3 90.6 
-1.2 (-
0.4cm3) 
-1.9 (-
0.7cm3) 
 V150 (%) 
59.3 55.7 55.2 
-3.6 (-
1.3cm3) 
-4.1 (-
1.5cm3) 
 V200 (%) 
28.7 26.0 26.5 
-2.7 (-
1.0cm3) 
-2.2 (-
0.8cm3) 
       
Urethra D10  (Gy) 
238.5 230.8 227.9 
-7.7 (-3.2%) -10.6 (-
4.4%) 
       
Rectum D2cm3  
(Gy) 
116.4 104.7 104.5 -11.7 (-
10.1%) 
-11.9 (-
10.2%) 
       
MC-SUP  
100%  
VOL 
Volume 
(cm3) 
53.4 - - - - 
D90 (Gy) 158.5 145.4 144.3 -13.1 (-
8.3%) 
-14.2 (-
9.0%) 
V100 (%) 100 90.3 89.5 -9.7 (-
4.7cm3) 
-10.5 (-
5.1cm3) 
MC-SUP: Single MC source superposition dose calculation (excludes ISA and tissue 
effects). 
MC-STR-TISSUE: Dose from MC simulation in a structure based tissue model (ignores 
calcifications). 
MC-CT-TISSUE: Dose from MC simulation in a CT based tissue model (includes 
calcifications). 
MC-SUP 100% VOL: The volume enclosed by the 100% isodose in the MC-SUP dose 
distribution. 
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Figure 15 compares isodoses illustrating the effects of calcifications, where 
(a) and (b) show an example where the calcification affects the 100% 
isodose, and (c) and (d) show an example where seed placement means that 
the calcification has little effect on the 100% isodose. Table 21 summarizes 
the DVH values from the dose distributions for the 10 patients with 
calcifications, for CT post-implant plans. MC-ISA results are excluded as 
these were similar to those shown in Table 2. The difference between MC-
CT-TISSUE and MC-SUP ranged from -2.7% to -7.4% for prostate D90, -
0.8% to -4.8% for prostate V100, -2.6% to -7.6% for urethra D10, -9.1% to 
-11.9% for rectal D2cm3, -7.5% to -10.2% for MC-SUP 100% VOL D90 
and -8.9% to -12.3% for MC-SUP 100% VOL V100. DVH parameter 
values were generally lower for MC-CT-TISSUE compared to MC-STR-
TISSUE, with maximum difference -3.6% for prostate D90, -2.9% for 
prostate V100, -4.0% for urethra D10. However prostate V200 values were 
higher for MC-CT-TISSUE compared to MC-STR-TISSUE, with maximum 
difference 1.2%. 
 
Sector analysis 
Sector analysis of TRUS based implant plans showed that ISA and tissue 
effects were very similar across all sectors, so results are not included here. 
Table 22 shows the results of sector analysis of the CT based post-implant 
plans for 30 patients without calcifications. The maximum reduction in 
V100 for any one patient in any prostate sector was -9.7% for the base 
anterior sector. For the 10 patients with calcifications the left, right and 
posterior base sectors had the highest percentage of calcification by volume 
with the maximum in any sector being 6.7%. The results of sector analysis 
for patients with calcifications were similar to those in Table 4 in terms of 
the pattern of V100 reductions across sectors, so are not included here. 
Overall each sector showed slightly higher reductions in V100 compared to 
patients without calcification with the base anterior sector having the 
highest mean (-6.4%) and maximum (-13.8%) reductions in V100.  
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Table 22 Sector analysis results (mean values) for 30 CT-based post-implant plans. 
Sector Base 
Ant 
Base 
Left 
Base 
Right 
Base 
Post 
Mid 
Ant 
Mid 
Left 
Prostate       
Sector volume (cm3) 1.8 2.2 2.2 1.5 3.2 4.1 
Seed density (seeds/cm3) 0.79 1.20 1.18 1.50 1.28 2.35 
       
MC-SUP V100 (%) 54.6 81.0 79.9 87.1 91.1 99.3 
MC-ISA V100 (%) 51.4 78.8 77.6 85.2 89.3 99.0 
MC-ISA – MC-SUP (%) -3.2 -2.2 -2.3 -1.9 -1.8 -0.3 
       
MC-CT-TISSUE V100 (%) 50.4 78.5 77.3 85.1 88.7 89.9 
 MC-CT-TISSUE – 
MC-SUP (%) -4.2 -2.5 -2.6 -2.0 -2.4 -0.4 
Sector Mid 
Right 
Mid 
Post 
Apex 
Ant 
Apex 
Left 
Apex 
Right 
Apex 
Post 
Prostate       
Sector volume (cm3) 4.2 2.7 2.3 3.4 3.3 2.4 
Seed density (seeds/cm3) 2.07 2.09 1.40 2.11 2.08 1.78 
       
MC-SUP V100 (%) 98.6 99.8 91.0 96.8 95.7 95.7 
MC-ISA V100 (%) 98.3 99.8 89.4 96.0 94.9 94.9 
MC-ISA – MC-SUP (%) -0.3 0 -1.6 -0.8 -0.8 -0.8 
       
MC-CT-TISSUE V100 (%) 98.2 99.6 89.0 95.9 94.8 94.7 
 MC-CT-TISSUE – 
MC-SUP (%) -0.4 -0.2 -2.0 -0.9 -0.9 -1.0 
MC-SUP: Single MC source superposition dose calculation (excludes ISA and tissue 
effects). 
MC-ISA: Dose from MC simulation in a water phantom (excludes tissue effects). 
MC-CT-TISSUE: Dose from MC simulation in a CT based tissue model. 
 
Comparison of the ISA effect for 6711 and 9011 seed models 
Table 23 compares the ISA effects for 6711 and 9011 seeds, using results 
from MC simulations in a water phantom, for the CT post-implant plans for 
the first 15 of the patients without visible calcifications. The range in values 
for the ISA effect across all 15 patients for 6711 were prostate D90 -2.2% to 
-3.9%, urethra D10 -2.0% to -13.9% and 100% sup dose volume D90 -3.0% 
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to -5.8%. For 9011 the range in values for ISA effect were prostate D90 
-1.2% to -1.9%, urethra D10 -0.7% to -12.3% and 100% sup dose volume 
D90 -1.5% to -3.0%. 
 
Table 23 Mean DVH values for 15 clinical cases comparing MC-SUP and MC-ISA to 
assess the ISA effect for 6711 and 9011 seeds.  
Structure DVH 
Parameter 
6711 seeds 9011 seeds 
 MC-
SUP 
MC-
ISA  
ISA effect MC-
SUP 
MC-
ISA  
ISA effect 
        
Prostate Volume 
(cm3) 
35.2  35.2  - 35.2  35.1  - 
D90 (Gy) 137.5  133.3 -4.2 (-3.0%) 133.8 131.6 -2.2 (-1.6%) 
D98 (Gy) 101.4  98.3  -3.1 (-3.1%) 98.6 97.0 -1.6 (-1.6%) 
V100 (%) 87.6 86.2 1.4 (-0.5 cm3) 86.3 85.6 0.7 (-0.3 cm3) 
V150 (%) 57.0 53.8 3.2 (-1.1 cm3) 54.1 52.3 1.8 (-0.6 cm3) 
V200 (%) 26.7 24.1 2.6 (-0.9 cm3) 24.7 23.2 1.5 (-0.5 cm3) 
        
Urethra D10 (Gy) 255.4  244.1 -11.3 (-4.4%)  248.5  240.5  -8.0 (-3.2%) 
Rectum D2cm3 
(Gy) 
119.2  113.7 -5.5 (-4.6%) 115.6  112.5  -3.1 (-2.7%) 
        
MC-SUP  
100%  
VOL 
Volume 
(cm3) 
50.6 50.6 - 49.1 49.1 - 
D90 (Gy) 158.8 152.8 -6 (-3.8%) 158.6 155.3 -3.3 Gy (-2.1%) 
D98 (Gy) 147.6 141.7 -5.9 (-4.0%) 147.6 144.4 -3.2 Gy (-2.2%) 
V100 (%) 100 95.5  4.5 (-2.3 cm3) 100 97.5 2.5 (-1.2 cm3) 
MC-SUP: Single MC source superposition dose calculation (excludes ISA and tissue 
effects). 
MC-ISA: Dose from MC simulation in a water phantom (excludes tissue effects). 
MC-SUP 100% VOL: the volume enclosed by the 100% isodose in the superposition dose 
distribution. 
4.1.4 Discussion 
This study has investigated the impact of ISA and tissue composition effects 
in prostate seed implant brachytherapy. The results show that there are 
differences between TG-43U1 (3) dose calculations and MC simulated dose 
distributions that take account of seed interactions and tissue composition. 
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However the differences are small compared to other uncertainties in seed 
implant brachytherapy. In this study, for 30 patients without visible 
calcifications, the mean decrease in post-implant prostate D90 due to ISA 
and tissue effects was -2.9%. Differences between the source model used in 
this study (which agrees with other recent investigations (106, 107, 126)) 
and TG-43U1 consensus data produce a reduction in mean prostate D90 of -
3.3%, similar in magnitude to the ISA and tissue effect. By comparison the 
mean reduction in D90 (as calculated by TG-43U1) from the TRUS based 
implant plan to post-implant was -19%. A study by Kirisits et al. estimated 
the combined uncertainties for post-implant planning as 11% (k=1), 
including uncertainty in source calibration, treatment planning reference 
data, ISA, tissue composition effects, imaging, contouring and anatomy 
changes from implant to post-implant (38). In that study, ISA and tissue 
composition effects were estimated to contribute 4% and 5% respectively to 
the uncertainty budget (38).  
 
This study has also investigated the ISA and tissue effect on the volume 
defined by the 100% isodose (MC-SUP 100% VOL) in post-implant data. 
The mean volume in the CT post-implant MC-SUP dose distribution, 48.4 
cm3, closely matched the TRUS implant PTV volume, 46.2 cm3, underlining 
the clinical relevance of investigating this volume for post-implant plans - 
although it is possible that seed placement errors may cause the post-implant 
100% isodose volume to be offset from the prostate. The ISA and tissue 
effects are larger for the MC-SUP 100% VOL compared to the prostate, for 
example the MC-SUP 100% VOL D90 was reduced by 8.1% and V100 by 
9.7%. This illustrates that the effects have most impact at the periphery of 
an implant. ISA contributes most of the dose reduction for the prostate but 
ISA and tissue effects are comparable for the 100% isodose volume. This is 
because ISA and tissue effects act differently on the dose distribution. ISA 
reduces the dose at all points inside the implant, although differences are 
more noticeable in lower dose areas which tend to be peripheral. As most 
prostate tissue models have higher effective atomic number and density than 
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water, the effect of modeling tissue is to increase absorbed dose inside the 
implant, but attenuation also generally increases, reducing dose peripherally.  
 
Carrier et al. (116) studied 28 post-implant patients planned with seed 
strength 0.76 U, mean seed density 1.7 seeds/cm3 and mean clinical D90 of 
169 Gy, prostate D90 was reduced by -6.8 Gy (-4.0%) and -4.1 Gy (-2.4%) 
by ISA and tissue effects respectively. Their study used the SelectSeed 
(Nucletron, an Elekta company (Elekta AB)) which is similar in 
construction to the 6711 seed model. In our study, we used a lower seed 
activity (0.379 U to 0.496 U) and higher mean seed density (2.6 seeds/cm3) 
but found a comparable ISA effect. The tissue effect measured by Carrier et 
al. (116) is greater than we observed for the prostate but smaller than we 
observed for the MC-SUP 100% VOL, which could be explained by 
differences in CT prostate contouring. Other studies that have investigated 
ISA and tissue effects in clinical implants have only modeled a small 
number of implants, but have found similar results, with D90 reductions in 
the range 2% to 6% (113, 117, 118, 124).  
 
This study also investigated ISA and tissue effects in TRUS implant plans. 
Compared to CT post-implant plans, the overall effect on DVH parameters 
is very similar. There was no correlation between the magnitudes of the 
effects in the two plans: it would not be possible to predict the post-implant 
ISA effect from the TRUS plan. 
 
Comparison of a simple tissue model where composition and density are 
assigned based on structures and a CT based model with composition 
assigned based on structures and voxel density assigned from CT data found 
maximum difference in any DVH parameter of 1.5% for patients without 
calcifications. This illustrates that a structure-based model would be 
sufficient to implement advanced dose calculations for TRUS-based implant 
plans when CT data is not available, at least for patients without 
calcifications. TRUS can also be used to identify patients with 
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calcifications, although CT would be required to quantify the calcification 
density. 
 
Investigation of the effect of calcification on prostate brachytherapy 
dosimetry is limited by lack of accurate knowledge of the composition of 
calcified prostate tissue. A study by Chibani et al. (113) assumed that 
calcification was uniformly and sparsely distributed throughout the prostate 
and found that 1% calcification lead to a -7.8% reduction prostate D90. In 
this study, we have modeled localised calcifications using the voxel density 
determined from CT data to estimate the relative proportion of prostate 
tissue and calcification in each voxel, and found a maximum D90 reduction 
of -7.4% with mean -4.5%. Although only 10 patients were modeled for this 
part of the study, they were selected from a group of 100 as having the 
largest volume of calcification, illustrating that although calcifications can 
have significant impact for an individual patient’s dosimetry, the expected 
impact over a group of patients is small.  
 
Sector analysis of CT post-implant plans has shown that ISA and tissue 
effects cause greatest reduction in 100% isodose coverage in anterior sectors 
throughout the prostate, and in all sectors at the base. These sectors are the 
most commonly under-dosed in post-implant plans and the results illustrate 
that ISA and tissue effects are not uniform but have more impact in lower 
dose and peripheral areas of an implant. In sector analysis of patients with 
calcifications, the pattern of dose reduction was the same for patients with 
calcification as for those without, and there was no correlation between the 
volume of calcification in a sector and the V100 reduction in that sector. 
This is because the dose shadow behind a calcification depends on the 
relative positions of seeds and calcifications and can occur in a sector 
adjacent to the calcification, particularly as calcifications observed in this 
study were located centrally in the prostate.  
 
The ISA effect depends on seed design and a study by Afsharpour et al. 
(128) found that the Selectseed was the most attenuating seed model with an 
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average 4.8% reduction in prostate D90 for clinical implants compared to an 
average 1.5% reduction for the least attenuating (IBt Optiseed - this is a 
103Pd source with a polymer shell encapsulation). The 6711 seed was not 
included in that study; it is similar in design to the Selectseed, but has a 
slightly smaller silver core. In this study the ISA effect is compared for 
6711 and the thinner 9011 model. The phantom measurements discussed in 
3.3 show that the 9011 is less attenuating in terms of dose at a point. The 
clinical data show that using the 9011 compared to 6711, the impact of ISA 
on all DVH parameters is reduced, with ISA effect values being almost half 
for 9011 compared to 6711. ISA effect for the 9011 is comparable to that for 
the IBt Optiseed. This benefit of reduced ISA effect using the 9011 seed 
must however be seen in the context of overall uncertainties in seed implant 
brachytherapy as discussed above. 
 
Previous investigations into ISA and tissue effects (113, 116-118, 124) have 
noted that, because the existing dose prescription is sufficient to achieve 
good patient outcomes, it might be necessary to reduce the prescribed dose 
if advanced dose calculation methods were routinely implemented in 
prostate seed implant brachytherapy. This study has shown that any such 
change would need to take account of the variations in ISA and tissue 
effects between sectors of the prostate, and between patients, for example 
due to calcifications. 
 
This study has some limitations. For the investigation of ISA, all seeds were 
assumed to have the same orientation. Tissue composition models are 
assumed and more accurate dosimetric results would be achieved if the 
composition of soft tissues and calcifications could be measured directly. 
Dose results are sensitive to CT artifact correction methods. In this study 
artifacts were corrected by replacing each a small volume around each seed 
with the mean HU of immediately surrounding voxels. This will not 
completely remove all artifacts as there are some streak artifacts that run 
across the CT data. However the close agreement between CT based and 
structure based models illustrates that these artifacts have minimal impact 
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on dose. Another limitation is that the artifact correction would remove any 
regions of calcification that are obscured by the seed CT image, so that the 
volume of calcification may have been underestimated. 
4.1.5 Conclusion 
Advanced dose calculation methods that take account of ISA and 
differences in tissue composition from water, show that the dose delivered 
in clinical I-125 seed implants is different from that calculated by TG-43U1. 
These differences lead to reduced DVH parameter values especially for 
patients with calcifications. Dose reductions particularly affect peripheral 
dose and areas of the implant with relatively poorer coverage, the impact on 
the volume encompassed by the 100% isodose is more significant that the 
impact on the prostate. However dose reductions are less significant 
compared to other uncertainties in post-implant dosimetry such as seed 
placement errors, anatomy changes and imaging and contouring 
uncertainties. 
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5 Multi-parametric MRI guided focal boost in 
HDR prostate brachytherapy 
This section describes work done to investigate the feasibility of 
incorporating mp-MRI in HDR prostate brachytherapy to deliver focal boost 
treatments, in a pilot study of 30 patients. The investigation includes 
evaluating uncertainties of tumour delineation using mp-MRI and image 
registration of MRI to TRUS. Dosimetry of focal boost treatments is 
compared to standard treatments to evaluate the level of boost dose that can 
be achieved while maintaining the same normal tissue dose constraints as 
for standard treatments. The first part of this section describes the pilot 
study using MRI scans acquired specifically for tumour delineation to 
incorporate into brachytherapy treatment planning. On completion of the 
pilot study, an investigation into incorporating staging MRI scan data for 
focal boost treatment planning was performed, as funding for further pre-
treatment MRI scans was not available. This work is described in the second 
part of this section.  
5.1 Initial feasibility study 
5.1.1 Introduction 
In radiotherapy for prostate cancer, it is standard practice to prescribe one 
dose level to the whole prostate, as prostate cancer is known to be a multi-
focal disease. Tumour control probability may be improved by delivering a 
focal boost dose to a DIL (98), as these lesions are the most common site of 
recurrence (11). Previous studies have investigated focal boost in 
radiotherapy. A study by Gauder et al. (132) of sextant biopsy guided dose 
escalation in permanent seed implant prostate brachytherapy treatments 
achieved 95% DIL coverage with 150% of the 144Gy prescription dose with 
no difference in acute and late toxicities compared to a group of patients 
who did not receive the dose escalation. Focal boost doses of up to 150% of 
prescription dose have been achieved in HDR prostate brachytherapy 
planning studies for DILs identified using MRI and MRSI (96) (95). Focal 
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boost dose has also been investigated for IMRT and volumetric modulated 
arc therapy (VMAT) treatments with DIL volumes identified using MRSI 
and DCE-MRI (97, 133, 134). 
 
Focal boost techniques require accurate methods for tumour delineation. 
Mp-MRI techniques such as T2W MRI, MRSI, DCE-MRI and DWI in 
combination, improve sensitivity and specificity of prostate cancer detection 
(56) (57) (58) (59). Prostate radiotherapy patients often receive neo-
adjuvant hormone therapy, and this has been shown to reduce the 
conspicuity of tumour tissue using mp-MRI in the prostate (135, 136). 
 
This study investigates the feasibility of using mp-MRI for tumour 
delineation and HDR prostate brachytherapy to deliver focal boost dose, in a 
group of patients who are being treated using HDR prostate brachytherapy 
in combination with external beam treatment. The majority of HDR prostate 
brachytherapy patients are given hormone therapy, so one aspect of the 
study is to investigate if tumour delineation for treatment planning is 
possible for these patients. The study also investigates how the achievable 
focal boost dose is affected if a margin is added to the tumour region, to 
account for delineation and image registration uncertainties.  
 
This pilot study of 30 patients does not have sufficient patient numbers to 
determine whether focal boost doses improve prostate cancer control 
however the patients in the study are followed up to assess whether there is 
any increase in normal tissue toxicities resulting from the focal boost 
treatment. This follow up was done by the clinical oncology consultants and 
registrars working with the patients but a summary of the results is included 
here for completeness. 
5.1.2 Method 
Patients 
30 patients (ages 57-77 years, mean 66 years) with biopsy proven prostate 
cancer, scheduled for prostate HDR brachytherapy between February 2011 
and November 2013, were recruited to the study. Informed consent was 
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obtained from all patients and the local ethics review committee approved 
the study. Patient prostate staging data is presented in Table 24. MRI scans 
took place in the week before HDR brachytherapy, 2.5 - 5 months (mean 4 
months) after biopsy. Of 30 patients, 27 had received neo-adjuvant hormone 
therapy for between 2 and 5 months (mean 3 months) prior to the MRI scan. 
For the first 15 patients in the study, MRI data was analysed retrospectively 
and patients received the standard treatment (15Gy to the whole prostate in 
a single fraction of HDR brachytherapy, followed by 37.5Gy in 15 fractions 
of external beam therapy to the prostate and seminal vesicles) (35). For the 
remaining 15 patients, a focal boost treatment was given if tumour could be 
identified in the mp-MRI data. Gastro-intestinal and genitourinary toxicity 
was recorded using CTCAE v4.0 (137) at 6 weeks and then 3 monthly 
intervals following treatment. 
 
MRI acquisition 
The mp-MRI techniques used were T2W MRI, DWI and DCE-MRI. MRSI 
was not used as it was thought this would make the scan time uncomfortably 
long and DCE-MRI is preferred over MRSI for prostate cancer localization 
according to a recent European consensus meeting (138). Scans were 
performed on an Avanto (Siemens AG, Munich, Germany) 1.5T scanner, 
using phased-array pelvic and spine coils for signal reception. Endo-rectal 
coils were not used as phased-array coils are adequate for prostate cancer 
detection (139) and because of the need to reduce distortion in the MRI 
images for treatment planning use. All MRI images were acquired in 
transverse-oblique planes such that slice-by-slice the posterior edge of the 
prostate remains in as consistent a position as possible. This is designed to 
assist matching of prostate position in MRI to TRUS image registration for 
treatment planning. T2W MRI used a turbo-SE sequence with repetition 
time (TR) 4970ms, echo time (TE) 87ms, echo train length 13, 0.7mm pixel 
size, slice thickness 2.5mm (no slice gap), 28 slices, field of view (FOV) 
220mm. DWI MRI used a single shot SE-EPI sequence with TR 3000ms, 
TE 77ms, 1.4mm pixel size, slice thickness 4.5mm (0.5mm gap), 14 slices, 
FOV 220mm, b-values 0, 150, 500 s/mm2 (first 15 patients) or 0, 150, 500, 
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750 s/mm2 (subsequent patients). ADC maps generated by the scanner from 
all 3 b-values were used for subsequent analysis. DCE MRI used a 3D 
spoiled gradient echo sequence with TR 4.4ms, TE 1.2ms, flip angle 21°, 
2x2x5mm pixel size, FOV 320mm and 20 slices (the superior 6 slices were 
added to the imaging volume for the purpose of reducing in-flow effects 
(140)). 200 acquisitions were acquired with 2s time resolution. A bolus 
injection of 0.1mmol/kg Dotarem® (Guerbet Group, Villepinte, France) was 
administered at 3ml/s after 10s scan time. A patient specific AIF was 
measured in the iliac artery, and pixel maps of Ktrans were generated by 
fitting a Tofts (76) 1-compartment model to concentration-time data 
(approximated using relative change in signal intensity (141)) obtained from 
the DCE acquisition, using Platform for Research in Medical Imaging (142). 
 
Tumour delineation 
A manual rigid registration was applied to align the DWI ADC and DCE 
Ktrans maps to the T2W images, to account for differences in prostate 
position due to patient movement or, for the DWI ADC map, distortion 
resulting from EPI susceptibility artefacts. The registration was evaluated 
from baseline images (the b=0 image for DWI, the first DCE acquisition for 
DCE). The focal gross tumour volumes (F-GTVs) for the treatment planning 
study were delineated based on having low intensity on T2W MRI, low 
ADC map values and high Ktrans map values, by one of two consultant 
radiologists, who had 18 years and 11 years experience of prostate MRI. To 
allow quantitative comparison of MRI data values, normal tissue regions 
were delineated when regions with high intensity on T2W MRI, high ADC 
map values and low Ktrans map values, contra-lateral to the tumour regions, 
could be identified.  
 
Treatment planning study 
The HDR prostate brachytherapy procedure involves the following steps, 
using the Oncentra Prostate™ v4.0 (Elekta AB) treatment planning system. 
HDR needles are inserted under TRUS guidance, a TRUS volume is 
acquired with the needles in position, the prostate, urethra and rectum are 
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contoured on the TRUS volume and a 3mm margin (0mm at the posterior 
boundary of the prostate), to encompass potential microscopic spread of 
disease, is added to create a PTV. This follows GEC-ESTRO 
recommendations although the terminology used here is different: the 
delineated prostate structure may be expanded to include any macroscopic 
extracapsular disease and/or seminal vesicle involvement, and the PTV is 
equivalent to the CTV defined by the GEC-ESTRO recommendations (15). 
Needles are reconstructed, a treatment plan is created using DVH-based 
inverse optimization (111) to achieve prostate V100>95% and PTV 
V100>90% (100% isodose = 15Gy). Note this study was completed before 
the recent GEC-ESTRO update which recommends PTV V100>95% (15). 
If necessary, small manual adjustments to dwell times are made to refine the 
treatment plan. The dose constraints for OARs are urethra D10 <17.5 Gy 
and rectum D2cm3 <11.8Gy, V100 = 0%. 
 
For the treatment planning study, T2W MRI was registered to the TRUS 
images acquired after needle insertion using the manual rigid registration 
function in Oncentra Prostate™ (Elekta AB). To allow for uncertainties in 
tumour delineation and image registration, a margin (determined from the 
uncertainty estimation work described below) on each F-GTV was used to 
generate a focal PTV (F-PTV) structure. F-PTV(s) were not allowed to 
intersect the urethra or extend beyond the prostate capsule. No margin is 
applied to account for microscopic tumour spread as prostate tissue outside 
the F-PTV is still prescribed the standard 15Gy treatment. 
 
For each patient in the study two treatment plans were generated: a standard 
plan prescribing the same dose to the whole prostate and a focal boost plan. 
For the first 15 patients in the study, standard plans were delivered and focal 
boost plans were generated retrospectively after treatment. For the 
remaining 15 patients in the study, focal boost plans were delivered (unless 
no tumour was visible in mp-MRI data) and standard plans were generated 
retrospectively after treatment. Focal boost plans were optimised to 
maximize dose to the F-PTV(s), but used the same dose objectives and 
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constraints for prostate, PTV, urethra and rectum as in the standard plans. 
For focal boost plans produced retrospectively, up to 2 additional HDR 
needles were added to target the F-PTV(s). Dose optimization was 
performed using DVH-based inverse optimization (111) with small manual 
adjustments to dwell times where necessary to improve the treatment plan. 
The objective for the optimizer was set to give 150-200% of the prescription 
dose to the F-PTV. 
 
Estimation of margin for uncertainty in tumour delineation and image 
registration 
The margin required for uncertainty in tumour delineation and image 
registration was investigated as follows. For tumour delineation, the MRI 
datasets of five patients, selected randomly from first 15 patients, were 
contoured four times in total, three times by the same consultant radiologist, 
with at least 4 weeks gap between each contouring session, and one time by 
another consultant radiologist, to give four different contours for each 
F-GTV. The four contours were used to estimate a margin for tumour 
delineation uncertainty by incrementally applying a margin (increasing the 
margin size one pixel at a time) to each contour until it completely covered 
each other contour for that F-GTV. The margin calculation was performed 
separately for each anatomical direction. To illustrate the method, Figure 16 
shows how the calculation would work for an idealised pair of contours, 
labeled as CTR1 and CTR2, on a single slice. In this example the margin 
would be 2mm anterior, 5mm left, 0mm posterior (as CTR2 is inside CTR1) 
and 0mm right (as CTR1 and CTR2 match). The method was also applied to 
superior and inferior directions. Results for all F-GTVs across the 5 patients 
were combined, and the 90th percentile value was taken as the margin 
required for tumour delineation error, as this represents the margin where 
one contour would cover another 90% of the time (90% was chosen as this 
matches the criterion often applied in external beam radiotherapy margin 
derivation (143)). 
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To assess inter and intra-observer variability in image registration, for the 
same five patients, the MRI-TRUS image registration was repeated five 
times in total by three physicists. A rigid registration has six parameters: a 
translation and an angle of rotation in each of 3 imaging planes (left-right, 
anterior-posterior and superior-inferior). Differences in image registration 
were assessed as follows. For each patient the standard deviation from five 
registration attempts was calculated for each of the six registration 
parameters. The margin was taken as two times the mean of the standard 
deviation values for the five patients, in each direction. Rotation values were 
converted to distances by calculating the distance corresponding to the 
rotation at the surface of a sphere of radius 2cm (to represent the prostate). 
The estimated margin was then applied to all 30 patient’s F-GTVs to 
generate F-PTVs for the treatment planning study as described above. 
 
 
Figure 16 Idealised example of margin calculation method for tumour delineation 
uncertainty study 
 
Margin consistency test 
The combined margin was tested for consistency on a further 5 patients. For 
these patients tumour delineation was repeated separately by each of the two 
radiologists, and the resulting F-GTVs were registered to TRUS treatment 
planning images. The F-PTV used in the treatment planning study was 
overlaid on the F-GTVs and the effectiveness of the margin was assessed by 
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calculating the percentage of the F-GTVs (from the repeat delineations) 
covered by the original F-PTV. 
 
 
 
5.1.3 Results 
Patient logistics 
Two patients were unable to have MRI scans for logistical reasons so were 
not included in the study. 2 patients were determined to be unfit for surgery 
after the MRI scan, however standard and focal boost treatment plans were 
produced for these patients and their results are included in the dosimetric 
results for this study.  
 
Tumour delineation 
In most cases small rigid registration shifts were required to align the mp-
MRI datasets. The median shift was 2.1mm (range 0-10mm). F-GTVs were 
identified in 25 of the 28 patients who had an MRI scan. The three patients 
in whom tumour tissue could not be identified were all in the second group 
of 15 patients considered for prospective treatment. F-GTVs had median 
volume 0.8 cm3 (range 0.1-23.0 cm3). Two F-GTVs (bi-lateral) were 
identified in 8 patients, giving a total of 33 F-GTVs in the 28 patients. Of 
these, 3 were in anterior central gland tissue, 4 involved peripheral zone and 
central gland tissue and 26 were confined to the peripheral zone. All 
F-GTVs were in areas positive for prostate cancer at biopsy. Normal tissue 
regions were identified in 13 patients and all normal regions were in areas 
testing negative for prostate cancer at biopsy. Table 24 lists the F-GTV 
volumes for each patient. Figure 17 shows an example of tumour 
delineation for one patient from the study. 
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Table 24 Clinical details, volumes and dosimetry results for the 30 patients included in 
the study. The F-PTV D90 and V150 are for the plan optimised for focal boost with 
additional needles added to target the F-PTV. 15Gy is 100% dose. Patients 8 and 28 
were not scanned so are not included. 
Patient Clinical  
Stage 
PSA 
(ng/ml) 
Gleason 
score 
Prostate 
Volume 
(TRUS) 
(cm3) 
Volume 
of 
F-GTVs 
(cm3) 
Volume 
of 
F-PTV 
(cm3) 
F-PTV 
D90 
(Gy) 
F-PTV 
V150 
(%)  
1 * T1c 5 3+4 24.3 4.1 9.0 20.7 77.5 
2 T2c 31 4+3 29.7 0.4 2.7 20.5 75.9 
 
   
 0.2 1.3 19.9 68.9 
3 T1c 4 3+4 29.7 3.7 9.5 20.2 70.6 
 
   
 0.2 1.1 20.9 75.8 
4 T3a 39 4+4 29.2 0.9 4.0 18.9 61.6 
5 T2c 11 4+3 58.3 0.2 1.4 25.0 99.4 
6 T2c 10 4+3 38.7 1.9 6.2 19.3 54.9 
7 * T3a 7 3+4 44.0 4.0 9.8 22.8 91.2 
 
   
 0.8 3.5 22.7 91.9 
9 T3a 3 3+4 23.7 1.1 4.9 20.4 66.5 
 
   
 0.3 1.6 22.8 91.6 
10 T3b 27 3+4 50.9 23.0 36.0 18.0 41.9 
11 T3a 35 3+4 31.4 2.6 7.6 20.5 73.7 
 
   
 0.2 1.2 24.4 97.7 
12 T3a 30 4+3 23.6 4.0 10.2 19.5 67.0 
13 T3a 21 4+5 19.0 0.4 2.4 20.1 74.2 
14 T3a 6 4+3 23.1 0.5 2.5 22.8 91.2 
 
   
 0.3 2.4 23.6 97.4 
15 T2c 5 4+3 24.2 0.4 3.0 23.0 92.8 
16 * T2c 8 3+4 29.7 5.5 12.6 21.1 81.6 
17 T1c 11 3+3 31.3 - - - - 
18 T3a 4 3+4 22.1 0.2 1.5 23.8 96.4 
 
   
 0.8 3.6 23.5 94.5 
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Patient Clinical  
Stage 
PSA 
(ng/ml) 
Gleason 
score 
Prostate 
Volume 
(TRUS) 
(cm3) 
Volume 
of 
F-GTVs 
(cm3) 
Volume 
of 
F-PTV 
(cm3) 
F-PTV 
D90 
(Gy) 
F-PTV 
V150 
(%)  
19 T3a 8 4+4 29.2 0.1 0.5 23.6 94.3 
 
   
 0.8 4.6 17.5 29.1 
20 T3a 15 4+3 22.0 1.1 4.6 23.2 93.1 
21 ** T3a 6 5+4 47.9 2.6 8.7 21.9 85.6 
22 T2c 5 4+3 19.8 1.8 5.8 19.7 71.9 
23 T3a 4 3+4 24.6 - - - - 
24 ** T3a 4 3+4 13.2 0.2 1.6 21.9 87.0 
25 T3a 7 3+4 34.7 1.4 6.1 20.1 70.7 
26 T3a 11 3+3 31.0 - - - - 
27 T3b 14 3+4 32.3 3.3 9.2 21.4 82.2 
29 T3a 21 3+4 59.3 0.8 2.9 24.6 97.5 
30 T2c 8 3+4 25.1 0.2 1.6 23.6 94.5 
* Did not receive neo-adjuvant hormone therapy. All other patients had undergone between 
2-5 months hormone therapy at the time of the MRI scan. 
** Not treated as unfit for surgery. 
 
The mean ADC values in F-GTV and normal tissue regions were 1.19 x10-3  
mm
2/s and 1.74 x10-3 mm2/s respectively. There was considerable inter-
patient variation with per-patient mean ADC values 0.87 - 1.48  x10-3 mm2/s 
for the F-GTV and 1.49 - 2.05 x10-3 mm2/s for normal tissue. For the 
patients where it was possible to delineate a normal tissue region, the 
difference between F-GTV and normal tissue ADC values was significant 
(p<0.0001). The mean Ktrans values in F-GTV and normal tissue regions 
were 0.16 min-1 and 0.07 min-1 respectively. Again there was considerable 
inter-patient variation with per-patient mean Ktrans values 0.09 - 0.48 min-1 
for the F-GTV and 0.01 - 0.22 min-1 for normal tissue. In spite of this 
overlap in ranges, for the patients where it was possible to delineate a 
normal tissue region, the difference between F-GTV and normal tissue Ktrans 
values was significant (p<0.005). 
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Figure 17 Example of tumour delineation on (a) T2 weighted MRI (b) DWI MRI ADC 
map (c) DCE-MRI Ktrans map superimposed on T2W MRI. (d) shows the F-GTV 
derived from (a), (b) and (c) 
 
Assessment of variability in tumour delineation and image registration 
In the tumour delineation uncertainty analysis a total of eight F-GTVs were 
delineated. An example of four separate delineations (each represents the F-
GTV combined from T2, DWI and DCE-MRI) for a single slice is shown in 
Figure 18. The margins for tumour delineation uncertainty were left 3.7mm, 
right 3.4mm, anterior 4.9mm, posterior 2.1 mm, inferior 3.8mm and 
superior 3.8mm. The margins for image registration uncertainty were left-
right 1.6mm, anterior-posterior 1.6mm, superior-inferior 2.8mm. The 
overall margin was determined by combining the tumour delineation and 
image registration uncertainties in quadrature giving left 4.0mm, right 
3.8mm, anterior 5.2mm, posterior 2.6 mm, inferior 4.7mm and superior 
4.7mm. The mean of these values is 4.2mm. Although some directional 
dependence was observed anterior-posterior for tumour delineation 
uncertainty, this is likely due to the majority of F-GTVs being close to the 
posterior border of the prostate. For these F-GTVs a large posterior margin 
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would not apply anyway as the F-PTV is restricted to the prostate capsule. 
For this reason and to simplify treatment planning, it was decided to use a 
single margin of 4.5mm in all directions. Table 24 lists the F-PTV volumes 
for each patient. 
 
Figure 18 Example of four separate delineation attempts for one F-GTV (for each F-
GTV, contours are combined from all mp-MRI data) 
 
Margin consistency test 
In the margin consistency test, the F-PTVs created using the 4.5mm margin 
in the treatment planning study covered 91.2% (mean for 5 patients, range 
74.1% - 100%) of the F-GTV volumes from repeat delineations by the two 
radiologists.  
 
Treatment planning study 
 
Table 24 shows the dose achieved in the focal boost optimised plan with 
additional needles for each tumour region. The median (range) volumes for 
F-PTV, prostate and PTV were 3.6 cm3 (0.5 cm3 – 36.0 cm3), 29.2 cm3 (13.2 
cm3 – 59.3 cm3) and 43.0 cm3 (21.6 cm3 – 81.3 cm3) respectively. Table 25 
shows DVH statistic values for the 28 patients, comparing the delivered 
treatment plans to the plans optimised for focal boost. Focal boost coverage 
was comparable in the retrospective and prospective phases of the study, 
with median F-PTV D90 20.7 Gy and V150 75.9% in the retrospective focal 
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boost plans for the patients who received the standard treatment, and median 
F-PTV D90 22.5 Gy and V150 90.1% in the delivered focal boost plans for 
the patients who received the focal boost treatment. The slightly better 
coverage in the latter group is probably due to the retrospective group 
containing the majority of patients with bi-lateral F-PTVs. Figure 19 shows 
an example comparing standard and focal boost plans for one patient. Figure 
20 shows a comparison of V150 values for each F-PTV for the treatment 
plans. From patient follow up assessments, in the patients treated with F-
PTV boost no Grade 3 toxicities were seen, 3 of 8 patients had Grade 2 
toxicity in the first 3 months, with median follow up 12 months. 
 
 
Figure 19 (a) MRI F-GTV registered to TRUS and used to generate F-PTV (b) 
isodoses from the standard plan (c) isodoses from the focal boost plan 
 
 
Figure 20 Comparison of V150 values for standard and focal boost plans for all F-
PTVs in the study 
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Table 25 DVH parameter values from the dose optimization study. Values shown are 
the median for 30 patients with the range of values shown in parentheses. 
 Plan D90 (Gy) V100 (%) V150 (%) V200 (%) 
Prostate* STD 17.1 (16.6 - 17.6) 99.6 (98.2 -100) 27.8 (18.4 – 39.1) 6.2 (4.0 – 11.1) 
 
FBOOST 17.1 (16.2 - 17.7) 99.5 (98.0 - 99.9) 39.9 (23.4 – 52.3) 9.9 (5.3 – 16.7) 
PTV STD 15.6 (14.5 - 16.5) 93.4 (87.3 – 96.6) 23.3 (16.3 – 32.0) 5.8 (3.9 – 9.3) 
 
FBOOST 15.7 (14.5 – 16.9) 93.6 (87.4 - 97.6) 33.0 (20.0 – 42.6) 8.5 (4.3 – 13.5) 
F-GTV STD 18.2 (16.3 – 22.2) 100 (98.7 - 100) 26.2 (0 – 88.5) 5.3 (0 – 35.3) 
 
FBOOST 24.0 (17.9 – 37.5) 100 (-) 97.3 (17.5 – 100) 41.9 (1.6 - 100) 
F-PTV STD 17.8 (16.7 - 19.3) 100 (98.6 - 100) 27.5 (5.7 – 62.1) 5.4 (0.1 – 20.0) 
 
FBOOST 21.4 (17.5 - 25.0) 100 (-) 82.2 (29.1 - 99.4) 25.6 (6.5 – 62.9) 
 
     
 
 D10 (Gy) D2cm3 (Gy) V100 (cm3)  
Urethra STD 17.2 (17.0 – 17.5) - -  
 
FBOOST 17.3 (17.0 – 17.5) - -  
Rectum STD - 8.1 (6.3 – 10.8) 0 (-)  
 
FBOOST - 9.0 (6.6 – 10.8) 0 (-)  
STD – standard plan delivering 15Gy to the whole prostate 
FBOOST – focal boost plan delivering 15Gy to the whole prostate and escalating dose to 
the F-PTV 
* Prostate is the whole prostate including F-GTV and F-PTV. 
5.1.4 Discussion 
This study has investigated the feasibility of mp-MRI-guided focal boost, 
using HDR prostate brachytherapy with TRUS based treatment planning. 25 
of 28 patients had undergone hormone therapy at the time of their MRI 
scan. Hormone therapy has been shown to reduce the contrast between 
tumour and normal tissue in mp-MRI techniques (92, 135, 136). Although 
use of staging MRI acquired before hormone therapy might avoid this 
problem, hormone therapy also causes a reduction of 30-40% in prostate 
volume and the % volume reduction can vary between central gland and 
peripheral zone (88), so that staging MRI might be less suitable for image 
fusion to plan HDR treatments. Use of staging MRI to plan focal boost 
treatments is investigated separately in 5.2. Tumour volumes were identified 
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in 25 out of 28 patients scanned in this study. For comparison, a study by 
Groenendaal et al (92) found that longer duration of hormone therapy was 
associated with reduced tumour conspicuity but identified tumour volumes 
in 18 out of 21 IMRT and I-125 seed implant patients who had received 
>3months hormone therapy. The majority of F-GTVs were in the peripheral 
zone. This may be biased by the fact that central gland tumours are less 
easily identifiable on DWI and DCE-MRI but in any case urethral dose 
constraints would limit the level of boost dose that could be achieved in 
central gland regions. 
 
When using mp-MRI for tumour delineation the question arises how to deal 
with areas of the prostate that are suspicious for tumour on some but not all 
of the mp-MRI datasets in an individual study. Differences could reflect the 
fact that DWI and DCE-MRI techniques probe different tissue 
characteristics or be caused by image registration errors between the mp-
MRI datasets (58), particularly as the EPI sequence used for DWI can cause 
artifacts that deform the prostate shape (although these are reduced by using 
right-left rather than anterior-posterior phase encoding). In this study the 
union of suspicious areas was taken as the F-GTV; this seems the safest 
approach given that the reasons for the inconsistencies are not fully 
understood. For example, a study by Alonzi et al (135) concluded that 
reduction in tumour Ktrans values caused by hormone therapy (that might 
cause a tumour to not be considered suspicious in DCE-MRI) can be 
associated with hypoxic areas of tumour, that would benefit from a higher 
radiation dose. In spite of these inconsistencies there was still a significant 
difference in both ADC and Ktrans values between F-GTV regions and 
normal tissue regions. The tumour ADC values were at the high end 
compared to other published studies (for example Groenendaal et al (58) 
quotes values from 4 different studies ranging from 0.9 - 1.38 x10-3 mm2/s). 
This could be an effect of hormone therapy, but may also be because the 
acquisition protocol did not include any b-values higher than 500 s/mm2, 
and our acquisition protocol has been adjusted for subsequent patients to 
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include b = 750 s/mm2.  The tumour Ktrans values are low compared to other 
studies, which could again be a consequence of hormone therapy. 
 
A limitation of this study is that tumour delineation and image registration 
procedures were not validated. Tumour delineation could be validated with 
template biopsy procedures and image registration could be validated by 
inserting markers into the prostate, but this would require additional 
invasive procedures for the patient. Instead uncertainties were estimated by 
looking at variability in repeat attempts using multiple observers. Image 
registration uncertainty was largest in the superior-inferior direction which 
is not surprising as matching the base and apex of the prostate on MRI and 
ultrasound is difficult. Image registration accuracy is also limited by use of a 
rigid registration to register MRI to TRUS, when TRUS is acquired with the 
patient in a different position from MRI and with the ultrasound probe 
deforming the prostate to some extent. For tumour delineation it was found 
that uncertainty was largest in the anterior direction. This could be because 
many peripheral zone tumours are located close to the prostate capsule, 
which provides a clearly defined posterior boundary. Also tumours tend to 
be more easily recognizable in the peripheral zone, compared to the central 
gland where there is overlap of signal characteristics between benign and 
malignant tissue. There are no published studies that have estimated prostate 
tumour margin in this way, but a study by Groenendaal et al (144) 
determined that a margin of 5mm accounted for errors in mp-MRI based 
tumour delineation, when compared to pathology results. As this is a focal 
boost study, an additional margin is provided by the fact that the whole 
prostate continues to receive the standard prescription dose. For focal 
therapy (treating just the tumour) larger margins would need to be 
considered. 
 
The size of the F-PTV and its proximity to the urethra and rectum 
determines how large a boost dose can be achieved. The boost doses 
achieved in this study are comparable to other retrospective planning studies 
and were achieved without changes to urethra and rectal dose constraints, 
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specific to a single fraction HDR treatment regime (145). For comparison, 
Kim et al. (96) retrospectively planned treatments and achieved focal boost 
V150 values of 82.4% on average for 13 patients with slight adjustment of 
dose constraints, although this level of boost could not be achieved for 2 
other patients in their study. Pouliot et al. (95), found boost dose of 120% 
could be achieved without affecting dose to surrounding normal tissue or the 
urethra, and boosts up to 170% were feasible with slightly increased urethral 
and rectal dose. In this study the median V150 coverage was 97.3% for the 
F-GTV (comparable to the studies mentioned above as these did not add a 
margin to the MRI delineated tumour regions) and 82.2% for the F-PTV. 
This demonstrates that focal boost techniques could be improved if better 
techniques for tumour localization and image registration can be developed. 
5.1.5 Conclusion 
The study has shown that mp-MRI-guided HDR prostate brachytherapy 
focal boost is feasible. Mp-MRI techniques can be used to define tumour 
regions in spite of the fact that the majority of patients have undergone 
hormone therapy. Increased focal boost dose can be achieved without 
violating urethral and rectal dose constraints and maintaining standard 
prostate/ptv coverage. No increases in the level of treatment related 
toxicities were observed in patients treated with the focal boost treatment. 
The level of dose boost is lower for larger tumour regions or tumour regions 
close to either the urethra or rectum. 
5.2 Retrospective investigation of focal boost 
planning based on staging scan sectors 
5.2.1 Introduction 
Following completion of the pilot study described in 5.1, it was decided to 
bring focal boost treatments into routine clinical practice. However due to 
resource constraints it was not possible to request pre-treatment MRI scans, 
so an additional investigation was performed into the feasibility of HDR 
focal boost planning based on staging MRI scans. This work is described in 
this section 
105 
 
 
Two aspects were investigated. Firstly any differences in tumour delineation 
between staging and pre-treatment MRI scans were assessed. Secondly focal 
boost optimization was compared for prostate sector and F-PTV based 
boost. This comparison was performed because of concerns that, for patients 
who receive hormone therapy, changes in prostate volume and morphology 
may mean that an F-GTV delineated in a staging scan cannot be accurately 
transposed to treatment planning TRUS. Focal boosting all involved sectors 
would effectively increase boosted volume and provide additional 
confidence that uncertainties in tumour delineation and image registration 
are accounted for.  
5.2.2 Method 
Tumour delineation 
For the tumour delineation part of this investigation, all patients from the 
pilot study described in 5.1 who had received a staging MRI scan in our 
centre were selected. This was 10 patients in total, and included one patient 
for whom it had not been possible to delineate tumour in the pre-treatment 
scan. All 10 patients had received hormone therapy for between 2 and 4 
months (mean 3 months).Patients who had been staged at other centres were 
not included because differences in the MRI protocols used in those centres 
meant that we did not feel that a comparison to the pre-treatment scans 
would be valid for those patients. F-GTVs were delineated on the staging 
scan sequences by the same consultant radiologists who had performed the 
pre-treatment scan delineations. At least one year had elapsed since the 
radiologists delineated the pre-treatment scans. The prostate was delineated 
to assess the effects of hormone therapy on prostate volume from staging to 
pre-treatment scan.  
 
The staging scan sequences that were reviewed were T2W and DWI MRI, 
as the staging scan protocol did not include DCE-MRI at the time these 
patients were scanned. MRI sequences were acquired using protocols as 
described in 5.1.2, except that the T2W MRI used a slice thickness of 3mm 
(and 0.3mm gap) as opposed to 2.5mm.  
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The sectors intersected by the F-GTVs in the scans were recorded. For this 
the prostate was divided into 12 sectors by dividing into three equal length 
sections superior-inferior, then dividing each of these sections into four 
sectors. Figure 21 illustrates the sector divisions and the sector numbering 
scheme used to refer to individual sectors in the analysis below. 
 
 
Figure 21 Prostate sector divisions and numbering scheme 
 
Optimisation 
Additional patients were randomly chosen from the pilot study to increase 
the number of patients in the optimization part of the study to 15 patients in 
total. To exclude the effect of any differences between F-GTV delineation 
in staging and pre-treatment scans, and to allow for uncertainties in tumour 
delineation and image registration, the sectors included in optimization were 
selected based on the F-PTVs used in the original focal boost study. All 
sectors that contained part of the F-PTV were included.  
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Table 26 Comparison of prostate volume, F-GTV volume and tumour sectors between 
staging and pre-treatment scans. Patient numbers refer to those in Table 24. Sector 
numbers refer to sectors as illustrated in Figure 21. Staging and pre-treatment scans 
were compared for the first 10 patients shown in this table. 
Patient Staging scan Pre-treatment scan TRUS F-PTVs 
Patient Prostate 
volume 
(cm3) 
F-GTV 
volume 
(cm3) 
Involved 
sectors 
Prostate 
volume 
(cm3) 
F-GTV 
volume 
(cm3) 
Involved 
sectors 
F-PTV 
volume 
(cm3) 
F-PTV sectors 
9 24.5 0.6 III, VII 21.2 0.9 III, VII  III, VII, VIII, XI 
 
   
 0.2 VIII  
18 32.4 0.2 VII 22.6 0.2 VII 1.1 VI, VII, VIII 
 
 1.1 VI, VIII  0.9 VI, VIII 3.0 
20 29.7 3.0 VII, IX 16.2 1.3 VII, IX 4.6 VII, IX 
22 
31.0 0.5 III, VII  
16.3 1.9 V, VII, 
IX, XI  
5.8 III, V, VII, IX, 
XI 
 
 0.6 IV, VIII  - -  
23 23.2 0.2 VIII 22.3 - - - - 
24 29.2 1.4 IV, VIII 13.5 0.4 VIII, XII 1.6 VIII, XII 
25 
44.2 2.0 VII, VIII 
24.9 1.5 VII, VIII 6.1 VII, VIII, XI, 
XII 
27  
34.8 2.5 
III, VII, 
VIII 
27.3 3.8 VII, XI, 
XIII 
9.2 VII, XI, XII 
29 48.4 1.5 VIII, XII 36.4 0.9 VIII, XII 2.9 VIII, XII 
30 29.7 0.8 VII, XI 19.3 0.3 VII, XI 1.6 VII, XI 
1 - - - 21.3 4.6 III, V, 
VII, IX, 
XI 
9.0 I, III, V, VII, IX, 
XI 
3 - - - 24.0 3.8 VII, XI, 
XII 
9.5 VII, VIII, XI, 
XII 
 
- - - 
 0.2 VIII 1.1 
7 
- - - 
44.5 3.9 VII 9.8 VII, VIII, XI 
 
- - - 
 0.9 VIII 3.5 
12 - - - 21.9 3.6 III, IV, 
VIII, XII 
10.2 III, IV, VI, VIII  
13 
- - - 
11.4 0.5 V, IX 2.4 V, IX 
15 
- - - 
21.9 0.4 VIII 3.0 VIII 
108 
 
For each patient, 3 plans were produced. Standard and focal boost plans 
optimised to the F-PTV were produced by the method described in 5.1.2, 
and sector focal boost plans were produced using the sector based 
optimization feature of Oncentra Prostate™ v4.0 (111). All plans used the 
same dose objectives and constraints for prostate, PTV, urethra and rectum. 
These were as detailed in 5.1.2 except that the PTV V100 dose objective 
was increased to 95%, due to a recent update to guidelines (15) (note this 
change means that the standard and F-PTV focal boost plans produced were 
slightly different from those created in 5.1.2). Sector focal boost plans were 
optimised to maximize dose to the involved sectors. Sector and F-PTV 
based focal boost plans used the same needle configurations, which in some 
cases included additional needles compared to the standard plans added to 
target the tumour volume. Dose optimization was performed using DVH-
based inverse optimization (111) with small manual adjustments to dwell 
times where necessary to improve the treatment plan. The objective for the 
optimizer was set to give 150-200% of the prescription dose to the F-
PTV/involved sectors. 
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Table 27 Median DVH values for the 15 patients in the optimisation study. For F-
GTV, F-PTV and sectors, the values shown are the median (range) of the combined 
values (for both F-GTVs/F-PTVS or all sectors) for each patient 
 Plan D90 (Gy) V100 (%) V150 (%) V200 (%) 
Prostate* STD 17.2 (16.6 - 17.5) 99.9 (99.3 -100) 33.3 (28.1 – 43.2) 10.1 (5.5 – 13.5) 
 
FBOOST 17.3 (16.6 - 17.8) 99.9 (99.0 - 99.9) 42.1 (32.1 – 52.5) 12.1 (8.7 – 20.5) 
 
SBOOST 17.3 (16.6 - 17.7) 99.8 (99.2 - 100) 43.4 (32.5 – 57.2) 12.3 (8.6 – 17.5) 
PTV STD 16.2 (15.5 - 16.6) 92.8 (87.3 – 97.2) 28.8 (26.2 – 36.7) 8.9 (5.4 – 11.5) 
 
FBOOST 16.3 (15.3 – 16.8) 91.6 (87.4 - 97.1) 35.0 (28.0 – 44.5) 10.1 (7.6 – 16.4) 
 
SBOOST 16.1 (15.3 – 16.8) 91.6 (87.4 - 97.1) 35.9 (28.5 – 45.3) 10.9 (8.0 – 13.7) 
F-GTV STD 18.3 (16.1 – 21.8) 100 (99.6 - 100) 35.8 (9.1 – 85.1) 6.1 (0.6 – 32.2) 
 
FBOOST 24.3 (20.5 – 30.4) 100 (-) 95.4 (73.1 – 100) 46.9 (14.5 – 91.4) 
 
SBOOST 22.3 (19.9 – 25.8) 100 (-) 88.7 (66.3 – 100) 29.9 (12.3 – 59.9) 
F-PTV STD 17.5 (15.8 - 19.3) 100 (97.5 - 100) 33.7 (16.0 – 56.5) 8.9 (2.5 – 16.7) 
 
FBOOST 21.0 (18.8 – 24.1) 100 (-) 77.2 (64.7 – 96.9) 30.2 (12.3 – 54.1) 
 
SBOOST 19.8 (18.9 – 24.2) 100 (-) 75.6 (49.7 – 96.7) 23.4 (10.1 – 48.1) 
Sectors STD 17.7 (16.8 - 18.3) 100 (99.0 - 100) 37.8 (14.4 – 49.4) 9.8 (3.3 – 18.6) 
 
FBOOST 19.0 (18.0 – 21.5) 100 (99.6 - 100) 62.2 (53.1 – 82.7) 20.9 (14.4 – 31.7) 
 
SBOOST 20.3 (18.7 – 22.8) 100 (-) 74.7 (56.9 – 91.1) 27.5 (16.1 – 38.7) 
 
     
 
 D10 (Gy) D2cm3 (Gy) V100 (cm3)  
Urethra STD 17.1 (17.1 – 17.2) - -  
 
FBOOST 17.2 (17.1 – 17.5) - -  
 
SBOOST 17.2 (17.1 – 17.5) - -  
Rectum STD - 8.4 (6.5 – 9.7) 0 (-)  
 
FBOOST - 8.9 (6.6 – 10.4) 0 (-)  
 
SBOOST - 8.9 (6.8 – 10.6) 0 (-)  
STD – standard plan delivering 15Gy to the whole prostate 
FBOOST – focal boost plan delivering 15Gy to the whole prostate and escalating dose to 
the F-PTV(s) 
SBOOST – focal boost plan delivering 15Gy to the whole prostate and escalating dose to 
the involved sector(s) 
* Prostate is the whole prostate including F-GTV and F-PTV/sectors. 
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5.2.3 Results 
 
Figure 22 Staging and pre-treatment MRI . (a) and (b) are from staging and pre-
treatment MRI s respectively for the same patient illustrating prostate and tumour 
shrinkage. (c) and (d) are from staging and pre-treatment MRIs respectively for a 
different patient and illustrate that tumour can be more difficult to distinguish in the 
pre-treatment MRI (post hormone therapy). Note in all cases the delineated tumour 
volumes were based on mp-MRI data, not just on the T2 weighted images shown. 
 
Tumour delineation 
Results for the 10 patients for whom staging and pre-treatment scan tumour 
delineations were compared are shown Table 26. For these 10 patients, the 
median prostate volume was 30.4 cm3 in the staging scan and 21.8 cm3 in 
the pre-treatment scan, corresponding to a median reduction in volume of 
28.3% (range 3.9% - 53.8%). Table 26 shows the sectors intersected by the 
F-GTVs in the scans for each patient. The following explains these results in 
overview: 
 
• For 5 patients (18, 20, 25, 29, 30) the sectors corresponded exactly. 
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• For 3 patients (9, 24, 27) the sectors overlapped but did not exactly 
match. In two cases this was due to delineation variation and in one 
case (patient 24) due to the large change in prostate volume between 
the two scans. 
• For patient 22, the tumour outlined in the pre-treatment scan did not 
correspond to the tumour outlined in the staging scan, although there 
was one sector in common. 
• For patient 23, for whom no tumour has been observed in the pre-
treatment scan, a small tumour was visible in the staging scan. 
 
Optimisation 
 
The sectors and F-PTV volumes are shown in Table 26. The results of the 
optimization study are shown in 
 
 
 
 
 
 
 
Table 27. The per-patient median volume of the boosted F-PTVs and sectors 
were 5.8 cm3 and 9.8 cm3 respectively. Median prostate conformal index 
(146) values were 0.624, 0.616 and 0.612 in standard, F-PTV boost and 
sector boost plans respectively. Median PTV conformal index values were 
0.867, 0.846 and 0.842 in standard, F-PTV boost and sector boost plans 
respectively. Figure 23 shows an isodose comparison for one patient in the 
study. 
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Figure 23 Comparison of isodoses for a patient with F-PTV in the right anterior and 
right posterior mid-gland sectors (V and VII). (a) no boost plan (b) F-PTV boost plan 
(c) sector boost plan. 
 
Table 28 compares the DVH values that were achieved in each sector of the 
prostate across all patients for standard and sector boost plans. In total 10 
anterior sectors and 38 posterior sectors were boosted. The median D90 and 
V150 for anterior sectors (I, II, V, VI, IX, X) was 18.4 Gy and 53.3%. For 
posterior sectors (III, IV, VII, VIII, XI, XII) the values were 21.0 Gy and 
80.6%. 
5.2.4 Discussion 
This study has investigated the feasibility of focal boost planning using 
staging MRI scans in terms of differences in tumour delineation between 
staging and pre-treatment scans and focal boost optimization using sectors 
and F-PTVs. All 10 patients for whom staging scans were available had 
received several months hormone therapy at the time of the pre-treatment 
scan and this resulted in reductions in prostate volume which varied for 
individual patients from a few percent to a reduction by more than half the 
initial volume. As well as reduced volume the relative proportions of central 
gland and peripheral zone can change (88) and this was observed for some 
patients in this study with the peripheral zone shrinking much more 
significantly than the central gland. As discussed in 5.1.4, differences in 
tumour delineation occur even when the same images are delineated on 
separate occasions and hormone therapy will reduce the contrast between 
normal and cancerous prostate tissue. It is therefore not surprising that there 
were differences in tumour delineation and in the sectors selected as 
involved in the tumour, between staging and pre-treatment scans. These 
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differences between pre-treatment and staging scans underline the 
importance of using mp-MRI to improve confidence in tumour delineation. 
A limitation of this study is that DCE-MRI was not available for the staging 
scans which may contribute to the differences observed compared to pre-
treatment scans. DCE-MRI is likely to be used in staging scans for future 
patients treated in our centre.  
 
Table 28 Median DVH values per sector across all patients in the study, comparing 
standard and sector boost plans. The sector numbers are explained in Figure 21. 
Sector 
Number 
of times 
boosted 
Standard plans Sector boost plans 
D90 (Gy) V150 (%) D90 (Gy) V150 (%) 
I 1 17.5 (-) 27.7 (-) 18.3 (-) 52.8 (-) 
II 0 - - - - 
III 4 18.0 (17.1- 18.3) 31.5 (22.6 – 38.4) 20.8 (19.0 – 22.5) 76.8 (57.0 – 90.2) 
IV 1 18.3 (-) 35.9 (-) 20.7 (-) 80.3 (-) 
V 3 17.3 (17.2 – 17.5) 38.7 (34.1 – 39.4) 18.5 (18.4 – 19.1) 58.1 (53.8 – 60.3) 
VI 2 17.4 (17.3 – 17.5) 42.0 (32.3 - 51.7) 17.9 (17.8 -18.1) 51.2 (45.4 – 56.9) 
VII 10 17.3 (15.8 – 18.2) 28.8 (14.4 – 44.8) 21.3 (18.4 – 24.0) 82.0 (48.5 – 95.7) 
VIII 9 16.9 (16.2 – 18.1) 25.6 (12.4 - 41.4) 19.8 (18.3 – 22.1) 74.7 (49.2 – 87.8) 
IX 4 17.4 (16.8 – 18.2) 42.1 (38.6 – 60.2) 18.9 (17.8 – 19.5) 66.4 (61.2 – 74.6) 
X 0 - - - - 
X1 8 18.4 (17.1 – 19.2) 47.5 (23.6 – 57.8) 22.7 (19.0 – 23.8) 90.5 (69.8 – 95.3) 
X11 6 18.3 (17.2 – 18.6) 52.3 (37.6 – 68.0)  20.8 (19.9 – 21.6) 79.5 (77.2 – 86.7) 
 
For the dosimetric part of this study, focal boost sectors were determined 
from the F-PTVs that had been boosted in the original study. This was to 
allow direct comparison of boost doses that can be achieved, not taking into 
account tumour delineation variations. The TRUS based F-PTVs in some 
cases included sectors that were adjacent to the sectors that were involved in 
the pre-treatment MRI F-GTVs. This is because of the margin applied when 
generating the F-PTVs, and illustrates that if sectors are selected based on 
staging scans, it is important to consider including sectors adjacent to those 
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sectors which contain visible tumour, to allow for the uncertainties 
discussed above.  
 
There are no published studies of sector based focal boost planning in HDR 
prostate brachytherapy. Optimising to the involved sectors rather than F-
PTVs was possible without compromising prostate and PTV coverage, and 
without exceeding OAR tolerances. Sector boost plans were similar to F-
PTV boost plans, although with slightly lower F-PTV boost dose. Because 
the involved sectors represent a higher proportion of the prostate volume 
than F-PTVs, the overall volume of the prostate that receives a boost dose is 
higher in sector boost plans Sector boost doses were higher for posterior 
sectors than for anterior sectors – generally the anterior sectors are closer to 
the urethra and smaller than the posterior sectors. Similar results were seen 
in the previous study for F-PTVs with lower boost doses achieved for F-
PTVs located closer to the urethra. 
5.2.5 Conclusion 
Although use of a pre-treatment MRI scan is preferable, focal boost 
planning based on involved sectors determined from staging scan data is 
feasible and can achieve focal boost doses comparable with the pre-
treatment MRI based F-PTV focal boost plans. Future HDR prostate 
brachytherapy patients in our centre will receive treatments planned this 
way. 
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6 Dosimetry modeling for focal prostate 
brachytherapy  
This section describes a dosimetric investigation into the feasibility of focal 
prostate brachytherapy treatments using LDR 125I permanent seed implants 
and HDR 192Ir monotherapy. Focal treatments using hemi-gland and ultra-
focal approaches are compared to standard whole gland plans. Plan 
robustness to source position errors is assessed. MC simulations are used to 
compare ISA effects for 6711 and 9011 sources in LDR 125I focal treatments 
and to assess attenuation by steel catheters in HDR 192Ir focal treatments. 
 
This section includes results from an LDR focal brachytherapy treatment 
planning study that was performed by another physicist. This work is 
included to allow comparison between LDR and HDR approaches and is 
clearly indicated in the text below.  
6.1.1 Introduction 
Both LDR and HDR brachytherapy treatments routinely target the whole 
prostate gland (13, 15). Prostate brachytherapy patients may suffer some 
side effects in terms of urethral, rectal and sexual function (15, 25). In focal 
prostate brachytherapy the aim is to reduce dose to the OARs by targeting 
treatment to areas of the prostate known to contain tumour, with reduced 
dose to the prostate gland as a whole (25). The objective is to achieve 
equivalent rates of tumour control as whole-gland treatments while reducing 
treatment related toxicities. There are few papers in the literature describing 
focal therapy treatment planning. Cossett et al. (24) describe a pilot study 
treating focal tumour volumes for 21 patients with an LDR technique. 
Kamrava et al. (27) completed a retrospective planning study for 10 patients 
comparing whole-gland and hemi-gland treatments for HDR. Todor et al. 
(147) describe a planning study for a focused LDR treatment using mixed 
isotopes to achieve two different dose levels, with a focal tumour volume 
receiving the higher dose level and the whole prostate treated to a reduced 
level. Nguyen et al. (28) describe a focal treatment targeting the peripheral 
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zone of the prostate. In addition, several groups have investigated or 
implemented HDR focal boost treatments, including our own study 
described in section 5. In focal boost treatments the whole prostate is 
treated, but the focal tumour volume is boosted to a higher dose level (93, 
95, 96, 148-150) – an approach intended to improve tumour control rates 
while keeping toxicities at a similar level. 
 
This study investigates three aspects of treatment planning for LDR and 
HDR focal prostate brachytherapy. Firstly it compares target and OAR 
doses for different treatment planning approaches: whole prostate, hemi-
gland and ultra-focal treatments. Secondly plan robustness is assessed to 
determine whether focal treatments are more sensitive to source position 
errors than standard treatments. Finally MC simulation of the treatment 
plans is performed to assess whether focal therapy plans are more sensitive 
than standard plans to dosimetric errors introduced by differences between 
TG-43U1 (3) and advanced dose calculation methods. For LDR treatments, 
the ISA effect is assessed for 6711 and 9011 seed models. For HDR 
treatments attenuation of dose due to delivering treatment through steel 
catheters is measured. 
6.1.2 Methods 
Patient selection and tumour delineation 
Treatment planning for this dosimetric modeling study was based on 
MRI data from a group at University College London Hospital performing 
clinical trials of focal therapy using HIFU (23), for 14 patients who were 
considered candidates for focal therapy according to the patient 
characteristics defined by a recent consensus report (25) for LDR focal 
therapy. Patients were aged 52 - 77 years and had low or intermediate risk 
disease. Patients were evaluated based on clinical data, T2W and DWI MRI, 
and template mapping biopsy data. MRI data was acquired on an Avanto 
(Siemens AG, Munich, Germany) 1.5T scanner using phased-array pelvic 
and spine coils for signal reception. T2W MRI used a turbo-SE sequence 
with slice thickness 3 mm and 0.7 mm pixel size. DWI MRI used a single 
shot SE-echo planar imaging sequence with slice thickness 5 mm, 1.5 mm 
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pixel size and b-values 0, 150, 500 and 1000 s/mm2. The MRI volumes 
were rotated so that the position of the prostate approximated that used in 
TRUS based treatment planning (flat posterior prostate capsule), as is 
practiced in our centre. A consultant radiologist with 18 years experience of 
prostate MRI delineated F-GTVs where suspicious regions in the MRI data 
agreed with tumour locations from template biopsy data. The prostate, 
urethra, rectum and bladder were delineated based on the T2W MRI.  
 
Target definition 
For both LDR and HDR treatments, three treatment plans were created for 
each patient: a standard whole-gland treatment (WG), a hemi-gland 
treatment treating the half of the prostate containing the tumour volume 
(HEMI) and an ultra-focal treatment treating the tumour volume plus a 
margin (UF). These target definitions were taken from an LDR focal 
therapy consensus report (25). For WG plans a 3mm margin was applied to 
the prostate (0mm posteriorly) to create a PTV (15). For HEMI plans the 
same margin was applied to the hemi-prostate, excluding the urethra, to 
create a hemi-PTV (H-PTV). For UF plans a margin of 6mm was applied to 
the F-GTV to create an F-PTV, constrained to avoid the urethra and to 
remain within the PTV defined for whole-gland plans.  
 
Treatment planning - LDR 
The LDR treatment planning part of this study was performed by another 
physicist (Bashar Al-Qaisieh), as follows:  
 
Plans were created using VariseedTM v8.0 (Varian Medical Systems, Inc., 
Palo Alto, CA, USA) and the 6711 source. Stranded seeds were used (with 
10 mm seed spacing) and seed positions were constrained to template grid 
positions. The prescribed dose was 145 Gy for all plan types. Plans were 
manually generated and the planning objective was to achieve as close as 
possible to 100% coverage of the prostate (WG plans), hemi-prostate 
(HEMI plans) or F-PTV (UF plans) with the prescription isodose. Dose 
constraints for OARs were the same for all plans: rectal D2cm3 < 145 Gy 
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and urethral D10 < 239 Gy (this is a local dose limit different from GEC-
ESTRO recommendations (14)).  
 
All other work described in this section was performed by the author. 
 
 Treatment planning - HDR 
The TPS used was Oncentra Prostate™ v4.0 (Elekta AB). All treatment 
plans assumed a single fraction monotherapy treatment with 19Gy 
prescribed to the prostate/hemi-prostate/F-PTV. This dose prescription has 
been used for single fraction whole-gland treatments in recent studies (151, 
152) and has been shown by modelling studies to be a suitable dose for 
single fraction treatments (153). For WG plans, virtual catheters were 
placed using our standard clinical approach - approximately 1cm apart 
around the periphery of the target as visualised at mid-gland, with 2-5 
additional catheters (depending on the size of the prostate) to cover the 
central regions, prostate apex and prostate base. For HEMI plans, catheter 
placing was similar with additional catheters near the urethra to try and 
cover the hemi-gland without increasing urethral dose. For UF plans 
catheter density was increased on the assumption that this would improve 
dose conformality for a small target. Catheters were spaced approximately 
0.75 cm apart across the full mediolateral and anteroposterior extent of the 
F-PTV as visualized on multiple transverse slices. The 0.75 cm spacing was 
achieved by placing catheters alternately 0.5 cm or 1 cm apart in the 
template grid and tracking the catheters to the desired position. This 
tracking is clinically realistic as we routinely steer catheters in this manner 
during clinical implants. DVH-based inverse optimization was used to 
generate the treatment plan, with small manual adjustments to dwell times if 
necessary. Dose constraints for OARs were the same for all plans: urethra 
D10 <22 Gy, D30 < 20.8 Gy and rectum D2cm3 <15Gy, V100 = 0% (151). 
Planning objectives were to aim for 100% prescription dose coverage of the 
prostate in WG plans, hemi-prostate in HEMI plans and F-PTV in UF plans. 
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Plan robustness 
Plan robustness to source position errors in focal therapy treatments was 
assessed as follows. For each patient and each plan (WG, HEMI and UF), 
DVH parameters were recalculated after applying random or systematic 
shifts to all source co-ordinates. For random source displacements, a 
different random shift was applied to each component (x, y and z) of each 
source co-ordinate, based on a Gaussian distribution of random numbers 
with mean zero and standard deviation varied to test different ranges of 
shifts. For systematic source displacements, a systematic shift was applied 
to move each source in a single direction only. For these calculations, 
source positions, structure sets and dwell times (HDR only) were exported 
from the TPS, shifts were applied and DVH parameters re-calculated using 
the dose calculation framework described in 2.4. 
 
For LDR plans random and systematic shifts were investigated. For random 
shifts, the standard deviation of the random number distribution was 
increased from 2mm to 5mm in 1mm steps. For systematic shifts, shifts of 
2mm and 4mm were applied separately to each anatomical direction 
(superior, inferior, right, left, anterior and posterior). 
 
For HDR plans only systematic shifts were investigated. Shifts of 2mm and 
4mm were applied separately in each anatomical direction. Random source 
position errors were not investigated as it was felt that for HDR prostate 
brachytherapy, random errors are likely to be small compared to systematic 
errors.  
 
Monte Carlo simulation - LDR 
MC simulation was performed for each plan to assess the effects of ISA, 
performed as described for clinical 125I simulations in 4.1.2. The same 
number of particle histories, 2 million per seed in the WG plan, was 
simulated for WG, HEMI and UF plans, to maintain similar levels of 
statistical uncertainty in the OAR DVH statistics for each plan type. All 
simulations were performed in a water phantom. 
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Monte Carlo simulation – HDR 
MC simulations were performed for each treatment plan to assess the 
dosimetric effect of steel catheters on delivered dose. Source positions, 
structure sets and dwell times were exported from the TPS and used to 
create input files for simulations in MCNPX v2.5.0 (101). The HDR 192Ir 
mHDR-v2r source and steel catheters were modeled as described in 0. A 
phase space model of the source was used in the treatment plan simulations 
to match the treatment setup, where the physical source occupies only one 
dwell position at any time. For all plans it was assumed that the catheters 
were inserted 1cm beyond the prostate base to account for the dead end 
space (this applied even to the UF plans where depending on the tumour 
location, insertion to a shorter depth may have been possible). The treatment 
was modeled in a 40cm radius water phantom. Dose was calculated over an 
8 x 8 x 8 cm3 cube centered at the mean source co-ordinate, using the 
MCNPX mesh tally. Each tally cell was 1 mm3. 100-200 million particle 
histories were simulated, depending on the number of source positions, to 
reduce the mean statistical component of uncertainty in individual tally cells 
below 1% inside the target volume in all cases. The dose analysis 
framework is described in 2.4.  
 
Figure 24 Example of F-GTV delineation on (a) T2 weighted and (b) DWI MRI 
 
RESULTS 
Tumour delineation 
Five patients where MRI data was inconsistent with template biopsy results 
were excluded from the dosimetric study as it was felt that whole gland 
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treatments would be more suitable for those patients. Of the nine patients 
included, two had low risk disease and Gleason score 3+3 and seven had 
intermediate risk disease and Gleason score 3+4. Mean PSA at diagnosis 
was 7 ng/ml (range 1.5 ng/ml – 15.2 ng/ml). On average 14% (range 6% - 
27%) of transperineal mapping biopsy cores were positive. The delineated 
F-GTV volumes ranged from 0.1 cm3 to 1.5cm3. F-GTVs were located in 
the peripheral zone for seven patients and in the central gland for two 
patients. Figure 24 shows an example of tumour delineation for one patient 
in the study. 
 
Treatment planning 
Figure 25 and Figure 26 compare isodoses for WG, HEMI and UF treatment 
plans for LDR and HDR treatments respectively.  
Table 29 and Table 30 summarize the mean DVH values for the 9 patients 
in the study, for LDR and HDR plans respectively. The range of values for 
each DVH parameter is also shown.  
 
 
Figure 25 Isodose comparison for LDR treatment plans showing (a) whole-gland 
treatment plan, (b) hemi-gland treatment plan and (c) ultra-focal treatment plan. The 
100% isodose corresponds to 145Gy. Prostate and hemi-prostate are shown in red, F-
GTV (focal-gross tumour volume) is shown in blue, PTV (planning target volume), H-
PTV (hemi-PTV) and F-PTV (focal-PTV) are shown in light blue, the urethra is 
shown in green and the rectum is shown in dark blue. 
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Figure 26 Isodose comparison for HDR treatment plans showing (a) whole-gland 
treatment plan, (b) hemi-gland treatment plan and (c) ultra-focal treatment plan. The 
100% isodose corresponds to 19Gy. Prostate, hemi-prostate and F-GTV (focal-gross 
tumour volume) are shown in red, PTV (planning target volume), H-PTV (hemi-PTV) 
and F-PTV (focal-PTV) are shown in white, the urethra is shown in pink and the 
rectum is shown in green. 
 
Table 29 Comparison of plan and DVH parameters for LDR focal therapy 
treatments: whole-gland (WG), hemi-gland (HEMI) and ultra-focal (UF). Values are 
the mean (range) for 9 patients. Seed density is measured for the prostate in WG 
plans, hemi-prostate in HEMI plans and F-PTV in UF plans. 
Plan WG HEMI UF 
No. of 
needles 27.8 (20 – 37) 17.2 (12 – 21) 11.8 (10 – 15) 
No. of seeds 81.1 (61 – 106) 55.6 (37 – 72) 24.6 (20 – 31) 
Seed density 
(seeds/cm3) 2.2 (1.8 – 2.7) 3.1 (2.5 – 4.0)  5.5 (3.8 – 7.2)  
    
Prostate    
Volume 
(cm3) 37.8 (22.7 – 58.6) 
D90 (Gy) 181.3 (177.9 – 188.6) 42.9 (33.2 – 54.7) 14.1 (10.7 – 17.9) 
V100 (%) 99.8 (99.1 – 100) 54.7 (41.2 – 62.8) 19.9 (15.4 – 24.9) 
    
Urethra    
D10 (Gy) 205.9 (183.8 – 236.8) 191.4 (161.6 – 215.6) 92.4 (47.9 – 194.4) 
Dmax (Gy) 294.4 (189.6 - 570.2) 229.7 (177.4 - 250.7) 134.3 (55.5 - 391.1) 
    
Rectum    
D2cm3 (Gy) 107.5 (85.0 – 131.6) 77.0 (39.2 – 105.1) 42.7 (13.7 – 86.7) 
    
Bladder    
D2cm3 (Gy) 80.5 (18.5 – 116.3) 54.7 (13.2 – 87.2) 17.6 (2.5 – 69.5) 
    
PTV    
Volume 
(cm3) 49.4 (30.4 – 76.0) 
D90 (Gy) 172.2 (165.4 – 176.8) 35.4 (27.4 – 45.5) 11.7 (9.2 – 15.2) 
V100 (%) 98.1 (96.1 – 99.2) 53.0 (42.1 – 59.8) 18.9 (14.0 – 23.9) 
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Plan WG HEMI UF 
    
Hemi-
prostate    
Volume 
(cm3) 18.4 (11.1 – 28.0) 
D90 (Gy) 183.6 (177.6 – 193.8) 195.7 (140.8 – 222.5) 31.8 (18.6 – 45.9) 
V100 (%) 99.9 (99.6 – 100) 97.8 (88.4 – 99.8) 40.5 (31.2 – 46.9) 
    
H-PTV    
Volume 
(cm3) 28.0 (17.4 – 41.5) 
D90 (Gy) 174.2 (168.0 – 182.6) 152.9 (102.1 – 176.4) 26.1 (16.5 – 39.5) 
V100 (%) 98.7 (97.2 – 99.8) 90.9 (74.9 – 96.4) 32.9 (24.7 – 40.2) 
    
F-GTV    
Volume 
(cm3) 0.7 (0.2 – 1.7) 
D90 (Gy) 241.1 (210.0 – 277.7) 267.0 (235.3 – 312.3) 272.4 (221.1 – 310.6) 
V100 (%) 100 (–) 100 (–) 100 (–) 
    
F-PTV    
Volume 
(cm3) 4.8 (2.8 – 8.2) 
D90 (Gy) 199.3 (182.8 – 215.3) 218.2 (176.8 – 241.2) 218.3 (199.0 – 243.3) 
V100 (%) 99.7 (97.9 – 100) 99.5 (96.5 – 100) 99.8 (98.7 – 100) 
 
Table 30 Comparison of plan and DVH parameters for HDR focal therapy 
treatments: whole-gland (WG), hemi-gland (HEMI) and ultra-focal (UF). Values are 
the mean (range) for 9 patients. 
Plan WG HEMI UF 
    
Needles 17.3 (14 – 19) 10.3 (9 – 11) 6.8 (6 – 9) 
TRAK 
(cGy@1m) 0.690 (0.508 – 0.932) 0.487 (0.351 – 0.654) 0.205 (0.147 – 0.270) 
    
Prostate    
Volume (cm3) 37.1 (22.3 – 57.3) 
D90 (Gy) 20.4 (19.9 - 20.9) 6.7 (5.8 – 8.0) 2.1 (1.6 – 2.8) 
V100 (%) 97.9 (96.5 – 98.5) 52.4 (43.2 – 59.7) 14.3 (10.7 – 17.5) 
    
Urethra    
D30 (Gy) 19.9 (19.5 - 20.5) 18.6 (17.1 - 19.7) 7.5 (4.0 - 12.9) 
D10 (Gy) 20.3 (19.8 – 20.8) 19.7 (18.5 – 20.5) 9.2 (4.5 – 16.0) 
Dmax (Gy) 20.7(20.1 – 21.6) 21.2 (19.9 – 22.1) 11.7 (4.5 – 21.9) 
    
Rectum    
D2cm3 (Gy) 12.5 (9.5 – 14.1) 9.8 (6.6 – 11.5) 4.6 (2.3 – 8.0) 
    
Bladder    
D2cm3 (Gy) 9.8 (3.2 – 14.9) 7.3 (2.3 – 11.4) 2.6 (0.4 – 9.2) 
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Plan WG HEMI UF 
    
PTV    
Volume (cm3) 48.2 (29.9 – 74.0) 
D90 (Gy) 19.9 (19.4 – 20.2) 5.8 (5.0 – 6.9) 1.8 (1.4 – 2.5) 
V100 (%) 94.8 (93.4 – 96.2) 50.3 (43.3 – 55.2) 13.6 (10.0 – 16.5) 
    
Hemi-
prostate    
Volume (cm3) 18.0 (10.8 – 27.4) 
D90 (Gy) 20.6 (19.9 – 21.0) 22.2 (21.1 – 23.4) 4.0 (2.7 – 4.9) 
V100 (%) 98.3 (96.7 – 99.0) 98.1 (96.0 – 99.2) 29.7 (22.7 – 39.3) 
    
H-PTV    
Volume (cm3) 27.3 (17.0 – 40.4) 
D90 (Gy) 19.7 (19.2 – 20.0) 18.6 (15.6 – 19.9) 3.4 (2.5 – 4.4) 
V100 (%) 94.3 (92.6 – 96.0) 88.6 (78.8 – 93.1) 24.1 (18.0 – 31.0) 
    
F-GTV    
Volume (cm3) 0.6 (0.1 – 1.5) 
D90 (Gy) 24.3 (21.2 – 30.1) 24.9 (21.1 – 28.6) 29.6 (24.7 – 34.0) 
V100 (%) 100 (99.7 – 100) 99.9 (99.4 – 100) 100.0 (99.8 – 100) 
    
F-PTV    
Volume (cm3) 4.4 (2.5 – 7.5) 
D90 (Gy) 21.4 (20.3 – 23.0) 21.9 (20.2 – 24.0) 23.0 (21.1 – 23.9) 
V100 (%) 98.0 (95.4 – 99.9) 97.3 (94.7 – 100) 98.2 (95.4 – 100) 
TRAK – Total reference air kerma 
 
Plan robustness - LDR 
Table 31 summarizes the changes in DVH parameter values for prostate, 
hemi-prostate, F-PTV, urethra and rectum with random shifts of 2mm to 
5mm. The target D90 and V100 values compared are for prostate in WG 
plans, hemi-prostate in HEMI plans and F-PTV in UF plans, as these are the 
structures in each plan where planning objectives aimed to achieve 100% 
coverage. Note that the DVH values in  
Table 29 were taken from the TPS, whereas the baseline DVH values in 
Table 31, Table 32 and Table 34 were taken from dose analysis framework. 
This is to remove the effects of differences due to the TG-43U1 (3) line 
source approximation and differences between MC source model and TG-
43U1 consensus data from the robustness and ISA analysis, as discussed in 
2.2. 
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Table 31 Impact on DVH parameters of random shifts in source dwell positions. All 
entries are mean values for 9 patients. The 0mm shift corresponds to the baseline 
(planned) values. Results are shown for whole-gland (WG), hemi-gland (HEMI) and 
ultra-focal (UF) plans. The target D90 and V100 values are for the prostate for WG 
plans, hemi-prostate for HEMI plans and F-PTV (focal-planning target volume) for 
UF plans. 
Shift Target D90 Target V100 Urethra D10 Rectum D2cm3 Bladder D2cm3 
 WG HEMI UF WG HEMI UF WG HEMI UF WG HEMI UF WG HEMI UF 
                
0mm 175.6 187.4 206.8 99.6 97.1 99.6 205.3 186.7 90.4 106.3 76.2 42.6 90.8 63.4 18.9 
2mm 167.7 172.0 176.6 98.2 95.5 97.4 223.7 202.2 95.9 107.8 77.3 43.2 91.2 64.1 19.1 
3mm 159.9 160.3 157.7 95.9 93.2 93.3 238.3 221.8 97.6 109.4 78.6 43.8 91.2 64.5 19.2 
4mm 151.0 149.0 140.8 92.4 90.0 86.2 253.4 232.6 101.9 110.8 80.5 44.7 91.6 65.5 19.6 
5mm 142.6 138.6 125.8 87.9 85.6 76.0 262.7 246.2 104.3 113.7 82.0 45.4 91.1 66.7 20.8 
 
Table 32 Impact on DVH parameters of systematic shifts in source dwell positions. All 
entries are mean values for 9 patients. The 0mm shift corresponds to the baseline 
(planned) values. Results are shown for whole-gland (WG), hemi-gland (HEMI) and 
ultra-focal (UF) plans. Target D90 and V100 values are for prostate for WG plans, 
hemi-prostate for HEMI plans and F-PTV (focal-PTV) for UF plans. 
Shift Target D90 Target V100 Urethra D10 Rectum D2cm3 Bladder D2cm3 
 WG HEMI UF WG HEMI UF WG HEMI UF WG HEMI UF WG HEMI UF 
                
0mm 175.6 187.4 206.8 99.6 97.1 99.6 205.3 186.7 90.4 106.3 76.2 42.6 90.8 63.4 18.9 
                
2mm inf 173.0 179.0 189.5 98.8 96.1 99.0 200.1 186.0 91.7 105.9 75.9 42.3 79.9 55.9 16.7 
2mm sup 174.5 187.1 201.4 99.0 97.0 98.7 205.2 185.1 88.2 105.8 76.0 42.5 102.8 70.8 21.1 
2mm post 173.2 186.9 190.0 98.9 96.5 98.0 206.7 181.9 81.5 130.2 94.2 52.7 76.6 53.6 16.2 
2mm ant 172.5 174.9 194.4 98.5 95.5 98.5 206.8 199.6 98.4 87.7 62.4 34.8 107.8 75.0 22.1 
2mm left 175.3 178.6 192.4 99.6 94.8 98.2 229.5 192.6 96.6 106.2 75.9 41.8 90.4 61.8 18.4 
2mm right 174.0 183.2 196.3 99.3 96.6 98.1 206.8 196.2 96.3 105.9 76.0 43.2 90.7 64.5 19.3 
                
4mm inf 162.3 159.4 146.2 94.3 92.1 90.1 198.1 186.8 92.4 105.3 75.0 41.5 69.8 49.0 14.8 
4mm sup 169.2 177.1 162.7 96.4 95.1 92.8 204.3 185.3 85.3 104.9 75.3 42.0 113.6 77.6 23.5 
4mm post 166.1 174.1 152.4 96.4 94.4 91.5 210.7 185.7 72.2 161.6 118.3 65.8 65.1 45.5 13.9 
4mm ant 161.1 152.8 161.3 94.3 91.0 92.5 211.4 229.1 105.8 73.0 51.7 28.7 126.8 89.1 25.9 
4mm left 172.2 159.8 162.2 98.6 90.3 92.9 350.7 295.2 130.5 105.9 75.1 41.0 89.7 60.0 17.9 
4mm right 170.1 165.7 162.3 98.0 92.8 93.0 237.3 231.3 116.7 105.2 75.4 43.7 90.2 65.2 19.7 
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Figure 27 and Figure 28 illustrate the variation of D90 and V100 values for 
planning targets with increasing random shift. 
 
 
Figure 27 LDR plan robustness to random seed displacement - target D90 values 
 
Figure 28 LDR plan robustness to random seed displacement - target V100 values 
 
127 
 
Table 32 summarizes the changes in DVH parameter values for prostate, 
hemi-prostate, F-PTV, urethra and rectum with systematic shifts of 2mm 
and 4mm applied in each anatomical direction. 
 
Plan robustness - HDR 
Table 33 shows the impact on key DVH parameters of the systematic shifts 
tested in the robustness analysis (mean values for 9 patients). The target 
D90 and V100 values compared are for prostate in WG plans, hemi-prostate 
in HEMI plans and F-PTV in UF plans, as these are the structures in each 
plan where planning objectives aimed to achieve 100% coverage.  
  
Table 33 Impact on DVH parameters of systematic shifts in source dwell positions. All 
entries are mean values for 9 patients. The 0mm shift corresponds to the baseline 
(planned) values. Results are shown for whole-gland (WG), hemi-gland (HEMI) and 
ultra-focal (UF) plans. The target D90 and V100 values are for the prostate for WG 
plans, hemi-prostate for HEMI plans and F-PTV (focal-planning target volume) for 
UF plans. 
Shift Target D90 Target V100 Urethra D10 Rectum D2cm3 Bladder D2cm3 
 WG HEMI UF WG HEMI UF WG HEMI UF WG HEMI UF WG HEMI UF 
                
0mm 20.5 22.3 23.2 97.9 98.2 98.3 20.2 19.8 9.2 12.6 9.9 4.6 10.6 7.9 2.8 
                
2mm inf 20.3 22.0 21.6 97.0 97.6 96.3 20.2 19.8 9.1 12.5 9.8 4.6 10.2 7.6 2.7 
2mm sup 20.3 21.8 22.4 96.9 97.1 97.4 20.2 19.9 9.2 12.6 9.9 4.6 8.6 6.4 2.3 
2mm post 20.4 22.2 21.4 96.7 97.3 94.7 20.3 19.9 8.5 14.8 11.8 5.4 8.3 6.2 2.2 
2mm ant 20.1 21.2 20.7 95.2 95.5 93.4 20.8 21.2 9.8 10.9 8.4 3.9 10.8 7.9 2.8 
2mm left 20.4 21.5 21.0 97.7 95.6 94.0 20.6 19.6 9.9 12.6 9.9 4.5 9.4 6.9 2.4 
2mm right 20.4 21.6 20.5 97.7 96.7 93.0 20.5 20.1 9.4 12.6 9.9 4.7 9.4 7.0 2.5 
                
4mm inf 19.9 21.0 18.2 94.0 95.0 87.0 20.3 19.9 9.0 12.4 9.7 4.6 11.0 8.2 2.9 
4mm sup 19.7 20.3 19.6 93.2 93.3 91.1 20.4 20.0 9.1 12.6 9.8 4.5 7.9 5.9 2.1 
4mm post 19.8 21.0 16.7 93.3 94.2 84.7 21.0 21.1 7.8 17.6 14.3 6.4 7.3 5.5 2.0 
4mm ant 18.7 18.8 16.0 89.6 89.6 82.2 22.3 25.3 10.4 9.6 7.3 3.4 12.5 9.0 3.2 
4mm left 20.2 19.2 16.5 96.5 89.3 83.2 22.0 20.1 11.5 12.6 9.8 4.4 9.3 6.9 2.4 
4mm right 20.2 19.5 15.5 96.4 91.0 81.2 22.1 21.2 10.7 12.6 9.8 4.7 9.3 7.0 2.5 
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Monte Carlo simulation - LDR 
Table 34 summarizes the impact of ISA on key DVH parameter values in 
each focal therapy plan, for plans using 6711 and 9011 seeds. 
 
Monte Carlo simulation - HDR 
Table 35 compares the mean baseline DVH values from the robustness 
analysis with corresponding results from the MC simulation study - any 
differences will be purely down to taking account of the steel catheters in 
the MC simulation. Note that the baseline DVH values in Table 30 were 
calculated using the TPS so are slightly different from those in Table 33 and 
Table 35 which were calculated using the DVH analysis framework 
described above. These differences are particularly noticeable for the 
bladder; this is most likely caused by differences in how the DVH 
calculations handle contour interpolation, as the bladder contour varies 
rapidly from slice to slice at the prostate base. 
6.1.3 Discussion 
This study has investigated the dosimetry of focal prostate brachytherapy 
for a group of patients who met the clinical characteristics defined for focal 
therapy by a consensus report for LDR focal brachytherapy (25). Two focal 
treatment approaches, hemi-gland and ultra-focal, as defined by the 
consensus report (25), were compared to standard whole-gland planning 
approaches. Cossett et al. (24) reported from a pilot study on LDR focal 
therapy treatments. 21 patients were treated with an ultra-focal approach 
with the treated volume covering on average 34% of the prostate or 13.7 
cm3. 145Gy was prescribed to the treatment volume achieving a mean D90 
of 183.2Gy and mean V100 of 99.3%. OAR doses were not reported. In this 
study higher F-PTV D90 values were achieved (mean 218.3 Gy) however 
this may be because the volumes were smaller (mean 4.8cm3). 
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Table 34 DVH parameter value differences between planned and MC simulation.  
 6711 9011 
 
Planned 
value 
MC 
simulation Difference  
Planned 
value 
MC 
simulation Difference  
Standard plan       
Prostate D90 (Gy) 175.9 173.1 -2.8 (-1.6%) 170.8 169.6 -1.2 (-0.8%) 
Prostate V100 (%) 99.6 99.4 -0.2 99.3 99.2 -0.1 
Prostate V150 (%) 54.4 51.7 -2.7 50.2 48.9 -1.3 
Urethra D10 (Gy) 202.7 199.9 -2.8 (-1.4%) 196.6 196.0 -0.6 (-0.3%) 
Rectum D2cm3 
(Gy) 106.2 103.6 -2.6 (-2.5%) 102.9 101.7 -1.2 (-1.2%) 
       
Hemi-gland plan       
Hemi-prostate 
D90 (Gy) 188.0 183.9 -4.1 (-2.2%) 183.2 181.0 -2.2 (-1.2%) 
Hemi-prostate 
V100 (%) 97.1 96.7 -0.4 96.7 96.5 -0.2 
Hemi-prostate 
V150 (%) 78.1 76.1 -2.0 75.5 74.4 -1.1 
Urethra D10 (Gy) 185.4 180.9 -4.5 (-2.3%) 180.0 178.2 -1.8 (-1.0%) 
Rectum D2cm3 
(Gy) 76.3 74.2 -2.1 (-2.7%) 73.9 72.8 -1.1 (-1.4%) 
       
Ultra-focal plan       
F-PTV D90 (Gy) 207.5 203.3 -4.2 (-2.0%) 202.9 201.2 -1.7 (-0.8%) 
F-PTV V100 (%) 99.7 99.6 -0.1 99.6 99.5 -0.1 
F-PTV V150 (%) 84.8 83.5 -1.3 82.5 81.9 -0.6 
Urethra D10 (Gy) 90.3 88.1 -2.2 (-2.5%) 87.6 86.6 -1.0 (-1.1%) 
Rectum D2cm3 
(Gy) 42.7 41.6 -1.1 (-2.8%) 41.3 40.7 -0.6 (-1.5%) 
 
Table 35 DVH parameter value differences between planned and MC simulation.  
 
Planned 
value 
MC 
simulation 
Difference 
(%) 
Standard plan    
Prostate D90 20.5 20.2 -1.3 
Prostate V100 97.9 97.4 -0.5 
Prostate V150 23.5 22.2 -1.4 
Urethra D10 20.2 19.9 -1.1 
Rectum D2cm3 12.6 12.4 -1.4 
    
Hemi-gland plan    
Hemi-prostate D90 22.3 22.0 -1.4 
Hemi-prostate -CTV V100 98.2 97.8 -0.4 
Hemi-prostate -CTV V150 38.3 35.8 -2.4 
Urethra D10 19.8 19.5 -1.5 
Rectum D2cm3 9.9 9.7 -1.7 
    
Ultra-focal plan    
F-PTV D90 23.2 22.8 -1.6 
F-PTV V100 98.3 98.0 -0.3 
F-PTV V150 61.8 58.9 -3.0 
Urethra D10 9.2 9.0 -1.8 
Rectum D2cm3 4.6 4.5 -2.0 
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HDR hemi-gland treatments were previously modeled by Kamrava et al. 
(27), who found similar target coverage to whole-gland treatments, but with 
urethral D2cm3 reduced from 95.2% to 69.3% of the prescription dose. In 
the current study, for hemi-gland treatments, hemi-prostate D90 and V100 
were slightly higher than whole-gland treatment prostate D90 and V100, 
and the mean urethral D10 reduced from 20.3 Gy to 19.7 Gy. This much 
smaller reduction in urethral dose is explained by two factors. Firstly the 
current study evaluated urethra D10 and D30, these have similar values to 
D0.1cm3 in the patients studied, and Kamrava et al. did observe a smaller 
reduction in D0.1cm3, from 106.7% to 97.7% (27). Secondly the current 
study attempted to cover the entire hemi prostate whereas Kamrava et al. 
(27) deliberately excluded the most anterior part of the hemi-prostate and a 
2mm margin around the urethra. This second point also explains why the H-
PTV coverage (mean V100 88.6%) is lower than PTV coverage in standard 
plans (mean V100 94.8%). These results illustrate that for hemi-gland 
treatments there is a compromise to be reached between treating the whole 
hemi-gland and achieving a reduced urethral dose. For some patients in the 
current study, urethra Dmax (maximum point dose) was higher for hemi-
gland plans than for whole-gland (although overall the mean difference was 
not statistically significant). A comparable urethral dose in hemi-gland 
treatments may still be acceptable if the objective of focal therapy is to spare 
the contra-lateral neuro-vascular bundle. Hemi-gland plans did achieve 20% 
- 30% reductions in mean rectum and bladder doses compared to whole-
gland plans for both LDR and HDR plans.  
 
There are no published studies reporting dosimetry for ultra-focal HDR 
brachytherapy treatment planning. The results of this study show that it is 
possible to deliver a high D90 to an ultra-focal target (mean dose 23 Gy or 
121% of the prescription dose for the F-PTV) while achieving significant 
reductions to OAR doses. Mean reductions from hemi-gland to ultra-focal 
plans for HDR were 53% for urethra D10, 53% for rectum D2cm3 and 64% 
for bladder D2cm3. The small size and irregular shape of ultra-focal targets 
mean that some over-treatment is inevitable if the objective is to achieve 
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100% coverage of the F-PTV. For ultra-focal plans in this study the mean 
volume of the whole-gland PTV receiving 100% dose was 13.6% for HDR 
plans and 18.9% for LDR plans, while the mean F-PTV volume was 9% of 
the PTV. This over-treatment may be beneficial providing an additional 
safety margin around the tumour.  
 
A limitation of this study is that the dosimetric results for ultra-focal 
planning depend partly on the size of the margin applied to the F-GTV. A 
margin of 4.5mm was estimated in 5.1.3 to account for tumour delineation 
and MR-TRUS image registration uncertainties in focal boost treatment 
planning and a study by Groenendaal et al (144) estimated a margin of 5mm 
for MR tumour delineation error, by comparison to pathology results. In 
focal boost treatments the whole prostate is treated to the prescription dose, 
which provides an additional safety margin compared to ultra-focal 
treatments. For this reason a 6mm margin was used in this study, 
constrained to the whole-gland PTV and to avoid the urethra. Results for 
ultra-focal plans also depend on the location and size of the target. In this 
study lesions were small and the majority of lesions were located in 
peripheral zone tissue. In two cases lesions were in the central gland close to 
the urethra. This did not impact F-PTV coverage but did lead to increased 
urethral dose; this is reflected in the wide range of ultra-focal plans urethra 
D10 values. If larger lesions were treated this would also lead to increased 
urethral dose, however patients with large lesions are less likely to be 
considered suitable for focal therapy. Further limitations of this study are 
that the prostate position and shape from the MRI data used for treatment 
planning will not be exactly as would be expected for TRUS based planning 
and that a treatment planning study can use ideal catheter positions that may 
not be achieved in practice. 
 
The results for plan robustness show that source position errors will have a 
greater effect on target dosimetry for focal therapy targets than for whole-
gland treatments. For LDR treatments random and systematic errors were 
simulated. In clinical implants these errors could be caused by errors in 
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source placement, prostate oedema and source migration after implantation. 
A study by Bues et al (154) estimated post implant source position shifts 
could be simulated using random shifts with standard deviation 4mm. In our 
study this level of random shift reduces whole-gland plan prostate D90 by 
14% but reduces ultra-focal plan F-PTV D90 by 32%. These are significant 
differences in the context of overall LDR prostate brachytherapy 
uncertainties, which were estimated as 11% (k=1) in a review by Kirisits et 
al. (38). 
 
For HDR plans, as our study assumes a single fraction treatment, inter-
fraction catheter movement does not need to be considered. However source 
position errors can still occur within a single fraction and the magnitude of 
these errors depends on the treatment protocol. For example, for CT based 
treatment planning, Whitaker et al. (155) observed a median caudal shift of 
7.5mm between planning scan and treatment delivery with any shift 5mm or 
greater being corrected before treatment delivery. That means a shift of 
4mm would not be corrected. On average for the patients in our study, a 
caudal shift of 4mm for all catheters would reduce whole-gland treatment 
prostate D90 by 2.8% and V100 by 4.0%, hemi-gland treatment hemi-
prostate D90 by 5.8% and V100 by 3.3% and ultra-focal treatment F-PTV 
D90 by 21.4% and V100 by 11.5%. For TRUS based treatment planning 
there is no need to move the patient between planning scan and treatment 
delivery, so shifts should be smaller. A study by Milickovic et al. (156) 
compared treatment planning TRUS scans to scans taken immediately 
before and immediately after treatment delivery, and measured mean 
catheter displacement of 1mm and mean prostate displacement of 0.57mm. 
Our results show that 1mm shifts have negligible impact on whole-gland 
and hemi-gland treatments, whilst ultra-focal treatment F-PTV D90 is 
reduced by 2.2% (mean for all directions). However a 2mm shift (the 
maximum shift observed in the study by Milickovic et al. (156) reduces 
ultra-focal treatment F-PTV D90 by 8.3% (mean for all directions), 
illustrating the sensitivity to source position errors. These results should be 
considered in the context of overall uncertainties in HDR prostate 
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brachytherapy - a review by Kirisits et al. (38) estimated that catheter shifts 
contributed 2% to overall (k=1) uncertainty of 5% in TRUS based treatment 
planning. 
 
MC simulation results for LDR plans show that there is little difference in 
the magnitude of the ISA effect for focal therapy treatments compared to 
whole gland treatments. This is in spite of the seed density in ultra-focal 
plans being on average 2.5 times greater compared to whole gland plans. 
Achieving 100% coverage of a small target results in a higher target D90 
compared to whole gland plans, so that the ISA effect remains at the same 
level in percentage terms even though the absolute dose that is attenuated 
increases. Comparison of the ISA effect for 6711 and 9011 seed models 
shows that the 9011 source approximately halves the ISA effect compared 
to 6711, as was seen for clinical whole gland plans in 4.1.3. 
 
There are no published studies of MC simulation of prostate dosimetry for 
HDR brachytherapy. Our results have shown that the presence of steel 
catheters in the implant has only a small impact on dose for whole-gland 
plans, reducing key DVH parameters by <1.5%. For focal therapy plans the 
impact is slightly increased, but still ≤ 2%, except for F-PTV V150 which is 
reduced by 3%. Therefore we conclude that there are no special 
considerations for focal therapy in terms of the differences between TG-
43U1 (3) and advanced dose calculations methods. 
 
This study has assessed LDR and HDR treatment planning for a single 
group of patients. LDR and HDR focal therapy treatment plans are very 
similar in terms of dosimetry. The greater flexibility in plan optimization 
that can be achieved in HDR treatment planning by varying source dwell 
times results in OAR doses in HDR focal therapy plans that are lower as a 
percentage of the prescription dose than can be achieved for LDR plans. 
Source position errors are less likely in HDR treatments so the greater 
sensitivity of focal therapy plans to position errors demonstrated in this 
study will have less impact for HDR focal therapy. However this is a purely 
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dosimetric investigation which does not take into account the impact on the 
radiobiology of the treatments given the very different dose prescriptions 
and dose rates. An additional factor in favour of LDR treatments is that the 
145Gy prescription dose is very well established for monotherapy whereas 
the 19Gy monotherapy prescription dose for HDR has only been used in 
clinical trials to date.  
6.1.4 Conclusion 
Hemi-gland and ultra-focal treatment options can achieve higher D90 values 
compared to standard whole-gland treatments and also give reduced dose to 
OARs. Focal therapy treatment plans are more sensitive to systematic 
source position errors than standard whole-gland treatments and this will 
have a bigger impact for LDR treatments compared to HDR. There are no 
special considerations for focal therapy in terms of the differences between 
TG-43U1 (4) and advanced dose calculations methods.
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7 Conclusion  
This research has investigated whether clinical prostate brachytherapy 
treatments can be improved through use of advanced dose calculation 
algorithms to better understand dose distributions, and more accurate 
targeting of dose to the prostate tumour using advanced imaging techniques. 
Prostate brachytherapy treatments using both LDR permanent implants and 
HDR temporary implants in combination with external beam have an 
excellent record in terms of patient outcomes. Nonetheless some patients do 
relapse after treatment and some patients suffer complications in terms of 
urinary and sexual function. Better patient outcomes may be possible with a 
better understanding of the relationship between dose and response which 
requires more accurate dosimetry and more accurate identification and 
targeting of tumour tissue within the prostate.  
 
Advanced dose calculation methods using MC simulation have been applied 
to LDR 125I permanent prostate implants and to HDR 192Ir implants to 
explore the impact of assumptions made in the TG-43U1 (3) dose 
calculation algorithm that is widely used in clinical practice. Experimental 
phantom work using a MOSFET based dosimeter has successfully validated 
results of MC simulations. The feasibility of incorporating mp-MRI tumour 
delineation into prostate brachytherapy treatment planning has been 
assessed, and dosimetry of focal boost and focal treatments based on MRI 
data has been investigated. The following outlines key conclusions from this 
work and ideas for clinical implementation and/or further research work in 
each area. 
 
Advanced dose calculations - LDR 
This study has shown that ISA and tissue heterogeneities do have an effect 
on dose distributions in LDR prostate brachytherapy. These differences lead 
to reduced DVH parameter values especially for patients with calcifications. 
Dose reductions particularly affect peripheral dose and areas of the implant 
with relatively poorer coverage, the impact on the volume encompassed by 
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the 100% isodose is greater than the impact on the prostate. Dose reductions 
are smaller than other uncertainties in post-implant dosimetry such as seed 
placement errors, anatomy changes and imaging and contouring 
uncertainties. The ISA effect can be reduced by using a thinner seed model.  
 
Clinical implementation and future work 
Application of advanced dose calculations in LDR seed implant 
brachytherapy is limited by the time taken to calculate dose for a clinical 
implant - it is not possible to use MC simulation or other advanced dose 
calculation methods for real-time treatment planning, although methods to 
use pre-calculated MC simulation results are under development (157). 
Another limitation is that for the low energy sources used in LDR 
brachytherapy, dosimetric accuracy is sensitive to tissue composition which 
cannot be determined from standard CT data. Tissue composition 
determination using dual energy CT is under investigation (158).  
 
MC simulations can be applied in post implant dosimetry, and could also be 
used for patients whose treatment is pre-planned (TRUS planning images 
acquired and treatment delivered in separate operating theatre sessions), 
although this is only a small proportion of cases in Leeds. Future work 
could include developing the MC simulation framework so that it becomes a 
routine part of post implant dosimetry. CT post implant data allows accurate 
density information to be incorporated into the simulation, although tissue 
composition (which has a larger impact on dosimetry than density) must still 
be assumed. This would be most likely to show an impact for patients with 
calcifications, and could allow a more accurate knowledge of dose-response 
relationships to be developed. The results in this study also show that 
advanced dose calculations would provide useful dosimetric information at 
the implant stage if the limitations discussed above can be overcome with 
advances in technology.  
 
MC simulations naturally calculate dose to the medium that the simulation 
is performed in (tissue), whereas TG-43U1 (3) calculates dose to water. 
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Future work could investigate methods of converting between dose to 
medium and dose to water to provide a better understanding of the 
differences between simulation results and TG-43U1 dose calculations. This 
conversion is uncertain for low source energies (40) and is still under 
investigation (159-161). 
 
Advanced dose calculations - HDR 
The impact of TG-43U1 (3) assumptions in HDR prostate brachytherapy is 
less than for LDR. This is due to the higher energy of 192Ir compared to 125I. 
Tissue is water equivalent at 192Ir energies (39), therefore dosimetric 
differences are due to dose attenuation by the steel catheters used to deliver 
the HDR source.  
 
Clinical implementation and future work 
Although the dosimetric impact would be small compared to other 
uncertainties, it would be straightforward to approximate the impact of these 
catheters in commercial treatment planning systems, as the impact of the 
catheter containing the source could easily be pre-calculated using MC 
simulation.  
 
Advanced imaging - MRI guided brachytherapy 
This study has investigated the use of mp-MRI techniques for prostate 
tumour delineation, to allow dose to the tumour to be escalated (focal boost) 
or treatment to target the tumour to reduce treatment related toxicities (focal 
therapy). The results show that mp-MRI-guided HDR prostate 
brachytherapy focal boost is feasible. Focal boost treatments planned on 
involved sectors determined from staging scans have comparable dosimetry 
to pre-treatment MRI based F-PTV focal boost plans, although differences 
in tumour delineation between staging and pre-treatment scans were 
observed. Mp-MRI techniques can be used to define tumour regions even in 
patients who have undergone hormone therapy. Increased focal boost dose 
can be achieved without violating urethral and rectal dose constraints and 
maintaining standard prostate/ptv coverage. No increases in the level of 
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treatment related toxicities were observed in patients treated with the focal 
boost treatment. The level of dose boost is lower for larger tumour regions 
or tumour regions close to either the urethra or rectum. 
 
The dosimetric investigation of focal therapy has demonstrated that hemi-
gland and ultra-focal treatment options can achieve higher D90 values 
compared to standard whole-gland treatments and also give reduced dose to 
OARs. Focal therapy treatment plans are more sensitive to systematic 
source position errors than standard whole-gland treatments and this will 
have a bigger impact for LDR treatments compared to HDR. There are no 
special considerations for focal therapy in terms of the differences between 
TG-43U1 (4) and advanced dose calculations methods.  
 
Clinical implementation and future work 
Focal boost treatments are now being implemented in Leeds. A key area for 
future work is to improve confidence and reduce variation in mp-MRI 
tumour delineation. For focal boost treatments a safety margin is provided 
because the whole prostate is still treated to the prescribed dose level, 
however for focal therapy treatments template biopsy validation of MRI 
results would be required. For ultra-focal approaches that target just the 
visible lesion, further investigation is required to determine the appropriate 
margin to account for uncertainties in tumour delineation, image fusion, and 
treatment source position errors. 
 
Studies have investigated the use of software based automatic tumour 
segmentation for tumour delineation in these scenarios (144, 162, 163). 
Although this approach would remove the variability in tumour delineation, 
it has not been demonstrated that these approaches are more accurate than 
radiologist delineation. A possible future approach would be to develop 
better software to present mp-MRI data to radiologists and incorporate some 
kind of automatic segmentation based on radiologist delineations. More 
advanced quantitative MRI techniques may also help, for example DWI 
MRI using models that take account of incoherent motion (164) and the 
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ability to apply advanced tissue models on a voxel basis in DCE-MRI. 
Addition of MRSI to the mp-MRI protocol would further aid tumour 
delineation but using all three of DWI, DCE-MRI and MRSI would require 
a scan time of at least 40 minutes. For three out of thirty patients it was not 
possible to delineate tumour using the mp-MRI data. Improved MRI 
techniques would also help in these cases, an alternative would be to 
perform template mapping biopsy to determine the tumour location. 
Techniques for using TRUS for tumour delineation, based on ultrasound 
elastography or contrast enhanced ultrasound are also under investigation 
(165, 166). These would be more convenient for brachytherapy treatment 
planning as the brachytherapy procedure is already based on TRUS.  
 
Image fusion of MRI delineated tumour volumes to treatment planning 
TRUS is a source of uncertainty in MRI targeted treatments. The presence 
of the TRUS probe in the rectum deforms the prostate. The prostate may 
also be deformed in the MRI scan depending on how much air is in the 
rectum at the time of the scan. The use of deformable image registration to 
increase the accuracy of fusion in these scenarios should be investigated. 
Treatment planning TRUS has low image contrast and mutual information 
based approaches to image fusion would be difficult to implement. However 
fusion could be calculated based on delineated prostate contours (167). 
Alternatively implanted markers could be used to assist image fusion. If 
staging scans are used for tumour delineation for patients treated after 
hormone therapy, changes in the prostate morphology may make image 
fusion unfeasible. In that case, as demonstrated in this study, sector based 
treatment planning may be a means of dealing with these uncertainties. 
 
The focal boost patients treated in this study also receive external beam 
therapy. The MRI delineated tumour volumes could be registered to the 
external beam planning CT scan and used to deliver a focal boost during the 
external beam treatment. An investigation into delivering focal boost 
stereotactic ablative radiation therapy using VMAT for 10 patients from the 
HDR prostate MRI pilot study concluded that this was technically feasible 
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although radiobiologically the tumour control probability increase that could 
be achieved depended on the alpha-beta ratio assumed for prostate cancer 
(168). 
 
Conclusion 
This research has investigated whether clinical prostate brachytherapy 
treatments can be improved through better understanding of dose 
distributions through use of advanced dose calculation algorithms, and more 
accurate targeting of dose to the prostate tumour using advanced imaging 
techniques. Source interactions and tissue effects have been shown to reduce 
the dose that is delivered to patients in LDR treatments, particularly for 
patients with calcifications, however the dosimetric impact is small 
compared to other uncertainties in LDR seed implant brachytherapy. For 
HDR treatments attenuation by steel catheters has only a small impact on 
dose distributions. Feasibility of mp-MRI guided focal boost HDR prostate 
brachytherapy has been demonstrated in terms of tumour delineation and the 
ability to dose escalate the DIL without increased dose to normal tissues. 
The dosimetric feasibility of LDR and HDR focal therapy treatments has 
been demonstrated. Focal therapy treatments have been shown to be more 
sensitive to source position errors than whole gland treatments. MC 
simulations of focal therapy treatments show that there are no additional 
concerns in terms of dosimetric accuracy compared to standard whole gland 
treatments. Advanced dose calculation and imaging techniques can improve 
clinical prostate brachytherapy treatments. 
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